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Classical proteomic techniques have been used in medicine for biomarker discovery and have 
recently entered the arena of neurodegenerative disorders. 
Biomarkers for disorders such as Huntington’s, Parkinson’s and Alzheimer’s diseases 
are currently being developed and tested for use in early detection,  disease progression, 
prognosis and response to treatment. However, psychiatric disorders have been less 
researched to date.  
In this thesis, a classic proteomic approach was used (1) to examine alterations in 
molecular pathways determined by a well known high-risk schizophrenia (SCZ) gene (DISC1); 
(2) to assert the effects of antipsychotic medication in the brain and plasma of F344 rats; and 
(3) to canvass the plasma of psychotic patients searching for biomarkers of the disease.  
It was found that DISC1 modulated the expression of dihydropteridine reductase, a key 
enzyme for biogenic amine synthesis and that of peptidyl-prolyl isomerase A, a protein 
involved in apoptosis. 
Antipsychotic treatment in rats exerted an effect on glucose and lipid metabolic 
pathways, mitochondrial function, immune system response, neuronal migration, 
differentiation and apoptosis.   
Alterations in calcium signalling pathways were detected in the plasma of psychotic 
patients, indicated by a significant reduction in plasma levels of gelsolin and an increment of 
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In 1911 Bleuler coined the word ‘Schizophrenia’ (fragmented mind) (SCZ) to describe a 
condition that afflicted a group of psychiatric asylum patients who presented with 
‘ambivalence’, ‘autism’, ‘affective incongruity’ and ‘disturbance of association of thought’. He 
had followed on Morel’s 1860 ‘démence précoce’ and Kraepelin’s 1896 ‘dementia praecox’ 
despairing prognostic concepts, and his description of that clinical entity was used by 
Schneider in 1959 to establish what was termed the ‘first rank’ symptoms: auditory 
hallucinations, delusional perception, delusions of passivity (thought insertion, withdrawal and 
broadcasting; made feelings, impulses and actions) and somatic passivity.  
Symptoms present in psychotic disorders can be clustered into five main categories: (i) 
positive-symptom dimension (delusions and hallucinations); (ii) negative-symptom dimension 
(lack of motivation, reduction in spontaneous speech, and social withdrawal); (iii) cognitive-
symptom dimension (difficulties in memory, attention, and executive functioning); (iv) 
depressive symptoms and (v) manic symptoms. The term schizophrenia is applied to a 
syndrome characterised by long duration of symptoms, bizarre delusions, negative symptoms, 
and few affective symptoms (non-affective psychosis) (van and Kapur, 2009). 
Nowadays, SCZ is conceptualised among clinicians as a polygenic and multifactorial serious 
mental disorder that tends to manifest itself in early adulthood, impairing the intellectual, 
emotional and social development and function of the individual.  
 
1.1.2. Diagnosis 
The diagnosis of SCZ remains based on clinical judgement. Symptoms of SCZ are traditionally 
described and categorised as either being part of newly emerging psychopathology, the so 
called ‘positive’ symptoms (i.e. thought disorder, hallucinations and delusions); or resulting in 
the sequestering of intellectual and emotional functions by the disorder itself and hence called 
‘negative’ symptoms (i.e. apathy, social withdrawal, self-neglect, loss of motivation, emotional 
blunting and poverty of speech); or as being responsible for altering normal cognitive 
functioning (i.e. episodic memory loss) (Picchioni and Murray, 2007). The study of cognitive 
symptoms is becoming increasingly important in SCZ research and the appropriateness of 
including them as diagnostic criteria has been put forward recently (Keefe, 2007). 
This state of abnormal salience and reality distortion (positive symptoms), social and 
emotional deficiencies (negative symptoms) and cognitive disturbances, results in observable 
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changes in behaviour which are deemed to be maladaptive and cause great distress to 
sufferers and carers.  
Whereas elsewhere in medicine diagnoses are being revised in the light of biological 
markers of disease process as they are being discovered, the diagnosis of SCZ remains 
empirical and currently relies solely on clinical assessment, symptom stability and pattern 
recognition by highly trained and skilled clinicians. With the introduction of semi-structured 
interviewing techniques and the use of operationalised diagnostic criteria, the process of 
diagnosis has become standardised and highly reliable once psychotic symptoms are elicited 
and firmly established.  
 
1.1.3. Epidemiology 
The lifetime risk of developing SCZ is estimated to be on average 0.7% (Saha et al.  2005), while 
the incidence of SCZ is thought to range from 7-40/100,000 (new) cases per year depending on 
whether broad or narrow diagnostic criteria are applied. A meta-analysis of 55 studies from 33 
different countries found a median annual incidence rate of 15.2/100,000 and identified 
urbanicity, migration and male gender as the factors contributing the most to incidence 
variation (McGrath et al.  2004). SCZ is a worldwide prevalent disorder with areas of higher and 
lower prevalence and a median point prevalence of 4.6/1000 (CI 1.9-10/1000), a median 
period (up to a year) prevalence of 3.3/1000 (CI 1.3-8.2/1000) and a median lifetime 
prevalence of 4/1000 (CI 1.6-12.1/1000) (Saha et al.  2005). 
Persons with SCZ used to be thought to ‘drift’ to inner city areas where less financial 
resources to sustain oneself are needed and where a heightened population density grants a 
certain degree of anonymity, making the psychotic patient less conspicuous and preventing 
involuntary hospital admission or detention. Nonetheless, it is possible that through some 
unknown factor such as illicit substance use, pre and perinatal health, social stress and 
adversity, environmental toxins, infectious diseases, nutritional variation or a combination of 
all of them, urbanicity may actually cause psychotic symptoms to appear (Pedersen and 
Mortensen, 2001).  
Migration has also been repeatedly purported to increase the risk of developing SCZ, 
particularly when the direction of migration is from a black majority country to a white 
majority one, or to areas with lower density of people with the same ethnic background as 





1.1.4. Environmental risk factors 
The role played by environmental factors in the onset and perpetuation of psychotic disorders 
has been clearly established. It is widely accepted that environmental agents can modulate 
gene function either by epigenetic mechanisms (i.e. by inducing methylation of specific gene 
sites and thus activating or inhibiting its expression), by driving specific changes in splicing or 
by protein modification (i.e. post-translational modification).  
These external factors wield their influence at different time points of brain 
development. In the antenatal stage, maternal infections, severe adverse life events and 
nutritional deficiencies in early pregnancy appear to be associated with higher risk of SCZ in 
the offspring (Penner and Brown, 2007) which may suggest a dysfunction on the maternal 
immune and/or stress responses. Older paternal age at conception is also thought to increase 
the risk of SCZ (Malaspina, 2001). During the perinatal period, obstetric complications resulting 
most likely in a relatively prolonged period of hypoxia have shown correlation with subsequent 
risk of developing SCZ (Geddes and Lawrie, 1995).  
There is also a season of birth effect by which patients with SCZ are more likely to have 
been born in late winter or early spring and which increases with latitude and severity of the 
winter season (Torrey and Miller, 1997). During childhood, parental separation or death 
(Morgan et al.  2007), childhood trauma (Read et al.  2005), adverse child rearing (Tienari et al.  
2004), urbanicity, migration and infection are thought to contribute to raising the risk for SCZ. 
In adolescence, social adversity, stressful life events (Norman and Malla, 1993), and the early 
and heavy use of cannabis (Semple et al.  2005) have been associated with increased the risk of 
the disorder. The manner in which these factors interact with each other and with a given 




A genetic basis for SCZ has long been suspected (Kendler and Diehl, 1993). SCZ is 
widely considered to be a polygenic and highly heritable disorder with 83% of the variance in 
liability due to additive genetic factors and the remaining 17% to unique environmental factors 
(Cannon et al.  1998), and has been described as a ‘threshold character whose phenotypic 
appearance would depend on the both the number of genes present and the amount of stress’ 
(Gottesman and Shields, 1967).  
Early institutional records established in the past century during the transition from 
the asylum system to the current more proactive approach to treating mental disorders, 
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recorded this familial segregation of mental illnesses. Later on, adoption studies reliably 
illustrated that the risk of suffering SCZ was increased by being the offspring of affected 
biological parents (Heston, 1966; Kety, 1983). Twin studies consistently found a higher 
concordance rate between monozygotic (40-50%) than between dizygotic twins (10-15%) 
(Sullivan et al.  2003).  
Chromosomal abnormalities in affected individuals and their families have consistently 
been described and replicated as conferring a higher risk of suffering SCZ (MacIntyre et al.  
2003). Examples of this are the deletion of 22q11 occurring in the Velo-Cardio-Facial Syndrome 
(VCFS) which contains the genes catechol-O-methyltransferase (COMT) and T-box 1 (TBX1); the 
balanced reciprocal translocation of 1q42/11q14 affecting the disrupted-in-schizophrenia-1 
(DISC1) gene; and alterations in the X chromosome.  
Genetic research advanced greatly after the complete sequencing of the entire human 
genome 10 years ago (Lander et al.  2001; Venter et al.  2001) and the conclusion of numerous 
linkage analysis studies, in which information from families with multiple affected individuals 
were used.  
As a result of these efforts, several regions of the genome thought to be associated 
with conferring risk for developing SCZ were identified. These are, in descending order of 
importance: 2p12-q22, 5q23-q34, 3p25-p22, 11q22-q24, 6pter-p22, 2q22-q23, 1p13-q23, 
22pter-q12, 8p22-p21, 6p22-p21, 20p20-p11, 14pter-q13, 16p13-q12, 18q22-qter, 10pter-p14, 
1q23-q31, 15q21-q26, 6q15-q23 and 17q21-q24 (Lewis et al.  2003). Regions 10p15-p13, 2 
centromere and 22q12 were later identified in a genome wide scan in sibling pairs (DeLisi et al.  
2002). Linkage analyses are of limited value. They signal over 4000 potential candidate genes 
thought to be involved in the disease process, are unable to specifically identify the individual 
risk genes and lack statistical power to detect small effect size genes. 
Association studies, which are usually done in samples of unrelated individuals, were 
thus conducted to try to identify which specific genes contributed to the disorder. They 
complemented linkage studies and are theoretically capable of identifying smaller effect size 
genes. Some of the genes that have been frequently detected are: neuregulin 1 (NRG1), 
dysbindin (DTNBP1), dopamine receptors 1-4 (DRD1-4), DISC1, catechol-O-methyl-transferase 
(COMT) and metabotropic glutamate receptor 3 (GRM3) (Tandon et al.  2008). In a recent 
genome wide association study published in Nature, Steffanson and colleagues found a 
significant association with markers in the major histocompatibility complex (MHC) region on 
chromosome 6p21.3-22.1, a marker located upstream of the neurogranin (NRGN) gene on 
11q24.2 and a marker in intron 4 of transcription factor 4 (TCF4) on 18q21.2 (Stefansson et al.  
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2009). The MHC region is crucial to the normal functioning of the immune response, whereas 
NRGN and TCF4 are thought involved in brain development, memory and cognition.  
Association studies are limited by the number of false positive and false negative 
results, the difficulty in replicating exactly the same markers and haplotypes in different 
clinical samples, and by population stratification. Table 1 provides a summary of the main 
findings in the genetics of SCZ. Thus far, no single gene has been unequivocally being linked 
with the disorder as being either sufficient or necessary. 
Moreover, the molecular pathways and cellular functions emerging from genetic 
studies thought to be altered in SCZ are still largely unknown. 
 
1.1.6. Gene-Environment interaction (G x E) 
The high heritability (around 80%) of schizophrenia is not only due to genetic 
influences but also genetic epidemiological studies have shown that gene–environment 
interaction in schizophrenia is common (gene–environment interaction). 
Efforts are being made in bringing together the different disciplines needed to 
examine models of disease causation based on various aspects of gene–environment interplay. 
Epigenetic factors susceptible to environmental influence might also affect twin heritability 
estimates. Meta-analytic work has suggested that paternal age above 40 years is associated 
with schizophrenia, indicating that epigenetic mechanisms might have a role (van and Kapur, 
2009). 
Co-participation of environmental exposure and background genetic vulnerability is 
thought to be common in multifactorial disorders such as psychosis. A well-known example of 
this is alcohol sensitivity in Oriental people which is strongly regulated by genetic 
polymorphism of the aldehyde dehydrogenase (ALDH2) gene. 
Recent G x E findings in psychiatry suggest that genes are likely to influence disorder 
mostly indirectly (impacting on physiological pathways and modifying the likelihood of 
developing a psychiatric disorder), rather than as direct causes of disorder per se.  
For example, the gene 5-HTTLPR has been shown to interact with environmental 
adversity to cause depression, reflecting underlying developmental mechanisms that affect the 
structural connectivity and functional interactions of a neural circuit involved in the regulation 
of emotional reactivity and extinction of fear. In schizophrenia, research has shown that the 
valine allele carriers of a functional polymorphism in the catechol-O-methyltransferase gene 
(COMT Val158Met), an important enzyme regulating prefrontal dopamine turnover, predicted 
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increased dopamine synthesis in the midbrain, suggesting that this allele may increase the risk 
for schizophrenia in interaction with stress and dopamine agonist drugs. Several studies 
suggest that valine-allele carriers may indeed be more sensitive to the psychotogenic effects of 
drugs of abuse or stress. 
The most solid evidence for an association with schizophrenia and related psychosis 
outcomes is for paternal age, migration, urbanicity, and cannabis use, the latter two 
particularly in the case of exposure during development.  The molecular mechanisms 
underlying this G x E interaction are not clear but it has been suggested that the synergistic 
effects result in a “sensitization”of mesolimbic dopamine neurotransmission. It is known that 
the genetic risk for schizophrenia is associated with underlying alterations in the dopamine 
system like increased dopamine synaptic availability, increased striatal dopamine synthesis, 
and increased dopamine reactivity to stress. Stress and dopamine agonist drugs release 
dopamine in mesolimbic areas and facilitate subsequent sensitization of dopaminergic 
pathways. Finally, there is evidence from human and animal studies that developmental 
trauma, defeat stress associated with ethnic minority group, prenatal hypoxia, and prenatal 

















22q12 2p12-q22 10p15-p13 6p21.3-22.1 (MHC) 
1q42/11q14 5q23-q34 2 centromere 11q24.2 (NRGN) 
 3p25-p22 22q12 18q21.2 (TCF4) 
 11q22-q24  6p22.3 (DTNBP1) 
 6pter-p22  5q35.1 (DRD1) 
 2q22-q23  11q23 (DRD2) 
 1p13-q23  3q13.3 (DRD3) 
 22pter-q12  11p15.5(DRD4) 
 8p22-p21  22q12 (VCFS) 
 6p22-p21  22q11.21-q11.23(COMT) 
 20p20-p11  7q21.1-q21.2 (GRM3) 
 14pter-q13   
 16p13-q12   
 18q22-qter   
 10pter-p14   
 1q23-q31   
 15q21-q26   
 6q15-q23   
 17q21-q24   







This catecholamine synthesized in 1910 by Barger and Ewens at the Wellcome laboratories in 
London and recognised as a key NT by Arvid Carlsson in 1958 has been thought to be involved 
in the pathological process of SCZ for the most part of the past 50 years.  
The main supporting evidence of its causal link to psychotic symptoms is the relatively 
effective dopaminergic blockade exerted by antipsychotic medication, and the excess 
dopamine release observed in the striatum and its associated acute psychotic state following 
amphetamine intake (Laruelle et al.  1996).  
A theoretical model for SCZ based on hypoactive dopaminergic activity in mesocortical 
regions and hyperactive dopaminergic activity in mesolimbic areas has been proposed to 
explain the emergence of negative/cognitive symptoms and positive symptoms of the disorder 
respectively (Davis et al.  1991). Alternative (or complementary) models invoke hypoactive 
tonic basal activity with hyperactive phasic dopaminergic responses to external stimuli, and 
differences in lateralization of neuronal transmission (Keshavan et al.  2008). 
Prefrontal, striatum and temporal lobe dopaminergic hypofunction mediated by 
genetic variation in dopamine-dependent genes results in deficits in Intelligence quotient (IQ), 
attention, executive function and working memory (Tan et al.  2009). These alterations can 
also be found in relatives of affected individuals with higher prevalence than in the general 
population.   
In contrast, a dopaminergic hyperfunction in the striatum (caudate and putamen), in 
terms of increased dopamine release and striatal dopamine receptor density may be 
responsible for deficits seen in procedural learning of fine motor actions, spatial working 
memory, attentional processes, increasing premature and perseverative responding (Simpson 
et al.  2010). This cognitive impairment appears early during the course of the disorder and is 
pervasive in nature, becoming most debilitating in the late stages of the disorder by affecting 
adequate social functioning.  
Additional evidence of association between cognitive functions and dopamine is that a 
small improvement in cognitive symptoms was detected after 2 months of antipsychotic 





b. Glutamate (GLU) 
Glutamic acid is a non-essential aminoacid which is ubiquitously present in the nervous system 
of vertebrates acting as an excitatory NT via N-methyl-D-aspartate (NMDA) receptors. 
Glutamatergic dysfunction is also thought to play an important role in the pathogenesis of the 
disorder. NMDA antagonists, such as ketamine and phencyclidine (PCP or ‘angel dust’) are 
capable of triggering psychotic symptoms and reduced expression of glutamate receptors has 
been observed in the pre-frontal cortex and hippocampus of patients with SCZ in post-mortem 
studies. Low concentrations of glutamate in the cerebrospinal fluid (CSF) of patients with SCZ 
(Kim et al.  1980), support the theory that hypofunction of the glutamatergic cortico-estriatal 
pathway may lead to the emergence of psychotic symptomatology by altering the filtering of 
sensory information at the thalamus. In addition, since glutamate is also involved in long-term 
potentiation, its purported effect is mainly thought to be associated with cognitive deficits and 
negative symptoms (Keshavan et al.  2008). 
 
c. Gamma-aminobutyric acid (GABA) 
A product of glutamate in GABA-ergic neurons, this inhibitory NT binds to receptors that are 
either part of a ligand-gated ion channel complex (GABAA) or G protein-coupled metabotropic 
receptors (GABAB). GABAA causes the opening of chloride ions (CL
-) channels altering the 
membrane potential and depolarizing (excitatory action) the neuron during the neonatal stage 
by allowing chloride out of the cell and then switching the flow during normal development in 
the adult brain, allowing chloride to enter the neuron and thus, hyperpolarizing it (inhibitory 
action). Post-mortem studies have shown reduced levels of GABA expression in prefrontal 
cortex and a possible compensatory upregulation of GABAA receptors. These alterations seem 
to correlate with working memory impairment in SCZ (Keshavan et al.  2008). 
 
d. Serotonin (5-HT) 
The serotonergic hypothesis of SCZ was first suggested in 1954 (Wooley and Shaw, 1954) 
based on the 5-HT antagonism effect that LSD (D-lysergic acid) had in the CNS. Although the 
initial hypothesis was of serotonin deficiency, it was soon reframed as of excessive 
serotonergic transmission. Hallucinogenic drugs are all partial 5-HT2 agonists and recent 
evidence shows that activation of 5-HT2A receptors in cerebral cortex increases glutamatergic 





Cholinergic, muscarinic, noradrenergic and endocannabinoid activity has also been shown to 
be altered in post-mortem studies of brain tissue of people with SCZ but the evidence to date, 
direct or indirect, is less compelling and rather incomplete. 
 
1.1.8. Neuropathology 
Post-mortem studies have their own limitations in psychiatric research (Lewis, 2002). Unlike 
neurodegenerative disorders like Parkinson’s or Alzheimer’s diseases, SCZ lacks 
pathognomonic lesions in the brain of affected individuals. 
Establishing prospective, antemortem assessments to affected and control groups 
both is difficult. Clinical diagnosis, psychopathology measurements at time of death, the effect 
of age heterogeneity, chronicity of the disorder, use of medication and/or illicit drugs, the 
impact of past or recent overdoses, manner and cause of death, suicide-related factors and 
agony time amongst others need to be reliably documented. In addition, post-mortem 
variability induced by post-mortem interval, preservation technique and freeze-thaw cycles for 
instance, are likely to induce pH changes that may affect mRNA transcripts by degrading them. 
This degradation may result in an abnormal structural or functional protein expression that 
might not be directly related to the disorder itself. 
 Details of neuropathological changes in SCZ, whether pathognomonic or not, remain 
elusive. For well over 100 years, researchers have attempted to identify and describe changes 
in the brain associated with the disease and other neuropsychiatric disorders such as 
Alzheimer’s disease and Parkinson’s disease have been already mapped to specific brain 
changes. More recently, there appears to be emerging evidence of a specific neuropathology 
associated with schizophrenia but the details and significance of these changes is not yet well 
understood. 
 
a. Gross pathology 
Post-mortem studies of the brain in people with SCZ have shown lower overall weight; 
alterations in brain symmetry; enlarged ventricles and structural changes in hippocampus, 
frontal and temporal lobe regions; thinning of grey matter in absence of gliosis; abnormal 
neuronal migration; dysfunctional apoptosis and synaptic and dendritic alterations (Brown et 
al.  1986; Harrison, 1999; Iritani, 2007; Selemon et al.  2002; Selemon and Goldman-Rakic, 
1999). Enlarged lateral and third ventricles, decreased brain size, cortical volume (especially in 
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the temporal lobes) and hippocampal volume have also been reported in first episode patients 
(Steen et al.  2006). 
 
b. Neurodegenerative neuropathology 
Signs of neurodegeneration in SCZ have not yet been conclusively found. There are no discrete 
lesions such as neurofibrillary tangles or plaques despite some patients experiencing profound 
cognitive deficits.  Evidence of gliosis has been reported (Stevens, 1982) but also rebutted 
elsewhere (Arnold et al.  1996; Schmitt et al.  2009), making the argument that a general 
inflammatory process occurs and accounts for the emergence symptoms unlikely. The 
generally accepted view is that gliosis is a coincidental or over imposed feature, probably 
resulting from focal lesions and infarcts in a subset of patients. Nonetheless, absence of gliosis 
does not preclude aberrant plasticity or neurotoxic changes in SCZ. 
 
c. Cellular changes 
Neurons in hippocampus (particularly those in glutamatergic pathways) and in the prefrontal 
cortex (GABAergic neurons mainly) are smaller than in the general population, suggesting 
smaller axons and dendrites resulting in fewer and less active synaptic connections. These 
changes are supported by microarray studies showing changes in presynaptic and synaptic 
functions (Mirnics et al.  2000; Mirnics et al.  2001). 
SCZ has also been associated with volume and neuronal changes in the mediodorsal nucleus 
and the pulvinar in the thalamus in postmortem studies (Byne et al.  2002). The former has 
extensive reciprocal connections with the prefrontal cortex and it may be that one of those 
areas is the primary focus of the common changes observed between them. 
These changes are observed in first episode patients and hence are thought to be independent 
of medication, albeit recent evidence from animal studies suggest that typical antipsychotic 
treatment may also have deleterious effects on neurotransmitter pathways and cognition 
(Terry, Jr. et al.  2005; Terry, Jr. et al.  2007b; Terry, Jr. et al.  2007a; Vernon et al.  2011). 
 
d. Neural connectivity 
Neuronal and synaptic changes identified mainly in the dorsolateral prefrontal cortex and in 
the hippocampus appear to indicate that SCZ is a disorder of neural connectivity. In the 
hippocampus, synaptic and dendritic alterations are suggested by the decreased expression of 
27 
 
SNAP-25 (synaptophysin) and others pre-synaptic proteins, which reflects a lowered synaptic 
density (Harrison and Eastwood, 2001).  In the dorso-lateral prefrontal cortex, levels of SNAP-
25 have been reported to be reduced in SCZ in many studies (Davidsson et al.  1999; Glantz 
and Lewis, 1997; Honer et al.  1999; Karson et al.  1999; Perrone-Bizzozero et al.  1996). Based 
on this and other synapse-related proteins reported reductions, the 'reduced neuropil 
hypothesis' of SCZ (Selemon and Goldman-Rakic, 1999) purports that axon terminals, dendritic 




Neuroimaging has been fundamental in determining biological correlates of SCZ. Magnetic 
resonance imaging (MRI) uses a strong magnetic field to excite the hydrogen atoms contained 
in the extra and intracellular fluids and detects the subsequent alignment resulting from the 
magnetization, transforming the signal into a visual representation of organs, soft tissues and 
bone structure. A series of structural findings have appeared to be consistent in SCZ; amongst 
them, an overall reduction in brain volume, thinning of grey matter, ventricle enlargement, 
and smaller temporal lobe structures like hippocampus (Heckers, 2001), amygdala and 
superior temporal gyri; smaller prefrontal cortex, thalamus, anterior cingulated and corpus 
callosum (Keshavan et al.  2008).  
Patients with SCZ also show abnormal cerebral symmetry (Crow et al.  1989), which is 
inversely correlated to early age of onset; and hemispheral dominance. Some of these changes 
appear in the early, prodromal stages of the disorder and are stable throughout the course of 
the illness although, in some cases, there seem to be a neurodegenerative component to the 
progression of these anatomical alterations. These changes are also seen to a lesser extent in 
other psychotic disorders such as bipolar affective disorder (BPAD) (Stoll et al.  2000) and in 
unaffected relatives, all of which prevent them from being considered pathognomonic or 
diagnostically relevant. Moreover, although most of these changes are present at illness onset, 
antipsychotic medication has been shown to induce structural changes in basal ganglia by 
increasing its volume (typical antipsychotics) (Navari and Dazzan, 2009) or decreasing it 
(atypical antipsychotics) while increasing thalamus and cortical grey matter volumes (Scherk 
and Falkai, 2006), suggesting a region-specific modulatory effect of antipsychotic treatment 
which could be mediated by their action on altered underlying molecular pathways. 
Positron emission tomography (PET) and single photon emission tomography (SPECT) 
is used in the study of a range of physiological processes in vivo like cerebral blood flow (CBF), 
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cerebral metabolic rate for glucose (CMRglc), cerebral oxygen metabolism (CMRO2), pre- and 
postsynaptic receptor density, NT release, enzyme activity and protein synthesis amongst 
others, by using positron emitter tracers such as carbon-11 (11C, t1/2 = 20 min), nitrogen-13 (
13N, 
t1/2 = 10 min), oxygen-15 (
15O, t1/2 = 2 min) and fluorine-18 (
18F, t1/2 = 110 min) (a substitute of 
hydrogen). In a recent review of PET studies, schizophrenic patients were shown to have 
reduced glucose metabolism, reduced blood flow in the dorsolateral prefrontal cortex, and 
reduced capability to increase blood flow in response to frontal lobe cognitive testing 
(Giovacchini et al.  2011). Similarly, they also showed decreased flow in the fronto-thalamic-
cerebellar circuitry as well as a greater reduction in binding of 11C-raclopride and 123I-
iodobenzamide (DRD2 antagonists) following amphetamine challenge, signalling a proportional 
increase of extracellular dopamine in schizophrenic subjects, which in turn correlates with the 
emergence of positive symptomatology.  
A most recent technique, diffusion tensor imaging (DTI) uses the fact that fluids move 
more freely and rapidly through the longer axis of the structure that contains them to create in 
vivo images of internal structures. The resolution of the technique is such that axon fibres can 
be individually identified (tractography). Recently applied to neuroscience, this technique has 
shown reduced structural integrity in white matter tracts in the corpus callosum, the cingulum, 
arcuate fasciculus and uncinate fasciculus in patients with SCZ (Kubicki et al.  2007). 
 
1.1.10. Infections and immunology 
Although the evidence for the involvement of infectious agents and immune system 
dysregulation in SCZ is at times contradictory due to confounding factors such as chronicity 
and severity of the symptoms, use of antipsychotic medication, smoking and poor general 
physical health in chronic patients, there is some evidence suggesting a link between infections 
and the emergence of psychotic phenomena. 
Early ecological studies in influenza epidemics and subsequent birth cohort studies 
have shown an association between gestational age and risk of SCZ which appears to be higher 
if the infection occurred during the first half of the gestation (Brown and Derkits, 2010). 
Infections mediated by toxoplasma gondii and the herpes simplex virus type 2 (HSV-2) are also 
considered to increase the risk of SCZ with an estimated odds ratio (OR) of 2.6 and 5.0 
respectively, contributing to 13% and 6% of the attributable proportion (AP) (the proportion of 
cases who would not have developed the disease if a cause were removed) of the cases 
(influenza virus has an OR of 3 and an AP of 14% of the cases). The issue of whether unique 
effects mediated by the responsible pathogen or a common mechanism lies at the heart of the 
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molecular alterations that eventually cascade into psychotic symptomatology is still 
unresolved. Infections associated with SCZ, as the ones mentioned above, differ form each 
other in terms of incubation time, duration and severity of symptoms, immune response 
elicited, capacity to cross placenta and blood-brain barrier and impact on brain development 
(Brown and Derkits, 2010), all of which seem to support the notion that individual infections 
and their associated unique characteristics are responsible for the heightened risk, however 
this is far from accepted by the majority of researchers.  
The alternative explanation is that infections would act through common pathways to 
alter brain development and increase susceptibility to SCZ involving mainly the host response 
to infection. This response can be either cell-mediated immunity (Type-1) directed against the 
intracellular pathogens, or through production of antibodies against extracellular pathogens, 
the so-called humoral (Type-2) response.  
Cytokines are secreted by immune cells (including glia in the CNS) as part of Type-1 
and Type-2 responses and act as markers of infection and inflammatory states and are soluble 
peptides that regulate all types and all cellular components of the immune system. They are 
also involved in critical roles during normal brain development. Cytokines regulate the 
expression of MHC Class 1 proteins in the cellular membrane, which main function is to 
present the antigen to the T lymphocytes for the subsequent antibody production and to 
contribute to synaptic remodelling and plasticity.  
Pro-inflammatory Type-1 activating cytokines such as Interleukin-2 (IL2), IL6, IL8, IL18, 
Interferon-γ (IFN-γ) and Tumour Necrosis Factor-α (TNF-α) stimulate cellular mediated immune 
response and are counterbalanced by anti-inflammatory Type-2 cytokines such as IL4, IL10 and 
IL13 which induce antibody responses. Patients with SCZ often show a blunted production of 
Type-1 cytokines and activation of Type-2 immune response in the early stages of the disorder 
(Muller and Schwarz, 2006). This is supported by pharmacological studies showing the 
therapeutic effects of cyclo-oxygenase-2 inhibitors (Riedel et al.  2005), and by the fact that 
neuroleptic treatment normalizes the production of Type-1 cytokines (Na and Kim, 2007). The 
therapeutic effect of COX-2 inhibitors seems to disappear in the later stages of the disorder 
(Muller et al.  2010). It appears that in the short-term, SCZ is particularly associated with 
disruptions in gene transcription, metal ion binding, RNA processing and vesicle-mediated 
transport, while the long-term illness is associated with inflammation, stimulus-response and 
immune function alterations (Narayan et al.  2008). 
Raised cytokines levels secondary to maternal infections have been associated not 
only with developmental brain damage in the offspring (Dammann and Leviton, 1997) but also 
with chorioamnionitis, periventricular leukomalacia and cerebral palsy, and are thought to be 
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responsible for microglia and astrocyte activation resulting in increased levels of nitric oxide 
(NO) and excitatory aminoacids, disruption of maturation of oligodendrocytes and subsequent 
appearance of white matter abnormalities in patients with SCZ (Davis et al.  2003). 
Raised levels of the cytokines IL1β, IL6, IL8 and TNF-α occur with most infections and 
have been associated with psychotic disorders (Brown and Derkits, 2010). One of the most 
robust findings in the immunological studies of SCZ is the shift from T-helper 1 (Th1)-like 
cellular to Th2-like humoral immune response (Monji et al.  2009). IL6 is discharged into the 
bloodstream after muscle contraction and acts to increase the breakdown of fats and to 
improve insulin resistance. 
This Type-1/Type-2 imbalance is played out in the CNS by microglial cells and 
astrocytes, since the former are derived from peripheral macrophages and secrete mainly 
Type-1 cytokines while the latter secrete Type-2 such as IL10. To support this claim, a marker 
of astrocyte activation which is thought to be associated with serotonin levels in brain and 
considered as one of the most potent trophic factors for serotonergic neurons, S100B, has 
been consistently found increased in the early stages of SCZ and is associated with structural 
damage as part of a neurodegenerative component of the disorder (Zhang et al.  2010b). In 
addition, astrocytes are the main source of the only known naturally occurring N-Methyl-D-
Aspartate (NMDA) receptor antagonist in the human CNS, kynurenic acid (KYNA) (Schwarcz 
and Pellicciari, 2002); a product of Tryptophan (TRP) metabolism, which is metabolized by the 
enzymes Indoleamine 2, 3-dioxigenase (IDO), and is induced by Type-1 cytokines and by 
tryptophan 2 3-dioxygenase (TDO), and has been found overexpressed in the brain of 
schizophrenic patients (Miller et al.  2004). KYNA accumulates following astrocyte activation 
and may lead to the emergence of psychotic phenomena through impaired glutamatergic 
transmission (Muller and Schwarz, 2006). 
NMDA antagonists such as phencyclidine (PCP) and ketamine are known to induced 
microglial activation in rats (Nakki et al.  1995). Microglial dysfunction as a result of glutamate-
mediated toxicity has been reported in a study of elderly schizophrenic subjects (Chang et al.  
2007) and microglial activation has also been found in post-mortem samples of frontal cortex 
and hippocampus of patients suffering from SCZ (Bayer et al.  1999). Despite these arguments 
in favour of a primary glial activation process, alternative explanations have also been offered 
for the changes observed and thus, when the authors of a post-mortem study on the brains of 
patients with SCZ and depression who committed suicide found an increased in microglial 
activation, they attributed it to a pre-suicide stress reaction (Steiner et al.  2008) and in one 
imaging study, the authors hypothesize that the microglial activation seen in the brains of 
patients might have been secondary to neuronal loss (van Berckel et al.  2008). Despite this 
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limitations and potential alternative explanations, a primary activation process cannot be 
totally excluded. 
In preclinical studies, the alterations of brain development seen in maternal immune 
activation animal models are very similar to the ones observed in DISC1 and NRG-1 knock-
down animal models and in a recent paper, Seshadri and colleagues demonstrated that DISC1, 
like NRG1, is expressed in neurons, astrocytes and microglia and exert their effects via a 
common pathway involving heterodimers of the receptors tyrosine-protein kinase ErbB2 and 
ErbB3 in a mechanism that appears to involve Akt signalling (Seshadri et al.  2010).  
Impaired Akt signalling has already been associated in SCZ (Bajestan et al.  2006; 
Mathur et al.  2010; Norton et al.  2007; Thiselton et al.  2008) and with obstetric 
complications (Joo et al.  2009), while ErbB3 modulates antigen presenting cell function and 
Type 1 Diabetes risk (Wang et al.  2010), which in a recent study has been linked to SCZ 
(Copeland et al.  2010), echoing mounting evidence for conceptualizing SCZ as a systemic 
disorder (Dickinson and Harvey, 2009), particularly of insulin resistance and chronic 
inflammation. 
 
1.1.11. Pharmacological treatment of schizophrenia 
The serendipitous introduction of chlorpromazine in 1950 and its first use in a patient with 
manic symptoms two years later heralded the advent of a group of compounds whose main 
effect was thought to be exerted through blockade of DRD2 in the mesolimbic pathway. First 
generation antipsychotics were butyrophenones, such as haloperidol and droperidol; 
phenothiazines, such as chlorpromazine, thioridazine, fluphenazine, trifluoperazine and 
promethazine; and thioxanthenes such as zuclopenthixol, clopenthixol and flupenthixol. These 
compounds exert their action in the mesocortical pathway (involved in motivation and 
emotional responses), in the nigrostriatal pathway (involved in production of voluntary 
movement) and in the tuberoinfundibular pathway (involved in the production and secretion 
of prolactin).   
Although the mechanism by which these drugs exert their therapeutic effect is still 
largely unknown (Karam et al.  2010), the DRD2 is coupled to Gi/o proteins to inhibit adenylate 
cyclase (AC) and to modulate voltage-gated K+ and Ca2+ channels. In addition, they cause 
troublesome side effects such as lethargy, anergia, dystonia, akathisia, rigidity, tremor, tardive 
dyskinesia and hyperprolactinemia. 
Second generation antipsychotics, also called atypical due to their apparent absence of 
extra-pyramidal side-effects, were introduced from 1970 onwards. These are clozapine (CLO), 
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olanzapine (OLA), risperidone (RIS), quetiapine, ziprasidone, amisulpride, zotepine, sertindole 
and paliperidone. These compounds block DA D2 receptors and also serotonin receptors 
(5HT2A and 5HT2C), α-adrenoreceptors, hystamine H1 receptors and muscarinic acetylcholine 
receptors, and are credited with alleviating not only positive symptomatology but also some of 
the negative symptoms of SCZ (Murphy et al.  2006). Aripiprazole (ARI), a dual dopamine 
autoreceptor agonist and postsynaptic D2 receptor antagonist is the first of the so called third 
generation of antipsychotic medication (Ozdemir et al.  2002). 
The use of allosteric enhancers of the NMDA receptor such as glycine, D-serine and D-
alanine has been tried with varied results (Buchanan et al.  2007), and GABA transmission 
enhancers such as MK-0777 and baclofen have also been tried (Karam et al.  2010). Similarly, 
the cholinergic system has also been the focus of recent interest as α7-nicotinic receptors and 
M1 muscarinic receptors are reduced in cortical areas of patients with SCZ and are likely to be 
involved in the cognitive deficits observed in this patient population (Karam et al.  2010). 
Certain agents, like clozapine and ARI that are partial agonists of 5-HT(1A) receptors 
appear to have neuroprotective effects against excitotoxic injury in vivo (Cosi et al.  2005).In 
addition, antipsychotics increase striatal metabolism by normalizing mitochondrial function 
(Kung and Roberts, 1999) and increase the expression of ionotropic glutamatergic receptors 
(Heresco-Levy, 2003; Tascedda et al.  1999). And while clozapine (Pedrini et al.  2011) and 
risperidone increase BDNF (Lee and Kim, 2009), haloperidol decreases it (Pillai et al.  2008). 
Antipsychotics have also other less known actions including effects on microglia and 
have a balancing effect on cytokines (Watanabe et al.  2010). An increase on IFN-γ, IL2 and 
TNF-α production following treatment with antipsychotics and a functional decrease of IL6 has 
been observed (Monji et al.  2009).  
Therefore, it is reasonable to assume that the antipsychotic effect of these compounds 
could be mediated by more than just NT receptor blockade. 
 
1.1.12. Neurodevelopment and neurodegeneration in 
schizophrenia 
The neurodevelopmental hypothesis of SCZ (Murray and Lewis, 1987; Weinberger, 1987) 
purports that changes to the developmental component in cerebral circuitry are ultimately 
responsible for the onset of symptoms that subsequently occur around the third decade of life 
in most patients. According to Weinberberg, “Schizophrenia is related to a defect in brain 
development. This defect predisposes to a characteristic pattern of brain malfunction in early 
adult life and to symptoms that respond to antidopaminergic drugs.” (Weinberger, 1996) 
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Although there is no conclusive evidence of developmental neuropathology associated 
with schizophrenia, traditionally, this theory is supported by the absence of detectable signs of 
brain damage such as widespread gliosis or neuronal loss, the observed presence of prodromal 
symptomatology, and the apparent absence of progressive and specific biochemical and 
molecular changes altering observable cellular processes which are present in traditionally 
viewed degenerative disorders such as Alzheimer’s disease (AD), Huntington’s disease (HD) or 
Parkinson’s disease (PD) (Lieberman, 1999).  
Indirect support to the neurodevelopmental hypothesis is weakly given by the 
presence of minor physical abnormalities (Green et al.  1989), reported evidence of 
neuropsychological abnormalities of children with schizophrenic mothers (Asarnow, 1988), but 
most importantly from two British birth cohorts epidemiological studies (Done et al.  1994; 
Jones et al.  1994) which showed that cognitive and social deficits as well as delayed 
neuromotor milestones during childhood were associated with a higher risk of developing 
schizophrenia in adulthood. Further evidence of neurodevelopmental abnormalities is given by 
the observed relationships between obstetric complications (Murray and Lewis, 1987) and 
prenatal viral exposure to influenza A2 virus during the second trimester (Mednick et al.  1988) 
and SCZ.  
The most consistent evidence that SCZ is a disorder of the brain has been given by 
structural neuroimaging studies. Although, recent evidence suggests that antipsychotic 
treatment is partly responsible for reducing overall brain volume, and increasing ventricular or 
fluid volume (Moncrieff and Leo, 2010). These studies have shown volume reductions in 
amygdala, hippocampus, temporal and frontal cortices, enlargement of ventricles and 
temporal lobe hemisphere asymmetries which, albeit present at the initial stages of the 
disorder, appear to become more prominent as the illness progresses and its associated 
symptoms worsen and became chronic (Lieberman, 1999).  
Nonetheless, it appears that there might be signs of astrocytosis and microgliosis 
present in the brains of people with SCZ (Schnieder and Dwork, 2011) . Other aspects of the 
disorder, such as the delayed onset, the progression of cognitive dysfunction observed in 
almost a third of the patients, the improvement observed with antipsychotic medication and 
the relationship between outcome and duration of untreated psychosis also signal the 
presence of a progressively worsening component in at least a subset of patients.  
At a cellular level, a progression in neuronal atrophy, decreased neuropil and 
alterations in neuronal density have been reported in the anterior cingulated cortex, nucleus 
accumbens, hippocampus and thalamus (Perez-Neri et al.  2006), suggesting graded apoptosis, 
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probably as a result of excessive glutamatergic stimulation and its subsequent caspase 
activation (Glantz et al.  2006). 
Glutamatergic hypofunction could be related to neurotoxicity (Chang et al.  2007) and 
hyperdopaminergic function (Halberstadt, 1995) as a result of loss of modulation. Chronic 
blockade of the NMDA receptors, which glutamatergic neurons use to stimulate GABAergic 
interneurons’ inhibition of pyramidal neurons in the frontal cortex, leads to a decrease in 
GABAergic transmission and an increase in dopamine release that eventually leads to 
neurodegeneration though excessive glutamate release (Perez-Neri et al.  2006). 
This is similar to the process seen following administration of ketamine and one that 
can be reversed with GABAergic agonists. In addition, NMDA receptor blockade by PCP 
reduced the phosphorylation of Akt and GSK-3β, decreasing the activity of the former and 
increasing the activity of the latter and inducing neurotoxicity during development; while 
depletion of GSK-3β by si-RNA attenuated caspase-3 activity blocked PCP-induced 
neurotoxicity (Lei et al.  2008). NMDA Receptor activation, on the other hand, results in the 
production of Nitric Oxide (NO) by the enzyme NO synthase (NOS). NO reduces dopamine 
reuptake and contributes to the hyperdopaminergic state and is also associated with 
glutamate neurotoxicity (Perez-Neri et al.  2006). 
Another molecule regulated by glutamatergic transmission is brain-derived 
neurotrophic factor (BDNF), a neurotrophin with neuroprotective properties. Reduced 
expression of BDNF and its receptor are likely to increase vulnerability to cell death (Perez-Neri 
et al.  2006). 
Lastly, deficiencies in energetic metabolism, such as oxidative stress and mitochondrial 
dysfunction have been reported in SCZ (Rezin et al.  2009; Scaglia, 2010; Wood et al.  2009). 
These alterations include mitochondrial hypoplasia, impairment in the phosphorylation system 
and altered mitochondrial-related gene expression (Ben-Shachar, 2009). Excessive NO 
concentrations are known to inhibit the mitochondrial respiratory chain. 
Moreover, dopamine inhibits mitochondrial respiration by over stimulating 
phospholipase C-related intracellular calcium release in the brain and inducing cortical neuron 
apoptosis (Zhang et al.  2010a). 
These two components, the neurodevelopmental and the neurodegenerative one, are 
not mutually exclusive and the course of the disorder is likely to be due to the interaction of 
both (Figure 1). Following the onset of frank psychosis (and usually florid positive symptoms) in 
late adolescence/early adulthood, SCZ often runs a progressively deteriorating course with the 
majority of patients manifesting an increased severity and persistence of negative symptoms, 
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cognitive deficits, social and functional impairment as the illness progresses from the early to 
the late stages. 
Therefore, it appears that molecular mechanisms implicated in the pathophysiology of 
SCZ are consistent with a progressive neurodegenerative process, which origin is almost 
certainly neurodevelopmental and hence, it is reasonable to assume that peripheral makers 











1.2.1. Definition and use 
A biomarker can be defined as ‘a characteristic that is objectively measured and evaluated as 
an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention’ (Biomarkers Definition Working Group, 2001) and following this, 
classified as Type 0: Natural history marker; Type 1: Biological activity marker and Type 2: 
Single or multiple marker(s) of therapeutic efficacy (Mildvan et al.  1997). In clinical trials 
terminology, a biomarker that substitutes for a clinical measure is a surrogate marker 
(Prentice, 1989; Rolan, 1997) and these are extremely valuable in medicine. Only a few have 
been proven to be reliable enough to be routinely used in clinical practice such as CD4 counts 
as an outcome measure in HIV/AIDS.  
The potential clinical uses of biomarkers are many, and include facilitating objective 
and/or early diagnosis, monitoring disease process, determining staging and prognosis, and 
perhaps most challengingly, predicting treatment response. 
The use of biomarkers in clinical trials to monitor outcome of therapy has huge 
potential to reduce the variability of clinical observations and in so doing increase the power of 
trials, reduce their costs and potentially facilitate the discovery of new medicines. Indeed two 
important processes designed to speed delivery of new therapeutics - the European Innovative 
Medicines Initiative (http://www.imi-europe.org/) and the US Critical Path initiative 
(http://www.c-path.org/) - rest very heavily on biomarkers. 
The ideal biomarker for neurodegenerative diseases must have certain specific 
characteristics: 
1. Accessible tissue. 
2. Measurements are easy to quantify, reliable and quick, and reproducible. 
3. Diagnostic biomarker should have small variation in the general population. 
4. Unaffected by factors not associated with the disorder under study. 
5. The biomarker changes linearly (either negatively or positively) with disease progression 
and in response to a disease modifying therapeutic intervention. 
It is unlikely that any one biomarker will fulfil all these characteristics, and it is likely 




Proteomics are currently being employed to identify unique protein profiles in 
Alzheimer’s disease (Ho et al.  2005), Parkinson’s disease (Johnson et al.  2005), Huntington’s 
disease (Zabel and Klose, 2004) and ALS (Poon et al.  2005) . Accumulating data will hopefully 
aid in identifying neurodegeneration-associated changes in protein expression that will 
ultimately be used as biomarkers (Henley et al.  2005). 
In neuropsychiatric disorders, the most promising biochemical markers to date have 
been found through the analysis of CSF of AD patients. A decrease in the beta-amyloid1-42 
peptide has been reported in 80–90% of Alzheimer’s disease patients and the decrease is 
associated with APOE epsilon 4 allele (Sunderland et al.  2003; Sunderland et al.  2004), 
suggesting that beta-amyloid1-42 might represent an early biomarker of AD. 
CSF total tau protein has been shown to be dramatically increased in Alzheimer’s 
disease (Sunderland et al.  2003). The measurement of beta-amyloid1-42 peptide and total tau 
together is reported to have a sensitivity of around 90% in Alzheimer’s disease diagnosis, 
which in combination with clinical evaluation and imaging ensures high accuracy of the clinical 
diagnosis (Blennow, 2004).  
In contrast to the findings in Alzheimer’s disease, CSF profiling in patients with 
frontotemporal dementia (FTD) reveals significantly decreased levels of CSF tau, which 
correlates significantly with frontal and temporal atrophy on volumetric imaging (Grossman et 
al.  2005). 
An interesting potential CSF biomarker for Huntington’s disease is orexin, which was 
shown to have a 72% reduction in CSF of Huntington’s disease transgenic mice compared with 
wild-type littermates (Petersen et al.  2005), suggesting that orexin could be used as a 
biomarker reflecting neurodegeneration. Significant atrophy and loss of orexin neurons in 
Huntington’s disease patients and atrophy and loss of orexin neurons in the lateral 
hypothalamus of Huntington’s disease transgenic mice was also described in the same study. 
 
1.2.2. Molecular biomarker discovery approaches in 
schizophrenia 
Molecular biomarker discovery involves the analysis of biological samples. These might be 
tissue biopsies and extracts from the organ or system under study, or bodily fluids such as CSF, 
blood, urine, tears or saliva. Psychiatric illnesses pose the obvious problem that the organ of 
interest is not directly accessible and thus, CSF, as a fluid in direct contact with the brain, is 
intuitively the most appropriate peripheral tissue to look for biomarkers in psychiatry. 
However, sampling it from schizophrenic patients poses its own challenges. On the other hand, 
blood has considerable potential as a tissue for biomarker discovery as it is routinely collected 
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and represents a complex and dynamic tissue for gene, protein and metabolite studies. Some 
evidence suggests that in some cases, changes in blood reflect changes taking place in the 
brain, suggesting that blood based biomarkers might have some utility in brain disorders 
(Prabakaran, Wengenroth et al. 2007).  
Conceptually, blood based markers of brain disease might occur in two ways. Firstly 
protein, metabolite or other molecules may cross from brain to blood. There is considerable 
interchange between CSF and blood and in some diseases the blood brain barrier may be 
disrupted, facilitating the substance exchange. Secondly, blood may reflect a signal of disease 
that is present systemically but only results in pathology causing symptoms in the brain. Either 
way, a marker that could be used as a biomarker in psychiatric illness may be present 
peripherally and could potentially be detected using the appropriate techniques.  
Other challenges for SCZ research include the heterogeneity of the disorder at 
nosological and molecular level (Craddock et al.  2006), the complex interplay taking place in 
the cell between already altered at baseline cell signalling pathways and environmental insults; 
the effects of long term medication and the inherent limitations of current research 
technologies (Schwarz and Bahn, 2008).  
Broadly speaking, there are two general approaches to molecular biomarker discovery. 
The most effective method to date has been a candidate approach – measuring molecules 
known to be associated with disease. Most of the examples of biomarkers in use in the clinic 
were derived from candidate studies; cholesterol as a biomarker predictive of cardiovascular 
disease, various hormonal markers reflecting germ cell tumour activity are examples of 
candidates that have been confirmed in large scale studies and are in clinical use. However, it 
is likely that there are many other markers of disease that cannot be predicted from 
knowledge of the pathology and may be discovered by the group of technologies variously 
known as data-driven approaches, unbiased technologies or, more prosaically, the ‘omics’. 
These include genomics for study of DNA variants, transcriptomics for mRNA, metabolomics 
for products of metabolism and proteomics for peptides and proteins. In the following 
sections, we will briefly describe each one of those and expand on the latter. 
Whilst for the most part the genome is a static, ‘trait’ measure (epigenetic changes 
apart), the transcriptome, metabolome and proteome (Schwarz and Bahn, 2008) are all 
dynamic, reflecting the changing needs of a cell or organ, disease status, and response to 
environmental stimuli. The transcriptome, metabolome and proteome can all be used to 
identify ‘state’ biomarkers, i.e. biomarkers that can be used to diagnose disease, to measure 
disease progression and/or as markers of the effectiveness of therapeutic intervention.  
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However, this ability to respond dynamically to changing conditions also provides a 
challenge to researchers as experimental variation (e.g. diet, pre-existing conditions, time of 
sampling, sample storage and handling) can itself affect the composition of the sample. 




The genome is the complete set of DNA carried by an organism, and virtually every cell in the 
body carries a complete copy. As such, the role of genomics in the discovery of biomarkers is 
aimed at determining if there is a genetic predisposition to disease (i.e. a ‘trait’ biomarker). 
Whole genome studies typically use arrays which measure many variants in most genes 
(Cichon et al.  2009).  
The technology is advancing rapidly with the number of variants increasing and the 
types of variants – single nucleotide polymorphisms, copy number variants, deletions, 
duplications, expansions and others all coming under increasing scrutiny and are helping to 
redefine the clinical phenotype (Cichon et al.  2009; Craddock et al.  2009; Fanous et al.  2007; 
Fanous and Kendler, 2008; O'Donovan et al.  2009). The cost of reading the entire genome is 
decreasing and at some point it is expected that this will become feasible for clinical studies. 
Nonetheless, this will be counterbalanced by the exponential complexity of data generated by 
such studies and by the costs of handling and analysing this data becoming singularly large.  
 
1.2.4. Transcriptomics 
The transcriptome is a set of mRNA (transcripts) that reflects genes that are expressed by a 
particular cell type. Like the genome, the transcriptome is most often studied using 
microarrays, and the technology is also advancing rapidly. First generation expression arrays 
were used to detect relative expression of gene transcripts by comparing the transcriptome of 
normal individuals with that of diseased individuals, for example. Increasingly, expression 
arrays are being used to estimate not just the total expression of a given gene but also to 
distinguish between differently expressed isoforms generated by alternative splicing. Many 
genes have multiple splice variants, and this seems to be a process of particular relevance in 
the brain, perhaps reflecting the generation of functional complexity from a relatively simple 
set of genes (i.e. not many more than simple organisms) (Calarco et al.  2007; Pan et al.  2008).  
Gene expression changes are generally validated using a separate method, ideally quantitative 
reverse transcription-polymerase chain reaction (RT-PCR).  
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In SCZ, these methods have already been fruitful when applied to brain tissue (Dean et 
al.  2009; Mitkus et al.  2008; Mudge et al.  2008; Perkins et al.  2007; Saetre et al.  2007) and 
in examining peripheral blood for biomarkers of the disorder (Chagnon et al.  2008; Ilani et al.  
2001; Nadri et al.  2002; Numata et al.  2007; Perl et al.  2003; Zhang et al.  2008). 
 
1.2.5. Metabolomics 
Metabolomics (Goodacre, 2005; Nobeli and Thornton, 2006) refers to the analysis of 
metabolites, including amino acids, lipids, nucleotides and sugars, from tissues and body fluids. 
The metabolome is downstream of the genome, transcriptome and proteome, and as such 
may reflect more closely cell activity at a functional level (Allen et al.  2003; Nobeli and 
Thornton, 2006). Lipidomics is the part of metabolomics that refers to the analysis of the 
specific metabolite family, the lipids (Wenk, 2005). Like proteomics, no single technique is 
capable of analysing all metabolites due to the large dynamic range of metabolite 
concentrations and sample complexity (Nobeli and Thornton, 2006).  
Two main technologies, Mass Spectrometry (MS) and Nuclear Magnetic Resonance 
(NMR) spectroscopy are currently in use for analysis of the metabolome, often in conjunction 
with various chromatographic techniques (typically gas chromatography (GC) for non-polar 
compounds, and Liquid Chromatography (LC) for polar compounds) to initially separate 
metabolite subsets. NMR spectroscopy can simultaneously measure different subsets of 
metabolites, although the NMR spectra associated with complex samples can be difficult to 
interpret. However, compared to MS, NMR spectroscopy has only moderate sensitivity, and is 
only able to detect the most abundant metabolites in plasma. 
There have been few studies of the metabolome in SCZ although the data presented 
thus far is very promising. For example, the CSF of 152 drug naïve patients with first onset SCZ 
was compared to healthy controls initially and to the subsequently treated same patient group 
using 1H nuclear magnetic resonance spectroscopy (1H-NMR) (Holmes et al.  2006). The 
authors identified higher glucose levels and lower acetate and lactate concentration in the CSF 
of drug naïve patients when compared to controls. No difference in glucose plasma levels was 
observed, suggesting a CSF or brain specific alteration. Moreover, treatment with atypical 
antipsychotics for an average of 9 days restored the altered glucose levels to normality in 50% 
of patients whereas treatment with a typical agent it did not (the authors are cautious 
interpreting this result as only 6 patients were treated with a typical antipsychotic medication). 
Intriguingly, patients presenting with relapse as opposed to first episode failed to return their 
metabolome to normal following treatment.  
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In another study by the same group, drug naïve paranoid SCZ patients and prodromal 
patients were studied and compared to healthy controls (Huang et al.  2007) using 1H-NMR 
and SELDI mass spectrometry. It was observed that 36% of prodromal patients showed 
proteomic abnormalities similar to the diseased group and 29% of them also shared similar 
metabolic profile. Unsurprisingly, only 29% of the group converted to the disorder within the 
three year follow up suggesting that the signature identified cannot be used to predict clinical 
outcome. 
The CSF lipidome has also been the subject of study in recent years (Fonteh et al.  
2006), and a lipidomic platform was successfully used to detect drug-specific changes in 
patients with SCZ treated with olanzapine, risperidone or aripiprazole (Kaddurah-Daouk et al.  
2007) showing that levels of two major phospholipid classes, phosphatidylethanolamine and 
phosphotidylcholine were significantly downregulated in SCZ and that both olanzapine and 
risperidone, but not aripiprazole, increased concentrations of triacylglycerols and decreased 
free fatty acids levels.  
1H-NMR was also employed to study the lipid profile of monozygotic twins discordant 
for SCZ which showed alterations in both affected and unaffected subjects which could be 
correlated with Global Assessment of Function (GAF) scores but only in the affected females of 
the sample (Tsang et al.  2006). 
 
1.2.6. Proteomics 
The proteome refers to the peptide and protein complement of a particular tissue, cell or fluid 
at a given time and also describes post-translational modifications that can affect protein 
activity and location. Challenges associated with studying the proteome include the large 
dynamic range of proteins and peptides, as well as the complexity (proteins differ in their size 
and charge) and number of proteins in the sample; therefore no one technique can be used to 
study the entire proteome. Nonetheless, proteomic approaches aim to identify changes in 
protein expression and/or modification and are constantly being developed to increase 
coverage of the proteome. 
a. Experimental design for proteomic studies 
There are many different approaches to proteomics, which differs from genomics and 
transcriptomics in that even using multiple methods, only a portion of the true proteome in 
any complex sample is currently accessible to analysis. For this reason candidate approaches 
will have considerable utility for the foreseeable future – both individual protein estimates and 
large scale multiplex analyses.  
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For the most part these are variants of immune-based detection but other candidate 
protein multiplexing methods including mass spectrometry based approaches such as multiple 
reaction monitoring are increasingly used. Multiplexing in fluid phase using antibodies bound 
to colour coded beads allows up to 100 analytes to be measured in a single sample meaning 
that using this, and other analogous solid phase multiplexing approaches, candidate protein 
arrays can measure very large numbers of proteins (Olsson et al.  2005).  
Experimental design in proteomics is in most cases a two-step process involving a 
discovery and a validation phase (Figure 2). There are a number of different proteomic 
methodologies available for biomarker studies which can be divided in biased and unbiased 
techniques. Unbiased techniques are used in the discovery stages of proteomic research for 
separation of analytes and to search for potential changes in any protein to be identified. 
These methods include: 2DPAGE and Liquid chromatography (LC). The biased techniques are 
used in the subsequent validation steps include all the affinity-binding methods such as 
Western blot, Enzyme-Linked ImmunoSorbent Assay (ELISA) and protein microarrays, which 
allows for in-depth profiling study on preselected proteins.  
Analysis of large-scale proteomics data sets are usually complex and require careful 
planning of the most appropriate experimental design. The 2DPAGE workflow consists of the 
following steps: 
1. Designing of the experiment. 
2. Performing the experiment: Protein isolation, running the gel and scanning of the images. 
3. Quantitation of the image: Background subtraction, spot segmentation and spot matching. 
4. Analysis of the data: Normalisation and test for differences. 
5. Interpretation and confirmation of results. 
Statistical and computational methods are crucially involved at every level except in 
step 2. 
A careful experimental design is necessary in order to reduce the complexity of the 
research question, to minimise non-treatment variability, to maximise estimation accuracy, to 
reduce the number of samples needed (reducing time and cost) and to chose the more cost-
effective platform or technology with which the experiments can be conducted. Adequate 
experimental designs are those that define the key hypothesis and identify the crucial 
variables to test, identify the most efficient experimental design, devise systems to identify 
and mitigate sources of variability, define statistical approaches to maximise power under 
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reasonable assumptions and estimate the required sample size based on effect size, variability, 
and desired false positive and false negative rates. 
Sources of variability could be found: 
1. At a biological level: Gender, diet, age, ethnicity, environmental factors, and genetic make-
up. 
2. At a technical level: Sample quality, experimenter, materials and measurement errors. 
3. At systems level: Platform used, instrumentation, settings for analysis (spot detection, 
matching and normalisation). 
Intersubject variability can be controlled by using a longitudinal design by which each 
subject acts as a control for himself prior to developing the condition under study or by 
carefully matching of known parameters such as gender, age, ethnicity, and other known 
environmental factors. The former is extremely difficult to achieve, particularly in 
neuropsychiatric studios and therefore, in the human sample selected for study in this thesis, 
subjects were matched for age, gender, ethnicity, alcohol, tobacco and cannabis use. Since 
atypical antipsychotic medication has been linked with the onset of metabolic syndrome and in 
order to minimise the effects of medication, which can also induce protein expression changes, 
cases were grouped in three subsets as follows: subjects treated with Olanzapine, subjects 
treated with Risperidone and subjects who were medication free at the time of sampling. 
All experiments presented in this thesis were performed by the author using the same 
standard protocol and each batch included an equal number of cases and controls to minimise 
the so-called ‘batch effect’. 
Analysis and interpretation of the data was performed using the same specialised 
software (Progenesis SameSpots) in conjunction with a biostatistician and an experienced 
postdoctoral researcher. 
Confirmation of results was obtained using an independent sample and a different 









b. Sample preparation 
Sample preparation is a key step in proteomic research and standardised protocols should be 
followed for sample capture and extraction, transportation, storage and handling to minimise 
experimental error and ensure reproducibility of results as proteins are easily degraded. 
Isolated cells, whole tissues or body fluids are the usual sources of protein samples, which are 
found amongst other molecules and cellular components.  
Proteins are very heterogeneous in terms of size, charge, solubility and structure and 
successful protein separation depends greatly on sample preparation and processing, which 
have to be adapted to the aim of the experiment and its target analytes. 
The main sources of variation in proteomic experiments occur during the pre-
analytical stage and account for over 90% of the total experimental errors. In addition, 
hundreds, if not thousands of samples, are needed for biomarker discovery experiments in 
clinical populations. For these reasons and in order to standardize the analytical process prior 
to deciding which techniques to use for the experimental design, it is paramount to consider: 
1. The clinical population under study and the biological variation due to gender, ethnicity, 
age, lifestyle and medication, among others, that surrounds the diseased subjects and its 
appropriately matched control sample. Exhaustive phenotypic data should be collected to 
fully characterize the population which the sample is derived from. This should include as 
many clinical and demographic variables as it is feasible to collect, as the existence of 
unknown molecular sub-phenotypes underlying similar clinical presentations is highly likely 
to exist in psychiatric populations. 
2. The origin of the sample. This will mainly be biopsy, bodily fluids or post-mortem tissue. 
3. The collection of the sample. In the case of blood-based experiments, a different subset of 
proteins will be obtained according to whether EDTA or citrate coated tubes have been 
used. 
4. The period of time elapsed between sample collection and processing, including the length 
and the temperature in which the sample was kept. 
5. The processing of the sample, including centrifugation speed, time and temperature; 
volume and composition (plasma, serum, RBC, WBC pellet) of aliquots (if body fluids) and 
homogenization (if solid tissue) or cell culture protocols followed. 
6. The storage of the sample with regards to temperature in which the sample is to be kept (-
80°C for best preservation) and number of freeze-thaw cycles. 
7. The amount of sample needed to conduct the experiments. 
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8. Other sample dependent aspects, such as enrichment or depletion strategies. In novel 
disease-related biomarker discovery techniques in body fluids, for low-abundance 
proteins, it is reasonable to consider depletion of highly abundant proteins such as 
albumin or immunoglobulins when the target protein is not-known. Depleted samples are 
less intricate in terms of composition and may offer an advantage for traditional 
separation proteomic techniques such as 2DPAGE. The main disadvantages of depletion is 
that potential targets can be depleted inadvertently and that, since 90% of the protein 
content in plasma can be attributed to the nine most abundant human serum proteins 
(albumin, IgG, haptoglobin, transferring, transthyretin, α1-antitrypsin, α1-acid glycoprotein, 
hemopexin and α2-macroglobulin) (Righetti et al.  2005), depleted plasma samples could 
easily fall below the levels of detection of current proteomic separation technologies. 
Enrichment strategies, such as subcellular fractionation, are not as common as the target 
protein should be known a priori, although they are of tremendous importance to 
elucidate the molecular basis of biological processes. 
c. Discovery phase 
This is a hypothesis-generating exercise which main aim is to examine the proteome as 
comprehensibly as possible in order to identify protein expression changes within the diseased 
(or treated) and the control groups. This is a particularly challenging effort since protein 
expression encompasses 10 to 12 orders of magnitude in bodily fluids, which makes the task of 
examining the proteome using a single technique an impractical task.  
Non-biased techniques such as two-dimensional gel electrophoresis and liquid 
chromatography are usually employed at this stage. The ideal outcome is to identify a limited 
number of potential candidates that are subsequently identified by employing MS-based 
techniques. 
d. Validation 
In the validation stage, the potential targets (analytes) need to be successfully identified in an 
independent sample using an alternative method of detection. The validation stage is no 
longer a hypothesis-generating step, but a hypothesis-testing one in which the search for 
analytes is guided and specific.  
This step involves the use of pre-existing antibodies and fluorescent probes targeted 
against epitopes of the analytes of interest. Antibody-based assays such as Western blot and 
ELISA are the preferred methods as hundreds of samples can be tested in a relatively short 
period of time. 
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Validation has to be performed at least in duplicate and is difficult due to several 
factors: 
1. Clinical sample factors: Finding an independent sample in which to replicate the findings is 
difficult as inclusion and exclusion criteria may vary between studies and different 
populations might be exposed to differential environmental agents that alter protein 
expression. A priori power calculations need to be performed to determine the number of 
cases and controls required for validation. In addition, larger samples are needed for 
validation (a few hundreds) than for discovery and thus, the matching between cases and 
controls for potential factors altering gene expression, such as age, gender, ethnicity, 
smoking status, alcohol use, lifestyle and diet are less likely to be as well matched. 
2. Biological sample processing, storage and preparation; In the case of blood-based 
biomarkers, factors such as the needle gauge used in venipuncture, the additives in the 
collecting tubes (i.e. citrate, ethylenediaminetetraacetic acid (EDTA)), the time between 
collection and processing and the temperature in which the tube is kept while transporting 
the sample from the place of extraction to the processing lab, the speed and time of 
centrifugation to obtain plasma or serum from whole blood, the storage temperature 
(ideally -80˚C) and the number of freeze-thaw cycles affect the activity of the proteases 
contained and samples are found in different stages of protein degradation. 
3. Assay factors: Specific antibodies have to be found commercially for the analyte under 
study. The selected antibody has to be able to recognize an epitope presented by the 
protein tertiary structure. 
e. Core proteomic techniques 
1. Two-dimensional polyacrylamide gel electrophoresis (2DPAGE) 
Unbiased techniques are those used to search for potential changes in any protein present in 
the sample. Perhaps the best established is 2-dimensional gel electrophoresis (2DPAGE) 
(O'Farrell, 1975; Righetti et al.  2005) coupled with mass spectrometry (MS). 2DPAGE separates 
proteins by isoelectric charge and molecular weight, and is capable of separating different 
isoforms and post-translational modifications of the same protein. A variant of this technique 
is the 2-dimensional differential gel electrophoresis (DIGE), in which two or three differentially 
pre-labelled samples are run in the same gel (Shaw et al.  2003; Tonge et al.  2001; Van den 




2. Liquid chromatography (LC) 
LC is a complementary approach to gel-based proteomic techniques. In High –Performance (or 
Pressure) Liquid Chromatography (HPLC) a pump, instead of gravity alone, is commonly used 
to move the liquid analyte or mobile phase through a column containing particles called the 
stationary phase which slows down the progress of the solution using specific chemical or 
physical interactions. 
The retention time is the time that it takes for a given mobile phase to elute (pass 
through a specific stationary phase) and it is considered to be a unique identifier of the 
sample. Thus protein separation can be obtained according to charge, using Ion Exchange 
Chromatography (IEX); according to size by employing gel filtration columns; according to 
hydrophobicity, using Reversed Phase Chromatography (RPC); and biorecognition through the 
use of Affinity Chromatography (AC).  
IEX is the first choice as it can be used with any sample regardless of its amount and 
concentration and can be performed under native or denatured conditions. Gel filtration is the 
easiest LC to perform but can only be used with low volumes and has low resolution due to its 
diluting rather than concentrating nature.  
RPC is capable, on the other hand, of concentrating diluted samples and can also be 
used to purify samples from salts and urea in a step prior to separation, which makes it an 
ideal choice for samples with high concentrations of salts or other additives. AC relies on the 
use of commercial and self-made ligands to specifically remove and isolate the target analyte 
(usually a protein considered not to be of interest or too abundant). 
3. Matrix-Assisted Laser Desorption/Ionisation (MALDI) 
Following 2DGE, MS is used to determine protein identity of spots that differ between 
samples. The spot is subjected to in-gel enzymatic digestion and protein fragments are 
separated according to their mass-to-charge ratios (m/z). This is achieved by ionising the 
digested analyte molecules using Matrix-Assisted Laser Desorption/Ionisation (MALDI) (Hortin, 
2006) or Electrospray Ionisation (ESI) (Cech and Enke, 2001; Fenn et al.  1989). The resulting 
gas-phase ions are detected using a mass analyser and the output of detected masses (called a 
peptide mass fingerprint) (Thiede et al.  2005) is compared to a database to determine the 
protein or peptide identity (Palagi et al.  2006).  
Primary structure of the peptide can be determined using Mass Selection/Mass 
Separation (MS/MS) or tandem MS whereby a narrow m/z range is set on the mass 
spectrometer to enable selection of specific ions (Shevchenko et al.  1996). These ions are then 




4. Quadrupole Time-of-Flight (Q-ToF) mass spectrometry 
These instruments combine a mass-filtering quadrupole analyser and a collision cell with a 
non-scanning reflector ToF analyser, allowing the user to acquire MS/MS data with high mass 
accuracy, resolution and sensitivity. This instrument is usually coupled with HPLC and has 
become the instrument of choice for proteomics since its initial application for oligosaccharide 
analysis (Morris et al.  1996). 
5. Surface-enhanced laser desorption/ionisation (SELDI) mass spectrometry 
Another approach to separation that does not rely on gels, uses solid phase matrices to ‘hold’ 
analytes from within a complex mixture prior to MS. Surface-enhanced laser 
desorption/ionisation (SELDI) (Kiehntopf et al.  2007; von et al.  2001; Yip and Lomas, 2002) is a 
modification of MALDI whereby an additional step is introduced to retain proteins according to 
their biochemical properties (i.e. strong cationic, strong anionic, reverse phase, hydrophobic, 
metal affinity).  
Retained proteins then undergo MALDI-MS and spectra from different samples are 
compared to determine their differences. This, unlike many of the approaches above, is a true 
high throughput approach but the output is a trace rather than a set of proteins. This trace 
may itself be a biomarker and different in controls and patients but it is difficult to see how 
this could be used in clinical practice and so most SELDI experimenters go on to identify the 
proteins and peptides resulting in trace differences between cases and controls. 
6. Separation and identification: Gel-free approaches 
Gel free mass spectrometry is increasingly applicable to biomarker studies for either 
hypothesis-driven discovery or validation stages. One approach is to label samples from 
different sets – patients and controls for example. Isotope-Coded Affinity Tag (ICAT) (Gygi et al.  
1999), isobaric tags for relative and absolute quantification (iTRAQ) (Ross et al.  2004), Tandem 
Mass Tags (TMT) (Thompson et al.  2003a) and other reagents have been developed to label 
peptides in such samples.  
ICAT isotopic heavy or light reagent labels the side chains of cysteinyl residues in 
reduced protein samples, whereas iTRAQ and TMT reagents chemically tag the N-terminal of 
peptides. Samples are then mixed together and analysed by MS; the ratio of the signal 
intensities of the tags is a reliable measure of the relative protein expressions in the original 
samples. Use of labelled internal standards enables quantitative data to be obtained. 
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Hydrophobic proteins are better represented using these gel-free approaches compared to 
2DGE. 
7. Western blots and ELISA 
The Western blot is a technique used to identify proteins in complex mixtures such as tissue 
homogenates or body fluids. The sample is treated to denature the proteins contained and 
these are subsequently separated using 1-Dimensional gel electrophoresis (there is no 
separation based on isoelectric focusing). The proteins are transferred to a nitrocellulose 
membrane where they are incubated with a primary antibody targeted towards and epitope of 
the target protein. Following a period of incubation with this antibody, a secondary antibody 
against it and containing a fluorescent probe is added to the sample. The membrane is 
scanned and the protein levels are evaluated using densitometry or spectrophotometry.  
Enzyme-linked immunoabsorbent assay (ELISA) uses 96-well microtiter plates with 
standardized and specific commercial antibodies in order to reduce experimental error, 
increase throughput and obtain semi-quantitative results using a standard curve.  
8. Protein microarrays 
Protein microarrays have evolved from the Western blot and ELISA techniques (also called 
“macroarrays”) following the incorporation of the basic technology advancements developed 
for genomics and transcriptomics studies. Microarrays use smaller sample volumes and allow 
for the characterisation of several biological events simultaneously with good reproducibility, 
high sensitivity and accuracy.  
This multiplex approach enables the study of protein-protein interactions, the 
detection and quantification of substrates and products of enzymatic reactions, and the 
identification of transcription factors for protein activation, amongst others. The carrier is 
usually a bead or piece of glass or silicon containing capture molecules which are usually 
antibodies targeting the specific analyte(s) of interest from cell lysates solutions or biological 
fluids such as plasma, serum or CSF. Other capture molecules used in recent years are nucleic 
acids, receptor, enzymes and proteins or antigens that can be used as capture molecules when 
the targets are specific antibodies.  
Label-based assays use specific tags against the target analyte to allow simultaneous 
detection following capture with immobilized antibodies although there is a risk of the tag 




Sandwich assays use immobilized antibodies to capture unlabeled proteins that are 
detected following incubation with another antibody, and can have higher specificity and 
detection sensitivity than label-based assays, as only one sample can be incubated at a time 
and employ two antibodies per analyte which dramatically reduce background interference 
signal.  
 
1.2.7. Proteomic studies in brain in schizophrenia 
A recent review of the published quantitative neuroproteomic studies of SCZ examined 11 
post-mortem proteomic investigations (Table 2), revealing that 16 (Table 3) grey matter and 8 
(Table 4) white matter proteins were differentially expressed in the same direction in two or 
more of those studies.  
Cellular assembly and organisation were particularly disrupted in both grey and white 
matter and the glycolysis-gluconeogenesis was the major signalling pathway altered in both 





Table 2. Summary of the 11 post-mortem brain proteomic investigations included in English et al. 2011.  
Brain Region Samples Findings 
PFC, BA10, gray matter 
24 SCZ, 23 bipolar disorder, 19 major 
depression, and 23 controls 
8 altered proteins, cytoskeletal and metabolism alterations 
dlPFC, BA 9, gray matter and white 
matter 
10 SCZ and 10 controls 215 altered proteins, metabolism and oxidative stress 
ACC, BA24, gray matter 10 SCZ and 10 controls 
42 altered proteins; 
metabolism, oxidative stress; cytoskeletal abnormalities 
ACC, gray matter 
15 SCZ, 15 bipolar disorder, 15 major 
depression, and 15 controls 
35 altered proteins, cytoskeletal and metabolism alterations 
dlPFC, BA 46, gray matter 17 SCZ, 20 bipolar disorder, and 20 controls 24 diagnosis biomarker peaks 
dlPFC, BA 9, gray matter 34 SCZ, 32 bipolar disorder, and 30 controls 
66 altered proteins: 18 proteins in SCZ, 55 proteins in bipolar disorder; 
metabolism and synaptic alterations 
ACC, BA 24, white matter 10 SCZ and 10 controls 32 altered proteins; metabolism, cytoskeletal, and synaptic abnormalities 
CC, genu 11 SCZ and 10 controls 
64 altered proteins; cytoskeletal, signal transduction, and metabolism 
alterations 
dlPFC, BA 9, gray matter, 
membrane microdomain fraction 
10 SCZ, 10 bipolar disorder, and 10 controls 
56 altered proteins by GeLC-MS/MS 
96 altered proteins by 2D-DIGE; 16 proteins altered by both methods; 
synaptic, cytoskeletal, and metabolism alterations 
IC, gray matter, layer 2 12 SCZ and 13 controls 
57 altered proteins; neuronal plasticity, neuritic outgrowth, cytoskeletal 
stability 
dlPFC, BA 9, white matter 35 SCZ, 33 bipolar disorder, and 35 controls 
70 altered proteins: 41 proteins in SCZ, 29 in bipolar disorder; metabolism, 






Table 3. The 16 candidate grey matter proteins altered in the same direction in two or more proteomic investigations of SCZ (English et al.  2011).  










Aldolase C, Fructose-Bisphosphate ALDOC 17cen-q12 P09972 Yes Yes Yes 
Creatine Kinase, Brain CKB 14q32 P12277 Yes  Yes 
Dynamin 1 DNM1 9q34 Q05193    
Dihydropyrimidinase-Like 2 DPYSL2 8p22-p21 Q16555 Yes  Yes 
Enolase 1 (alpha) ENO1 1p36.3–p36.2 P06733 Yes  Yes 
Enolase 2 (gamma, neuronal) ENO2 12p13 P09104 Yes  Yes 
Glial Fibrillary Acidic Protein GFAP 17q21 P14136 Yes Yes Yes 
GLU-Ammonia Ligase GLUL 1q31 P15104   Yes 
Guanine Nucleotide Binding Protein, beta 
Polypeptide 1 
GNB1 1p36.33 P62873 Yes Yes Yes 
Internexin Neuronal Intermediate Filament 
Protein, Alpha 
INA 10q24.33 Q16352 Yes Yes Yes 
N-Ethylmaleimide-Sensitive Factor NSF 17q21 P46459    
Phosphoglycerate Mutase 1 PGAM1 10q25.3 P18669  Yes Yes 
Peroxiredoxin 2 PRDX2 19p13.2 P32119 Yes Yes Yes 
Septin 3 SEPT3 22q13.2 Q9UH03    
Triosephosphate Isomerase 1 TPI1 12p13 P60174 Yes  Yes 
Ubiquitin Carboxyl-Terminal Esterase L1 UCH-L1 4p14 P09936 Yes Yes Yes 






Table 4. The 8 candidate white matter proteins altered in the same direction in two or more proteomic investigations of SCZ (English et al. 2011).  












Dihydropyrimidinase-like 2 DPYSL2 8p22-p21 Q16555 Yes  Yes 
Inositol-Monophosphatase 1 IMPA1 8q21 P29218    
Neurofilament, Light Polypeptide NEFL 8p21 P07196  Yes  
Parkinson Disease 7 PARK7 1p36.33 Q99497   Yes 
14-3-3 zeta YWHAZ 8q23.1 P63104    
L-Lactate Dehydrogenase Chain B LDHB 12p12.2 P07195   Yes 
Peroxiredoxin 2 PRDX2 19p13.2 P32119 Yes Yes Yes 
Stathmin 1 STMN1 1p36.1 P16949  Yes  
ACC = anterior cingulate cortex; BA = Brodmann's area; CC = corpus callosum; dlPFC = dorsolateral prefrontal cortex.
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1.2.8. Proteomic studies in cerebrospinal fluid in schizophrenia 
A search on proteomic studies of CSF in SCZ (using the key words ‘human’, ‘CSF’, ‘SCZ’ and 
‘protein’ in PubMed) retrieved 281 entries. The majority of the studies are performed using 
the ‘classical’ workflow of gel electrophoresis or liquid chromatography coupled to mass 
spectrometry.  
Reportedly upregulated proteins found in the CSF of patients with SCZ were found to be: 
1. Angiotensin I-converting enzyme (ACE) (1306 amino acids; 149715 Da) (Wahlbeck et al.  
1993; Wahlbeck et al.  2000). 
2. Neural cell adhesion molecule 1 (NCAM1) (858 amino acids; 94574 Da) (Poltorak et al.  
1997; Vawter et al.  2001). 
3. S100 calcium binding protein B (S100B) (92 amino acids; 10713 Da) (Rothermundt et al.  
2004; Schmitt et al.  2005). 
4. Neuron-specific enolase (ENO2) (434 amino acids; 47269 Da) (Li et al.  2006; Vermuyten et 
al.  1990). 
5. IL6 (212 amino acids; 23718 Da) (Garver et al.  2003; van Kammen et al.  1999). 
6. IL2 (153 amino acids; 17628 Da) (Licinio et al.  1993; McAllister et al.  1995).  
These proteins are mainly involved in immune response (ACE, NCAM1, S100B, Il-6 and 
Il-2) and calcium signalling (NCAM1, S100B, ENO2, Il-2), although mechanisms involved in the 
modulation of dopamine, apoptosis, cell adhesion and proliferation, axon guidance, glucose 
metabolism also appear to be affected. 
Proteins downregulated in the CSF of patients suffering from SCZ are: 
1. Neurotensin (NTS) (170 amino acids; 19795 Da) (Binder et al.  2001; Widerlov et al.  1982). 
2. Thyrotropin-releasing hormone (TRH) (242 amino acids; 27404 Da) (Banki et al.  1992; 
Sharma et al.  2001). 
3. Transthyretin (TTR) (147 amino acids; 15887 Da) (Huang et al.  2006a; Wan et al.  2006). 
4. Brain derived neurotrophic factor (BDNF) (247 amino acids; 27818 Da) (Issa et al.  2010; 
Pillai et al.  2010). 
5. Cholecystokinin (CKK) (115 amino acids; 12669 Da) (Beinfeld and Garver, 1991; Garver et 
al.  1990).  
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The pathways highlighted as being potentially altered in SCZ by these analytes are 
dopamine and glutamatergic transmission, apoptosis, insulin secretion and nervous system 
development. 
Neurotensin and cholecystokinin are brain and gastrointestinal neuropeptides which 
role in the CNS is not entirely ascertained but are thought to be involved in G-protein couple 
receptor signalling pathways and in modulation of dopaminergic and glutamatergic 
transmission in nigrostriatal and mesocorticolimbic pathways, and may have hypothermic and 
analgesic effects.  
Thyrotropin-releasing hormone and transthyretin regulate thyroid function by 
regulating the biosynthesis of TSH in the anterior pituitary gland and acting as a 
neurotransmitter/ neuromodulator in the central and peripheral nervous systems in the case 
of the former and by probably transporting thyroxin from the bloodstream to the brain in the 
case of the latter.  
Brain derived neurotrophic factor, promotes survival and differentiation of selected 
neuronal populations during development and participates in apoptosis, long term 
potentiation (LTP) and depression (LTD) and in axonal and dendritic modulation and plasticity. 
BDNF binds to Trk (tropomyosin-receptor-kinase) receptor B which is a single transmembrane 
catalytic receptor with intracellular tyrosine kinase activity and which ligand is usually 
Neurotrophin. 
Proteins found in CSF which direction of expression (either up or downregulation) had 
been replicated in SCZ in at least two independent studies along with the references for the 
studies mentioned in this section are listed and summarised in Table 5.  
Other proteins to consider as potential biomarkers for SCZ have been detected in the 
CSF of schizophrenic subjects but they have not been replicated to date. Additional evidence of 
their involvement in the pathological process of psychosis is given by evidence of their 
presence in other tissues and by their involvement in other neuropsychiatric disorders and are 
summarised in Table 6, where references are also provided.  
Downregulated analytes are: Nerve growth factor (NGF) (241 amino acids; 26959 Da). 
NGF regulates sympathetic and sensory nervous systems and is involved in apoptosis, memory, 
inflammatory response and nerve growth. NGF binds to the receptor TrkA and participates in 
anti-apoptotic neuronal mechanisms and NT synthesis; glycogen synthase kinase 3 beta (GSK-
3β ) (420 amino acids; 46744 Da). GSK-3β  is part of the Wnt signalling pathway and regulates 
glycogen synthase. Its activity is regulated by phosphorylation (Akt, protein kinase (PK) A, PKC, 
ribosomal S6 kinase (RSK) and ribosomal protein S6-p70-protein kinase (S6K) and 
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dephosphorylation (protein phosphatase (PP) 1 and 2A) and by binding to protein complexes 
(with beta catenin). It is thought to be involved in synaptic plasticity via regulation of the 
NMDA receptor trafficking; orexin A (hypocretin-1) (HCRT) (131 amino acids; 13363 Da) is a 
neuropeptide thought to influence food intake and regulate the sleep-wake cycle through 
hypothalamic G-protein-couple receptors (orexin/hcrt-1 hypocretin receptors, OX1 and OX2); 
and chromogranin A (parathyroid secretory protein 1) (CHGA) (457 amino acids; 50688 Da), a 
pancreastatin which inhibits glucose induced insulin release from the pancreas. 
Upregulated proteins are: neurosecretory protein VGF (VGF) (615 amino acids; 67258 
Da) which is upregulated by nerve growth factor and may be involved in regulation of cell-cell 
interactions during brain development; and the synaptosomal associated protein 25 (SNAP 25) 
(206 amino acids; 23315 Da) which has a role in synaptic transmission and regulation of insulin 
and glutamate secretion. Both analytes seem to be upregulated in CSF in a pilot study and a 
replication by the same authors (Huang et al.  2006a; Huang et al.  2007). High throughput 
proteomic techniques have been used to examine CSF (SELDI-TOF),  liver (2D-DIGE), red blood 
cells (2D-DIGE) and serum (ELISA) in independent cohorts of patients with SCZ (Huang et al.  
2008) consistently showing decreased levels of apolipoprotein A1. 
Other candidates that are detectable but which expression can not be clearly 
determined in CSF are Neurogranin (NRGN) (8 amino acids; 7618 Da), which binds to 
calmodulin in the absence of calcium and exert its action during synaptic development as a 
third messenger substrate for PKC; Ras-related protein (RAB3) (220 amino acids; 24984 Da), 
which is involved in exocytosis and NT release; growth-associated protein 43 (Neuromodulin) 
(GAP43) (238 amino acids; 24803 Da), highly expressed in neuronal growth cones during 
axonal regeneration and growth and synaptotagmin (SYT1) (422 amino acids; 47573 Da) a 
membrane protein serving as Ca(2+) sensors for vesicular trafficking and exocytosis and NT 
release at synapses. The former three are downregulated in the brain of schizophrenic patients 












CSF in SCZ 
Detected in CSF in other 
neuropsychiatric 
disorders 
Main Cell processes involved 





CSF (↑ in chronic patients) 
(Wahlbeck et al.  1993) 
(Wahlbeck et al.  2000) 
Parkinson’s CSF (↓) 
(Zubenko et al.  1985) 
Alzheimer’s CSF (↓) 
(Zubenko et al.  1985) 
(Miners et al.  2009) 
 
Regulation of vasoconstriction/vasodilatation, hormone catabolic process, 
mononuclear cell proliferation, modulation of dopamine turn-over in brain 






(Poltorak et al.  1997) 
(Vawter et al.  2001) 
Parkinson’s CSF (↑) 
(Yin et al.  2009) 
Alzheimer’s CSF (↑) 
(Yin et al.  2009) 
 
Axonogenesis and axon guidance, cell adhesion, cytokine-mediated 
signalling pathway, positive regulation of calcium-mediated signalling 






(Rothermundt et al.  2004) 
(Schmitt et al.  2005) 
 
Alzheimer’s CSF (↑) 













(Vermuyten et al.  1990) 
(Li et al.  2006) 
Alzheimer’s CSF (↓) 
(Cutler et al.  1986) 
 








(van Kammen et al.  1999) 
(Garver et al.  2003) 
Parkinson’s CSF (↑) 
(Muller et al.  1998) 
Acute phase immune response, bone remodelling, cell redox homeostasis, 









(Licinio et al.  1993) 
(McAllister et al.  1995) 
 
Parkinson’s CSF (↑) 
(Mogi et al.  1996) 
 
T cell differentiation, anti-apoptosis, cell adhesion, elevation of cytosolic 
calcium ion concentration, negative regulation of: heart contraction, 
inflammatory response, lymphocyte proliferation, protein 
phosphorylation; positive regulation of: cell growth and proliferation, 













CSF in SCZ 
Detected in CSF in other 
neuropsychiatric disorders 







(Widerlov et al.  1982) 
(Binder et al.  2001) 
 
 Regulation of blood vessel size, signal transduction, modulates 
dopaminergic transmission and enhances GLU exotoxicity 





(Banki et al.  1992) 
(Sharma et al.  2001) 
 
Depression CSF (↑) 
(Banki et al.  1988) 
Alzheimer’s CSF (↑) 
(Pekary et al.  1991) 
 
Negative regulation of GLU secretion, positive regulation of insulin 
secretion, response to ethanol, corticosterone and glucose 







(Huang et al.  2006a) 
(Wan et al.  2006) 
 
Parkinson’s CSF (↓) 
(Abram et al.  1990) 
 
Intra/extra cellular transport, hormone binding 






(Pillai et al.  2010) 
(Issa et al.  2010) 
Parkinson’s CSF (↑) 
(Salehi and Mashayekhi, 
2009) 
Alzheimer’s CSF (↓) 
(Li et al.  2009) 
 







(Garver et al.  1990) 
(Beinfeld and Garver, 1991) 
Bipolar Disorder CSF (↓) 
(Verbanck et al.  1984) 
Activation of PKC activity by G-protein couple receptor protein 
signalling pathway, axonogenesis, negative regulation of appetite, 
neuron migration, positive regulation of apoptosis, cell 
proliferation and mitochondrial depolarization, regulation of 
sensory perception of pain, release of cytochrome c from 













SCZ Bipolar Disorder Parkinson’s disease Alzheimer’s disease Main Cell processes involved 






(Kale et al.  2009) 
Serum (↓) 
(Xiong et al.  2010) 
Plasma (↓) 
(Barbosa et al.  2010) 
 
Serum (↓) 
(Lorigados et al.  2002) 
Hippocampus and CSF (↑) 
(Hock et al.  2000a; Hock et al.  
2000b; Mashayekhi and 
Salehin, 2006) 
Apoptosis, inflammatory response, 
activation of phospholipase C, 
axonogenesis, response to electrical 
stimulus and to glucocorticoid stimulus 
Glycogen synthase 






(Kozlovsky et al.  2004) 
Prefrontal cortex (↓) 
(Kozlovsky et al.  2000) 
No evidence 
(Lesort et al.  1999) 
But Li inhibits GSK-3β  
(Hong et al.  1997) 
Substantia nigra and 
upper pons (↑) 
(Nagao and Hayashi, 
2009) 
 
Associated with Tau 
phosphorylation 
(Ferrer et al.  2005; Hanger et 
al.  1992) 
Axon guidance, canonical Wnt receptor 
signalling pathway, hippocampus and 
superior temporal gyrus development, 










(Dalal et al.  2003) 
Genetic association 
(Fukunaka et al.  2007) 
No evidence 
(Schmidt et al.  2010) 
Brain (↓) 
(Thannickal et al.  2007) 
CSF (↓) 
(Drouot et al.  2003) 
Possibly 
(Kang et al.  2009) 
Activation of phospholipase C, elevation 
of cytosolic calcium concentration, 
negative regulation of DNA replicatio, 











(Landen et al.  1999) 
Brain (↓) 
(Iwazaki et al.  2004) 
Serum (↑) 
(Guest et al.  2010) 
Genetic association 
(Takahashi et al.  2006) 
No studies CSF (↓) 
(O'Connor et al.  1993) 
Brain  (↑) 
(Weiler et al.  1990) 
CSF (↓) 
(Blennow et al.  1995) 
Regulation of blood pressure, apoptosis, 
inhibition of dopamine release, calcium-







Detectable in CSF 
(Davidsson et al.  1999) 
Brain (↓) 
(Broadbelt et al.  2006) 
Genetic association 
(Ruano et al.  2008; Stefansson 
et al.  2009) 
Animal models of mania: 
(↑) in amphetamine treated 
animals and (↓) by chronic 
Li treatment 
(Szabo et al.  2009) 
No studies Brain (↓) 
(Davidsson and Blennow, 1998; 
Reddy et al.  2005) 
CSF (↑) 
(Thorsell et al.  2010) 

















SCZ Bipolar Disorder Parkinson’s disease Alzheimer’s disease Main Cell processes involved 





Detectable in CSF 
(Davidsson et al.  1999) 
Brain (↓) 




(Gitler et al.  2008) 
 
Brain (↓) 
(Blennow et al.  1996; 
Davidsson et al.  2001) 
Axonogenesis, GLU secretion, 
mitochondrion organization, sensory 









(Huang et al.  2006a) 
CSF (VGF23-62 ↑) 
(Huang et al.  2007) 
Hippocampus and prefrontal 
cortex ( VGF ↓) 
(Thakker-Varia et al.  2010) 
Cortex (VGF ↓) 
(Cocco et al.  2010) 
Cortex (VGF ↓) 
(Cocco et al.  2010) 







Detectable in CSF 
(Davidsson et al.  1999) 
Brain (↑) 
(Sokolov et al.  2000) 
No studies Yes (?) 
(Glavan et al.  2009) 
Yes (?) 
(Glavan et al.  2009) 
Synaptic transmission, detection of 
calcium ion, regulation of Ca-dependent 










Detectable in CSF 
(Davidsson et al.  1999) 
Brain (↑) 
(Blennow et al.  1999; Sower et 
al.  1995) 
Brain (↓) 
(Eastwood and Harrison, 1998; 
Tian et al.  2007; Webster et al.  
2001; Weickert et al.  2001) 
Brain (↓) 
(Eastwood and Harrison, 
2001; Tian et al.  2007) 
CSF (↓) 
(Sjogren et al.  2000) 
 
CSF (↓) 




(Sjogren et al.  2000) 
Brain (↓) 
(Callahan et al.  1994) 
Genetic polymorphism 
(Poduslo, 1993) 
Glial derived S100B inhibits PKC 
phosphorylation of neuron-specific GAP-
43 (Sheu et al.  1994), activation of PKC 
activity by G-Protein coupled receptor 
protein signalling pathway, cell 
differentiation, nervous system 
development 
Synaptosomal 







(Thompson et al.  1999) 
CSF (↑) 
(Thompson et al.  2003b) 
Parietal Cortex (↑) 
(Gray et al.  2010) 
No human studies Cortex (↑) 
(Dessi et al.  1997) 
Cortex (↓) 
(Greber et al.  1999) 
Axonogenesis, calcium ion-dependent 
exocytosis of neurotransmitter, growth 
hormone secretion, regulation of insulin 
secretion, synaptic transmission 
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1.2.9. Proteomic studies in urine in schizophrenia 
Urine is easily accessible and is a cell free and relatively simple tissue, something that can be 
both an advantage and a limitation. In addition, urine volume, composition and pH differ 
greatly in healthy individuals depending on diet, fluid intake, circadian rhythm, first-void versus 
midstream samples and exercise, making patent the need for standardised protocol for sample 
collection and processing prior to proteomic analysis. An international effort in setting these 
can be found in The Human Kidney and Urine Proteome Project website (www.hkupp.org). 
Several proteins not necessarily related to renal diseases can be detected and are 
currently used in the clinical setting. This is the case for albumin in cardiovascular disease and 
β-human chorionic gonadotropin in pregnancy.  
Biomarker discovery in urine involves collection of urine in sterile recipients, 
centrifugation, protein fractionation (Pieper et al.  2004) and protein separation and 
identification of candidate proteins using 2D-PAGE coupled with MS; or using MS/MS or SELDI 
(Barratt and Topham, 2007). 
In SCZ, urine has been examined for potential markers of the disorder since the early 
1950s (Morgan and Pilgrim, 1952) with little or no success. Urinary products identified include 
amino acids (McGeer et al.  1956), immunoglobulins , glycoproteins, the ‘pink spot’ (Bourdillon 
et al.  1965; Siegel and Tefft, 1971; Stabenau et al.  1970) and hormones (Lovegrove et al.  
1965) and more recently, capillary electrophoresis coupled to mass spectrometry (CE-MS) has 
been used to examine the composition of urine and CSF (Wittke et al.  2005). To date, no 
conclusive biomarker of SCZ has been found in urine. 
 
1.2.10. Proteomic studies in plasma in schizophrenia 
For human studies, plasma is preferred to serum as changes to the proteome occur in vitro 
during the process of coagulation (Omenn et al.  2005). Sample preparation includes sample 
capture, transportation, storage and handling and is dependent on the aim of the experiment, 
techniques used and type of sample under study. Blood should be collected by trained 
phlebotomists using a 25G or a 23G needle to avoid mechanical cell lyses in EDTA coated tubes 
since EDTA is a more effective calcium chelator than citrate. Tubes are usually centrifuged as 
soon as possible at 3000 rpm for 8 minutes at 4°C to stabilize labile biomarkers and plasma is 
aliquoted and immediately frozen in liquid nitrogen or at -80°C. Repeated thaw-freeze cycles 
should be avoided and whenever possible, platelet depletion will be preferred to prevent the 
release of proteins by activated platelets. Protease inhibitors cocktails may interfere with 
subsequent MS experiments on the sample and their use is not routinely advised. 
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The analysis of the human proteome poses several challenges. The first one is its large 
dynamic range. In plasma, the concentration of the most abundant protein is 15 orders of 
magnitude more than that of least abundant proteins and, as we mentioned before only 10 
proteins contribute to 90% of the whole mass of plasma proteins (Righetti et al.  2005).  
A number of approaches to this problem have been adopted, none entirely 
satisfactory. One approach is to deplete the sample of the most abundant proteins such as 
albumin and immunoglobulins in blood for example (Pieper et al.  2003), but this risks 
indiscriminate depletion of proteins of interest as those most abundant proteins tend to be 
scaffold or carrier proteins, as well as rendering the sample concentration of protein too small. 
This low concentration will require the use of larger sample volumes which may not be 
possible due to limited availability of sample or to the limitations of the technique to 
accommodate it. Another approach is to fractionate the sample and to look at intracellular, 
extracellular, nuclear or mitochondrial content specifically. This works well also but with the 
drawback that the analytical challenge is multiplied by the number of fractions drawn and that 
fractioning may imply a loss of sample. 
Recent evidence suggests that the study of blood cells such as circulating lymphocytes 
might offer a suitable alternative to studying brain metabolism in neuropsychiatric disorders 
such as depression, stress, Alzheimer’s disease (AD) and SCZ (Gladkevich et al.  2004) . 2DGE-
MS was successfully used by Prabakaran and colleagues on liver and red blood cells to identify 
protein alterations related to oxidative stress in SCZ (Prabakaran et al.  2007) and a series of 
studies have identified gene expression changes in circulating blood cells that differentiate SCZ 
from controls (Middleton et al.  2005). 
Thus, a bibliographic search was conducted using the terms ‘plasma’, ‘SCZ’ and 
‘protein’ and 1194 papers were obtained. The earliest papers were by Man et al., published in 
1947 and describing variations in plasma aminoacids and nitrogen during exacerbations of the 
disorder and periods of recovery (Man et al.  1947b) as well as following prefrontal lobotomy 
(Man et al.  1947a).  
The search was narrowed down by using the following terms: ‘blood’, 
‘electrophoresis’, ‘SCZ’ and ‘protein’ and 139 papers were retrieved and those form 1975, the 
year in which 2DPAGE was established as a proteomic technique were studied (88 in total). 
Papers reporting discovery in cell lines (lymphoblastoid, red blood cells and platelets) were 
also included. 
Proteins identified as upregulated in serum according to one study only are: 
1. Alpha-2 globulin and beta-globulin (Varma and Hoshino, 1980).  
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2. IgG heavy chain (50 kD prolactin binding protein) (Walker et al.  1992). 
3. 60 kDa Human Heat-Shock Protein (HSP) that is the P1 mitochondrial protein (Kilidireas et 
al.  1992). 
4. Retroviral protein (HERV)(ERV9) (Huang et al.  2006b). 
5. Chromogranin A (parathyroid secretory protein 1) (CHGA) was also upregulated in serum 
(Guest et al.  2010). 
6. Neuron-specific enolase (gamma enolase, enolase 2) was found to be increased in serum 
of patients with SCZ (Medina-Hernandez et al.  2007) and it was found to be decreased in 
the plasma of people with bipolar disorder in another study (Machado-Vieira et al.  2007). 
The following have been found upregulated in plasma in one study: 
1. Reelin was found in plasma of patients with SCZ, depression and bipolar disorder (Fatemi 
et al.  2001). 
2. α1-antitrypsin, serum amyloid P-component, α1-microglobulin, antithrombin III and 
vitamin D binding protein (Wan et al.  2007). 
Whereas the following were found downregulated in the plasma of patients with SCZ: 
1. Haptoglobin beta chain, α1-antitrypsin, complement factor B precursor, apolipoprotein A-
IV, and apolipoprotein A-I (Yang et al.  2006). 
2.  Apolipoprotein E appeared to be downregulated in the plasma of both in SCZ and bipolar 
disorder patients (Dean et al.  2008). 
The following appeared to be differentially expressed in cellular fractions:  
1. FA/GSK-3 α (activity and levels in lymphocytes were downregulated according to a study 
by Yang and colleagues in 1995 (Yang et al.  1995). 
2. H2B (histone), an acid protein from the plasma membrane of lymphocytes was found to be 
downregulated (Sourlingas et al.  2003). 
3. In a study of red blood cells, selenium binding  protein (SBP1) and glutathione-S-
transferase (GSTA3) were found to be upregulated; whereas, serum albumin (ALB), actin 
(ACTB), erythoid α spectrin (SPTA1), apolipoprotein A1 (APOA1), thioredoxin peroxidase 
(peroxiredoxin 5) (PRDX5) and heat-shock  70kDa protein-like 1 (HSPA1L) appeared to be 
downregulated (Prabakaran et al.  2007). 
4. The Fyn protein was downregulated in platelets in another study (Hattori et al.  2009). 
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Another proteins detected in plasma and for which differential expression has not 
been found are creatin kinase BB isoenzyme (Lerner and Friedhoff, 1980); Platelet MAO (Yu et 
al.  1982) or erythrocyte membrane proteins (Fritze et al.  1988). 
Proteins for which two or more studies have been conducted and the changes in their 
expression are concordant are shown in Table 7 and a summary of those proteins for which 
expression has been found to be concordantly differentially expressed in at least two different 
tissues (plasma, CSF, brain or white matter) is shown in Table 8.  
Most proteins identified using proteomic techniques so far have an average molecular 
weight of 39964.2558 daltons (Da), ranging from NRG (7618 Da) to ACE (149751 Da). 
 
1.2.11. Limitations of blood-based proteomic biomarkers 
Plasma is collected almost effortlessly and in large quantities from human populations and 
constitutes one of the most informative samples for assessing the state of health of the 
individual. The study of human plasma using proteomic techniques has the potential of 
yielding information about all the differentiated sub-proteomes of the body, as plasma 
contains detectable quantities of combinations of proteins that are tissue-specific and 
potentially informative of disease states. The plasma proteome has been examined using 
2DPAGE coupled with LC/MS/MS for the past 30 years resulting in the identification and 
characterization of hundreds of plasma proteins, facilitating the creation of the Plasma 
Proteome Project (PPP) by the Human Proteome Organisation (HUPO) 
(http://www.hupo.org/research/hppp/). The main aim of the PPP is to stimulate large-scale 
analysis of human plasma and serum and open sharing of results so that a foundation for 
biology- and disease-driven components can be established. To date, over 1929 protein 
sequences at a false discovery rate of 1% have been identified and annotated (Farrah et al.  
2011). 
The first challenge posed by plasma is that it has a large dynamic range, exceeding 1010 
(from albumin at around 45 mg/mL to some cytokine at 1-10 pg/mL), whereas proteomic 
techniques have a narrower level of detection 104 to 106 and candidate biomarkers are likely to 
be low abundant. Highly abundant proteins (those found at concentrations higher than 
1µg/mL are involved in proteolysis, binding, transport, coagulation and immune response and 
are mostly synthesised by the liver and the intestines. 
Plasma proteins are classified as (1) “classic” proteins whose function depends on their 
presence in plasma, and (2) transient, secreted proteins which utilise plasma for transportation 
or for dilution and filtered removal effects (Anderson and Anderson, 2002; Farrah et al.  2011). 
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“Classic” proteins account for approximately 13% of the total plasma protein content and are 
well characterized and used for diagnostic purposes (i.e. C-reactive protein, serum amyloid, 
myogoglobin and ferritin amongst many others). Classic proteins are mostly secreted by the 
liver and intestines and perform their function (proteolysis, inhibition, binding, transport, 
coagulation and immune response chiefly) in the blood, where they are found at a 
concentration > 1 µg/mL (Jacobs et al.  2005). 
The second class of proteins contains the subgroup of secreted proteins (cytokines, 
receptor ligands and hormones) that utilise plasma as a vehicle for transportation and 
mediation of cellular responses, and a subgroup of intracellular proteins believed to originate 
from cellular damage or leakage. This less characterised group of proteins with low total 
concentrations ranging from µg/mL to pg/mL is probably the most interesting one for potential 
biomarker studies and the more challenging to work with. 
Direct proteomic plasma analysis, particularly for this second group of proteins, is 
extremely challenging because of the many factors surrounding intrinsic plasma proteins 
variations, sample collection, processing and storage methods, prior to protein analysis, 
detection and identification. For that reason, it is crucial to attempt optimisation of the 
process by preparing the sample prior to analysis, enriching the content of the proteins of 
interest to improve their detection and by improving current technology to allow better 
detection and more accurate identification of analytes of interest.  
The target of most proteomic studies is to identify candidate biomarkers to 
differentiate between diseased and normal states of health, or to improve prediction, 
detection, and prognosis or treatment response. These disease-related biomarkers would only 
appear in plasma during abnormal physiological states as a result of altered cellular pathways 
in the tissue of interest. Therefore, these targets will only be present in extremely low 
quantities in plasma, testing the technical range of detection of proteomic technological 
platforms. However, it is unlikely that there will be any single technology capable of covering 
the full dynamic range, at least for the foreseeable future 
A second challenge of blood-based biomarker studies is posed by the complexity of 
proteins. Proteins have different isoforms, they are secreted and metabolised in different 
ways, they may bind to other proteins to form stable complexes or to achieve a particular 
function, they bind to other molecules and substrates such as lipids, they have active and 
inactive forms, and a potentially large number of post-translational modifications. 
This level of complexity has made necessary the development of increasingly 
sophisticated bioinformatics tools and mass spectrometry techniques. Sample separation 
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techniques, which can be either gel (2D PAGE with silver or fluorescent staining) or non-gel 
(LC) based, are necessary as a first step to reduce the complexity of the sample, and a 
combination of those is likely to be needed as a first step in discovery approaches. This initial 
step inherently results in a reduced range of analytes being examined, leaving some potentially 
useful biomarkers outside the detection range of subsequent analysis.  
Different gel-staining techniques have their own limitations and although differential 
gel electrophoresis (DIGE) allows for direct case-control comparison within the same gel, silver 
staining is considered to be more sensitive. Mass spectrometry-based proteomic techniques 
(such as multiple reaction monitoring, LC/MS/MS, isobaric tagging, MALDI and SELDI) are also 
varied and their use will depend largely on the experimental design of the study. 
A ‘candidate protein approach’ by which antibodies are used detect specific analytes 
can also be helpful in hypothesis-driven experiments. The obvious limitation is the availability 
of a specific and sensitive commercial antibody but recent advances such as the Luminex 
xMAP® system has allowed multiplex assay of up to 100 proteins relatively rapidly and reliably. 
Another limitation of this approach is that its outcome either confirms or refutes the original 
hypothesis but does not generate new ones which, in a discipline as relatively new to 
proteomics such as psychiatry, may narrow discovery and prevent new hypothesis generation. 
Once a protein or a group of proteins have been found to be differentially expressed in 
disease-related states, it is necessary to validate and to replicate the finding. Validation is 
performed by using a different technique in the discovery sample, this time using a hypothesis-
led approach. The main challenge in validation is that different, albeit overlapping proteome 
are canvassed as a result of the differences in the detection ranges of the techniques used. 
Replication is usually achieved by using an independent sample to the one used in the 
discovery phase. The limitations in human based studies are obvious: no two samples are 
identical, and since protein expression is altered by environmental factors as much as by 
genetic ones, the chances of validating the target are severely reduced. The advantage is the 
high reliability of the finding if validation occurs.  
A final stage of biomarker discovery is asserting whether the potential candidate can 
be used in clinical trials as an indicator of treatment response, or have enough negative and 
predictive power  to serve as a diagnostic marker, or whether it makes for a reliable surrogate 
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   Activation of PKC activity, axonogenesis, neuron migration. 
Positive regulation of apoptosis, cell proliferation and 
mitochondrial depolarization. Regulation of sensory perception of 





Table 8. Protein candidates from SCZ Proteomic studies ordered by gene locus.  
Protein Name Symbol Gene Locus Accession Number 
Molecular 
Weight 
Plasma CSF Brain 
White 
matter 








Brain derived neurotrophic factor BDNF 11p13 P23560 27818 Y Y 
  
Neural cell adhesion molecule 1  NCAM1 11q23.1 P13591 94574 Y Y 
  








l-Lactate Dehydrogenase Chain B LDHB 12p12.2-p12.1 P07195 36638 
   
Y 
















Haptoglobin α2 chain HP 16q22.1 P00738 45205 Y 
   




















Transthyretin (Prealbumin) TTR 18q12.1 P02766 15887 Y Y 
  
Peroxiredoxin 2 PRDX2 19p13.2 P32119 21892 
  
Y Y 




Nerve Growth Factor  NGF 1p13.1 P01138 26959 Y Y 
  




Stathmin 1 STMN1 1p36.1 P16949 17303 
   
Y 
Parkinson Disease 7 PARK7 1p36.33 Q99497 19891 
   
Y 
























Cholecystokinin CKK 3p22-p21.3 P06307 12669 Y Y 
  
















Interleukin-2  IL2 4q26-q27 P60568 17628 Y Y 
  
Interleukin-6 IL6 7p21 P05231 23718 Y Y 
  




Neurofilament, Light Polypeptide NEFL 8p21 P07196 61517 
   
Y 
Dihydropyrimidinase-Like 2 DPYSL2 8p22-p21 Q16555 62294 
  
Y Y 
Inositol-Monophosphatase 1 IMPA1 8q21 P29218 30189 
   
Y 
14-3-3 zeta YWHAZ 8q23.1 P63104 27745 
   
Y 








SCZ is a clinical entity that arises as a result of abnormal brain functioning. The phenotypes 
that clinicians identify with this diagnostic category are likely to be the result of complex 
interactions between diverse, albeit probably convergent, molecular pathways and 
environmental influxes. Assuming that such a pathological process exists and can be detected, 
is unlikely to mirror the diagnostic categories or the detailed subdivisions of diagnosis in ICD-
10 or DSM-IV. The concept of SCZ is mostly helpful for conveying clinical prognosis but it is less 
so for helping explaining those symptoms in terms of the cellular or molecular processes that 
cause them.  
At the core of this disorder (or group of disorders) there may be an undetermined 
number of genes, spread throughout the genome and coding for proteins with structural or 
functional roles, which additive effect disrupt brain development and function largely by 
altering the delicate interplay existing at the core of molecular and signalling events leading to 
aberrant cytostructure and rendering neuronal transmission largely inefficient. Convergent 
evidence for linkage studies and proteomic studies in SCZ that have been conducted mainly 
using a hypothesis-free approaches are already identifying putative altered molecular 
pathways in processes such as neuronal migration and differentiation, axonogenesis, 
apoptosis, inflammatory response, mitochondrial function, calcium metabolism, glutamate 
release and NT uptake; and cellular response to glucocorticoids, insulin, hypoxia, cocaine, and 
amphetamines. 
Environmental factors such as in utero adverse events, peri-natal hypoxia, childhood 
trauma, cannabis use and adverse social events appear to modulate and in most cases 
precipitate the onset of frank psychotic symptomatology resulting in the diagnosis of SCZ. 
Once established, psychotic symptomatology is linked to wide spread abnormal 
neurotransmission and hence, alterations in dopamine signalling, along with abhorrent 
glutamatergic, gabaergic, cholinergic, noradrenergic, endocannabinoid and serotonergic 
transmission are consistently found in people with schizophrenia. In addition, post-mortem 
and neuroimaging studies report structural anomalies such as reduced overall brain weight, 
alterations of hemispheral symmetry, enlarged ventricles, thinning of grey matter, abnormal 
neuronal migration and apoptosis and alterations in synaptic connection, prunning and 
dendrite function; and functional alterations such as abnormal cerebral blood flow, metabolic 
rate for glucose, oxygen metabolism, receptor density and neurotransmitter release. These 
alterations appear to precede the onset of symptoms and, in certain patients, their 
progression leads to an end-stage state of marked cognitive deficit not too dissimilar from the 
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clinical picture seen in dementing neurodegenerative disorders, which suggest that a core 
neurodevelopmental process is furthered aggravated by a neurodegeneration component. 
Systemically, people with schizophrenia appear to have altered immunological 
responses, with blunted levels of type-1 activating cytokines and raised levels of type-2 (anti-
inflammatory) cytokines and a shift from cellular to humoral immune response which is also 
present centrally in glial cells. In addition, schizophrenia patients display deficiencies in 
energetic metabolism and mitochondrial function which have been detected peripherally and 
centrally. 
This suggests that the proteomic profile of peripheral tissues may show subtle 
differences in SCZ. These differences could be attributable to changes on the brain but also 
may suggest that SCZ is part of a heterogeneous group of ‘signalling disorders’ in which the 
brain alteration responsible for the symptoms accompanies a peripheral change that might be 
detectable.  
To date, relatively few attempts have been made to seek biomarkers in SCZ using so-
called unbiased or data-driven technologies such as proteomics. However, there are 
indications that such an approach is not only possible but also productive.  
Molecular biomarker research can be done using genomic, transcriptomic, 
metabolomic and proteomic techniques. Genomic studies have identified mostly trait markers, 
that is whether a genetic predisposition exist that confers a higher risk to developing 
psychosis, although state markers are currently being investigated using epigenetic 
approaches. Transcriptomic concerns the study of RNA transcripts and they it has been 
successfully used in examining post-mortem brain tissue and peripheral blood samples. 
Metabolomic research examines analytes such as lipids, aminoacids, nucleotides and sugars 
which are downstream from the genome, transcriptome and proteome and closely reflects cell 
activity.  
Proteomic techniques have already been applied in SCZ research using post-mortem 
brain tissue, CSF, lymphocytes, serum and plasma. The following proteins have been found in 
at least two of the former tissues: brain derived neurotrophic factor (BDNF); neural cell 
adhesion molecule 1 (NCAM1); enolase 2 (gamma, neuronal) (ENO2); transthyretin 
(Prealbumin) (TTR); peroxiredoxin 2 (PRDX2); nerve growth factor (NGF); cholecystokinin 
(CKK); interleukin-2 (IL2); interleukin-6 (IL6) and dihydropyrimidinase-like 2 (DPYSL2). 
Nonetheless, the extent to which these alterations are consequence of the disorder(s) 
that lay at the core of the symptoms, or are the reflections of environmental modulators, the 
treatment the subjects were receiving or the circumstances surrounding sample collection, 
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processing and storage, which could be of particular relevance in post-mortem studies, for 
instance, is unknown. 
In this thesis, a consistent proteomic approach following established standard 
operational protocols for collection, preparation and storage of the samples will be used to (1) 
study a molecular model of the disorder using a DISC1 knock-down human neuronal cell line; 
(2) the effects of medication on glial cells and (3) in the brain and plasma of F344 rats; and (4) 
to canvass the plasma of people with psychosis for surrogate markers of the disease.  
The discovery phase was performed in neuronal and glial cell cultures, animal brain 
tissue, and animal and human plasma using two dimensional gel electrophoresis for protein 
separation in complex samples coupled with mass spectrometry for protein identification. The 
validation phase for potential biomarkers that could help identify underlying molecular 
changes responsible for psychotic symptoms; serve as diagnostic markers, or markers for 
severity of symptoms, or to refine the clinical phenotype; to inform drug discovery and serve 
as markers of toxicity or of biological action of antipsychotic treatment was done, when 








2.1. Materials for 2DPAGE 
Material Supplier 
Acrylamide PAGE, PlusOne, 40% GE Biosciences 
Acetic acid BDH 
Agarose, low melting point Sigma 
Ammonium hydroxide Sigma 
Ammonium persulphate Sigma 
Bromophenol blue Sigma 
Citric acid Sigma 
CHAPS BDH 
DeStreak rehydration solution GE Biosciences 
Dithiothreitol Sigma 
Ethanol VWR 
Formaldehyde solution Sigma 
Glutaraldehyde solution Sigma 
Glycerol, for molecular biology, min.99% Sigma 
Glycine Sigma 
Hydrochloric acid Sigma 
Immobiline Drystrip gels, pH 3-11 NL, 18cm GE Biosciences 
IPG Buffer, 7-11 NL GE Biosciences 
IPGphor Strip Holder Cleaning Solution GE Biosciences 
Iodoacetamide, SigmaUltra Sigma 
Isopropanol Sigma 
Mineral Oil Sigma 
Napthelene sulphonic acid Sigma 
Piperazine diacrylamide (PDA), 1,4-Bis(acryloyl)piperazine, 
crosslinker for electrophoresis 
Biorad 
Resolving Buffer 4x (Protogel) National Diagnostics 
Silver nitrate VWR 
Sodium acetate, SigmaUltra, min. 99% Sigma 
Sodium dodecyl sulphate (SDS), for molecular biology, ~99% Sigma 
SDS, 20 % solution Sigma 
Sodium hydroxide Sigma 
Sodium thiosulphate pentahydrate, SigmaUltra, min. 99.5% Sigma 
Strip Holder Cleaning Solution GE Biosciences 
TEMED Sigma 
Thiourea Sigma 
TMD-8,  Sigma 
Trizma base Sigma 
Trizma base, SigmaUltra, min. 99% Sigma 
Ultrapure Acrylamide 30% (ProtoGel) National Diagnostics 
Urea, SigmaUltra Sigma 
 
Chemicals were purchased from Sigma-Aldrich Chemical Company, VWR international and GE 
Biosciences, unless otherwise stated. Ultra pure water (ddH2O) from an Elga Maxima water 




2.2. A-Z of solutions 
Acrylamide Solution  
(12 gels) 
Acrylamide/PDA solution (10%)(250 ml) 
Resolving Buffer solution (1.5M Tris-HCL pH8.8) (1x) (187.5 ml) 
Ultra pure water (300 ml) 
Sodium thiosulphate (0.08%) (3 ml) 
SDS (0.1%) (3.75 ml) 
Ammonium persulphate (0.067%) (5 ml) 
TEMED (1/1500) (500 l) 
Agarose sealing solution SDS electrophoresis buffer containing: 
0.5% agarose 
0.002% bromophenol blue 
Bradford solution 1:5 
Developing solution  0.005% citric acid 
0.15% formaldehyde 
IPG rehydration buffer 3 ml DeStreak Rehydration Solution 15 μl IPG Buffer (pH3-11 
NL) 
PBS-Tween (PBS-T)  5 tablets PBS in 1l dd H2O 
0.2% (v/v) Tween 20 
PBS-T-milk  PBS-T 
5% (w/v) dry non-fat milk (Marvel) 
Ponceau Solution 4% (v/v) glacial acetic acid 
0.7% (w/v) Ponceau S 
Ponceau 0.2 g 
Trichloroacetic acid (TCA) 5 g 
dd H2O up to 100 ml 
Resolving gel  125 mM Tris-HCl, pH 8.8 
0.1% (w/v) SDS 
10% (w/v) stock acrylamide 
0.10% (v/v) TEMED 
10 l/ml of 10% (w/v) ammonium 
SDS electrophoresis buffer
  
25 mM Tris-base 
192 mM glycine 
0.1% (w/v) SDS 
SDS equilibration buffer 50 mM Tris-HCl pH 8.8 
6 M urea 
30% (v/v) glycerol 
2% SDS 
0.002% bromophenol blue 
Sealing solution Agarose (0.5%) 
SDS electrophoresis buffer 
Silver stain solution 0.013% (w/v) silver nitrate 
10 mM HCl 
0.013% (v/v) ammonium hydroxide 
Standard lysis buffer (50ml) 9.5M Urea 
2% CHAPS 
0.8% Pharmalyte pH 3-10 (optional) 
1% DTT 
Strong fix 40 % ethanol, 
10 % glacial acetic acid 
Stop solution  5% (w/v) Tris-base 




Stacking gel  125 mM Tris-HCl, pH6.8 
0.1% (w/v) SDS 
3.75% (w/v) stock acrylamide 
0.15% (v/v) TEMED 
6 l/ml of 10% (w/v) ammonium persulphate 
Tris buffered saline (TBS) 25 mM Tris pH 8.0 
140 mM sodium chloride 
5 mM potassium chloride 
Transfer buffer 25 mM Tris, pH 8.3 
182 mM glycine 
20% (v/v) methanol 
TBS-TB  TBS-T 
5% (w/v) BSA 
Weak fix 5 % ethanol 
5 % glacial acetic acid 
Western blot Acrylamide 
Solution 
Ultrapure Acrylamide 30% (Protogel) 10 ml 
Resolving Buffer 4x (Protogel) 7.5 ml 
ddH2O 12.2 ml 
APS (10%) 300 l (Add immediately before pouring) 
TEMED 30 l (Add immediately before pouring) 
Western blot Stacking Gel Ultrapure Acrylamide 30% (Protogel) 2 ml 
Resolving Buffer 4x (Protogel) 3.75 ml 
ddH2O 9.2 ml 
APS (10%) 70 l (Add immediately before pouring) 
TEMED 15 l (Add immediately before pouring) 
Wet Transfer Buffer 25 mM TRIS (7.6 g) 
192 mM Glycine (36 g) 
20% v/v Methanol (500 ml) 
0.025% w/v SDS (3.13 ml of 20% stock) 





2.3. Sample preparation: collection, processing and 
storage 
 
2.3.1. Neuronal cell culture and treatment (Chapter 3) 
 
a. Culturing of CTXOE03 cells 
The CTXOE03 neural progenitor cell line is a karyotypically normal, conditionally immortalized 
line derived from first trimester human cortical neuroepithelium (Pollock et al.  2006) and 
obtained from ReNeuron Ltd. Cells were grown on laminin at 37°C (5% CO2) with 10ml DMEM 
F12 media per T75 flask, supplemented with human albumin serum (0.75ml, 20%),  transferrin 
(1ml, 50mg/ml), putrescine DiHCl (8.1 mg/ml), insulin (0.25 ml, 10mg/ml), progesterone (1ml, 
20μg/ml), L-glutamine (5ml, 200 nM), sodium selenite (1 ml, 20 μg/ml), bFGF (0.5 ml, 10 
μg/ml), EGF (1 ml, 10 μg/ml), and 100nM 4-OHT.  
 
b. RNAi Transfection of CTXOE03 cells  
RNAi transfection was carried out using the NTER system (Sigma). Transfection of cortical cells 
was carried out twice: 24 hours after seeding and again 72 hours later. There were 4 RNAi 
conditions - ‘Control RNAi’, ‘RNAi1’, ‘RNAi2’ and ‘No RNAi’ – with six T75 flasks in each 
condition (designated A-F). Cells in the ‘Control RNAi’ condition were transfected on each 
occasion with 10nM Stealth Negative Control Duplex (Medium GC), which is non-homologous 
for any known vertebrate transcript. Cells in the ‘RNAi1’ condition were transfected on each 
occasion with siRNA specific to DISC1 (DISC1 HSS120484 CCCUCAACUUGUCACUUAAAGAAAU; 
exon 7). Cells in the ‘RNAi2’ condition were transfected on each occasion with a second siRNA 
specific to DISC1 sequence (DISC1 HSS120484 CCCUGAGGAAGAAAGUUAACGAUAU; exon 8). 
Cells in the ‘No RNAi’ condition were not treated with any siRNA.  As an index of transfection 
efficiency, a separate T75 flask of CTXOE03 cells was transfected in the same manner as above 
but treated with BLOCK-iT Alexa Fluor Red Flourescent Oligo, in place of the respective siRNAs 
used for the other conditions. Cells were harvested six days after initial siRNA transfection. 
Cells were removed from flasks using versene and pelleted by centrifugation at 900RPM for 5 
min, with two PBS washes. From each T75 flask, half of the cells were pelleted for subsequent 






c. cDNA synthesis and qPCR 
cDNA synthesis was carried out using Superscript III (Invitrogen), following DNase treatment of 
extracted total RNA. qPCR to assess DISC1 RNA knockdown was carried out using SYBRGreen 
measurement. DISC1 primer sequence: forward primer = tgaagtcacactggcgtttc; reverse primer 
= tgcttttgctttgtttcctg. POLR3C (housekeeper) primer sequence: forward primer= 
gacgaaaccatcttcctgct; reverse primer = catccaggcacctcctttat. A Relative Standard Curve was 
generated and the dilutions given arbitrary values based on their relative concentrations. H2O 
was used as a blank. Six cDNA samples in each of three RNAi conditions (RNAi1, RNAi2, and 
Control RNAi) were assayed in duplicate. 
 
2.3.2. Rat brain tissue and plasma (Chapter 4) 
Thirty-six adult male inbred F344 rats, weighing 225-250g on arrival, were housed in cages 
with a standard 12-hour light/dark cycle at 22oC. Access to water and food consisting on a 
standard diet for rodents were provided ad libitum. Weight gain was monitored for the 14 
days of treatment duration.  
The environment including temperature, humidity, ventilation, lighting and noise was 
maintained according to standards set by the Home Office in the Code of Practice for the 
housing of animals used in scientific procedures (21/03/2005).  
Animals subjected to the same treatment (haloperidol, citalopram or control) were 
housed together in cages of four individuals each which resulted in three cages per treatment 
arm (each arm consisted of 12 animals). Animals were sacrificed in three consecutive days to 
minimise batch effects as follows: four ‘test’ animals and four controls were sacrificed on day 
one; 12 haloperidol-treated animals and 4 control animals on day two; and 12 citalopram-
treated animals and four controls on day three. 
The subcutaneous implantation of chronic continuous dosing Alzet® osmotic mini-
pumps to deliver the selected treatment was performed by Dr Natesan according to the 
procedure described by Samaha et al (Samaha et al.  2007). In brief, animals were anesthetised 
and minipumps containing vehicle (VEH; 0.5% glacial acetic acid/H2O solution), haloperidol, or 
citalopram were implanted thorough a 1.5-cm-wide incision in the animal's lower back and 
inserted between the scapulae. The dose of the antipsychotic was chosen based on D2/3 
receptor occupancy level determined in Sprague Dawley rats to ensure that clinically 
appropriate levels were achieved (Natesan et al.  2008) while the dose of citalopram was 
adjusted according to the equivalent human dose as current practice in animal studies 
(Hesketh et al.  2007). Haloperidol was administered to the equivalent of 0.5 mg/kg/day and 
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citalopram to 10 mg/Kg/day. Both agents were dissolved in the common solvent system which 
served both as vehicle and to treat the control group. 
Animal manipulations, sacrifice and relevant tissue dissections, excisions and 
extractions were performed by Dr Natesan. Animals were sacrificed by decapitation on day 14 
of treatment. Brains were removed and the striatum area was dissected, washed on 0.1% 
DEPC (diethyl pyrocarbonate), snap frozen by placing them in isopentane (methylbutane, 
C5H12) over dry-ice and subsequently stored at -80°C. Brain lysates were obtained using a 
standard lysis buffer, in which 30 g of urea were dissolved in ddH2O, making a total volume of 
50 ml. 0.5 g amberlite was added and the solution was stirred for 10 minutes before being 
filtered. Following filtration, 1 g CHAPS, 0.5 g DTT and protease inhibitors were added to 48 ml 
of the solution and it was then aliquoted into 1 ml and stored at -80°C until use. 
Brain tissue was homogenized at approximately 100mg/ml in lysis buffer using a 
manual tissue grinder. The tissue was subjected to grinding for 2 to 3 minutes with an up and 
down twist motion until all tissue was homogenised. The homogenised sample was then 
transferred to a clean microtube and spun at 15000 rpm for 20 minutes. The resulting 
precipitated tissue pellet was discarded and the supernatant was retained as the total lysate. A 
Bradford assay (Bradford, 1976) was subsequently performed to calculate the protein 
concentration for each sample. 
Truncal blood from sacrificed animals was collected in EDTA coated tubes immediately 
after decapitation using single-use sterile funnels and EDTA tubes. The tubes were placed at 
4oC for one hour and then spun at 3000 g for 8 minutes at 4oC. 
Plasma was aliquoted in 0.5 ml Eppendorf tubes and stored at -80oC until needed for 
proteomic analyses. 
 
2.3.3. Human plasma (Chapter 5) 
Samples were collected using a 23 gauge butterfly needle and vacutainer needle holder 
following standard venipuncture in the cubital region, in the area of anastomosis between the 
radial and the ulnar veins or in the braquial vein, slightly proximal to this area. To avoid 
coagulation of the sample, a 9ml K3EDTA tube (Greiner Bio-One, Cat # 455036X - EDTA tube, 
lavender lid) was used. The sample was immediately kept at +4C until being processed, with 
the time between collection and processing of the sample never exceeding two hours. The 
tube was labelled with the subject barcode with no phenotypic information given at this stage. 
The sample was then centrifuged at 3000 rcf (xg), 8 minutes at +4C and plasma was aliquoted 




2.4. Determination of protein concentration (Bradford 
assay protocol) 
Protein concentrations of plasma samples were determined according to the method of 
Bradford (Bradford, 1976) using bovine serum albumin as a standard. Bradford solution was 
made 1:5. Samples (2 l) were mixed with Bradford reagent (1 ml) and the absorbance was 
read after 20 minutes at 595 nm. 
Three tubes / vials per sample were labelled and placed in a rack. A 1/100 dilution of 
each sample was made (3 per sample). BSA standards were made up. Bradford reagent was 
diluted 1:5 with ddH2O. Diluted Bradford reagent was pipette (1 ml) into each optic cuvette 
using an automatic pipette. Into each cuvette, 10 μl standard or sample was added ( 1 x 
reference, 3 x each standard, 3 x each sample). 
Cuvettes were then vortexed to homogenise the contents and incubated for 10 
minutes to 1 hour. Samples were read using the spectrophotometer @ 595 nm.  
 
2.5. Two dimensional polyacrylamide gel 
electrophoresis (2DPAGE) 
 
2.5.1. First dimension 
Samples were defrosted on ice to minimise protein degradation and then mixed (vortex) and 
centrifuged (1 min, 13000 rpm, RT). The volume of plasma determined to contain 50 µg of 
protein (approximately 1 l) was dissolved in IPG rehydration buffer (3 ml DeStreak 
Rehydration Solution containing 15 μl IPG Buffer (pH3-11 NL)) as follows: for running 18cm 
Immobiline DryStrips, 350 μl total volume was used per strip. The sample comprised no more 
than 100 μl of the total volume and hence, Eppendorfs containing 350 μl – Xsample volume of IPG 
rehydration buffer + Xsample volume were prepared and left at room temperature for 30 min to 
allow protein denaturation, followed by a 5 min spin at 13000 rpm. 
Immobiline pH gradient (IPG) strips of 18 cm length (pH 3-11) were used to immobilise 
individual proteins according to their isoelectric point. The strips were rehydrated and focused 
using the IPGphor (Amersham Amerham biotech, UK) platform. For the rehydration phase, 
350 l of the plasma/rehydration solution were placed in each individual strip holder and 
subjected to a current of 50 A per strip for 12 h at RT. The subsequent IPG electrofocusing of 




Phase Voltage (V) Duration (h) 
Rehydration 50 μA/strip 12 
Hold 500 2 
Gradient 500-1000 2 
Hold 1000 2 
Gradient 1000-8000 2 
Hold 8000 8 
Total  28 
 
The strips were taken off the strips holders and frozen overnight at -80C prior to 
second dimension separation. The strips were taken off the freezer and thawed at RT before 
being equilibrated in order to re-solubilise the proteins and to reduce disulfide bonds (-SH-SH-). 
The strips were equilibrated gently in an orbital shaker, individually placed in cylindrical glass 
tubes containing 10 ml of SDS equilibration buffer with dithiothreitol (DTT) (2% w/v) for 15 
min. Sulphide (-SH) groups were subsequently blocked with 10ml of solution containing SDS 
equilibration buffer and 2-iodoacetamide (2.5% w/v). Dithiothreitol (DTT) is a small-
molecule redox reagent (C4H10O2S2) used to reduce the disulfide bonds of proteins and to 
prevent further intra and intermolecular disulfide bonds from forming between cysteine-
residues of proteins. Since DTT cannot reduce buried (solvent-inaccessible) disulfide bonds, it 
has to be added to a urea containing solution (SDS equilibration buffer).  
Iodoacetamide is an alkylating sulfhydryl reagent used for peptide mapping and binds 
covalently with cysteine, so the protein cannot form disulfide bonds. Iodoacetamide is highly 
toxic. 
 
2.5.2. Second dimension 
SDS-PAGE 2D acrylamide gels were made in-house using the Ettan Dalt II gel caster system 
(Amersham biotech, UK) and electrophoresis plates (1.5 mm-thick spacers). A 10% acrylamide 
solution was made immediately before use and poured into the caster. The gels were allowed 
to polymerise overnight. 
The IPG gel strips were cut to size at both ends, taking care not to alter the hydrated 
gel and inserted between the two glass sheets of each plate and gently slid down until 
reaching the upper surface of the polymerise gel where they were sealed in place using a 
solution containing agarose (0.5% w/v) dissolved in SDS electrophoresis buffer by boiling it. 
Electrophoresis was performed using the Ettan Dalt II (Amersham biotech, UK) separation 
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unit. The gels were kept at a constant current of 5 watts per gel for 1 hour then subjected to a 
current of 80 watts per gel for up to 10-12 h or until the bromophenol dye used in the sealing 
solution had completed its run across the vertical axis of the gel. The electrophoresis 
separation unit was kept at 15C. 
 
2.5.3. Protein staining and detection 
Available staining approaches include silver staining, Coomassie blue, Ponceau solution, amido 
black, India ink and radiolabelling (3H, 14C, 35S, 32,33P or 125I). The gel cassettes were unloaded 
from the caster and the gels extracted and placed in separate plastic staining boxes. Proteins 
were fixed to the gel matrix using 40% ethanol / 10% acetic acid for 1 h at room temperature 
and then left in a solution containing 5% ethanol / 5% acetic overnight. Gels were stained with 
an optimised and adapted version of the protocol described by Hochstrasser et al. 
(Hochstrasser et al.  1988). This method has been proven to have high sensitivity and reduced 
intra and inter-experiment variability. 
For preparative mass spectrometry silver staining was performed using a separate 
staining kit with slight modifications (Silver Plus one, Amerham biotech, UK) as follows: 
 Step 
Fix 40% ethanol/10% acetic acid 1 h 
Soak in 5% ethanol/5% acetic acid Overnight 
Rinse in water 5 min 
Soak in 0.5M Sodium acetate, 1% gluteraldehyde 30 min 
Rinse in water 4x15 min 
Soak in 0.05% Naphthalene sulphonic acid 2x30 min 
Rinse in water 4x15 min 
Silver stain  
For 12 gels (1.5 l): 12g silver, 750 ml ddH2O, 20ml 
ammonium hydroxide and 3ml 10M sodium hydroxide) 
25 min 
Rinse in water 4x4 min 
Develop (0.005% citric acid and 0.1% formaldehyde) As required 
Stop solution (5% tris and 2% acetic acid) 
As spots start developing and 
background begins to appear 




2.6. Gel scanning, image and statistical analysis for spot 
selection 
Gels in all experiments were scanned immediately after being developed using a Images were 
scanned using a Bio-Rad GS-710 calibrated imaging densitometer and proprietary software 
(Bio-Rad, Seoul) and acquired as 12-bit .tiff files. Images of individual gels were cropped and 
saved in .tiff format for posterior image analysis which was performed using Progenesis 
SameSpots software (Nonlinear Dynamics, UK).  Progenesis SameSpots software was selected 
on the basis that it was quicker and easier to use than MELANIE software, which had been 
successfully employed at the Lovestone lab previously. In addition, expression analysis studies 
using Progenesis SameSpots as part of the HUPO Reproducibility Study 
(http://www.fixingproteomics.org/advice/hupo_reproducibility_introduced.asp) have been 
shown to be reproducible cross-labs. 
Such analysis involved the selection of a reference image as template for the 
overlaying and alignment of all the sample images in the experiment, followed by setting up 
detection parameters, filtering of irrelevant or wrongly detected spots and statistical analysis 
of established groups for comparison using fold change values and p-value (ANOVA), q-values 
(FDR), fold change and spot quality aspects such as definition and consistency.  
Firstly, images were subjected to a process of quality control with feedback on 
intensity and saturation levels and corrective steps with in-built tools (flip, rotate, invert, and 
crop) before conducting the analysis (Figure 3).  
One image per set was selected on the basis of overall quality as the reference image 
for the group against which the remaining images were to be aligned to. The alignment was 
performed step-wise using built-in visual tools (Figure 4) (‘Whole Image’ showing the two gels 
to be aligned overlapped with their spots represented in different colours (pink for the 
reference image and green for the image to be aligned to it); ‘Vector editing’ allowing for a 
smaller area of the gel to be examined in detail and to add manual and automatic vectors 
linking the same spots in both gels; ‘Transition’ for obtaining a dynamic representation of both 
gels fading in and out and facilitating the visualization of changes in positioning that needed to 
be corrected by the use of vectors. This is performed until the only changes shown are those of 
signal intensity in a fixed spatial location with no lateral movement; ‘Checkerboard’, or a 
composite of both gels used as a proxy measure of alignment accuracy). 
An average of 50 vectors per image was added manually to known protein patterns. 
Automatic vectors were subsequently added by the software using an image recognition 
algorithm to correct the alterations the gel matrix contained and the different spatial locations 
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of proteins relative to their theoretical points of anchorage. Images were then ‘aligned’ (Figure 
5). All the identified spots underwent an analysis process that included spot detection, 
background subtraction, normalisation and matching. The resulting spots were outlined and 
could have been filtered and deleted according to average normalised volume, area or by 
manual selection (Figure 6). All the spots considered as such by the program were brought 
forward for the next stage of the image analysis. Images were grouped according to the 
experimental design set up in order to conduct the comparative analysis of expression. The 
individual images were grouped according to treatment arms (control, haloperidol, 
citalopram). Different comparisons were performed (3 groups ANOVA and 2 groups non-
parametric testing (haloperidol vs. control; citalopram vs. control and haloperidol vs. 
citalopram). 
A list of spots was presented for review (Figure 6). Spots were statistically ordered 
according to p-value from the one way ANOVA and fold change. Each spot was assigned a 
unique identifying number that was maintained throughout the experiment and on every 
analysis performed regardless of the grouping the images are subjected to. The visual aids 
displayed in this interface (i.e. expression profile, 3D and 2D montage and full image outline) 
allowed for an effective selection of potentially relevant spots (Figure 7). Spots could also be 
tagged to create sub-sets within the main analysis, using complementary data such as 
phenotypic information, for instance. Notes were also added to each spot to be included in the 
final report. 
The statistical analysis was initially performed using the built-in Progenesis Stats 
software (a statistical resource containing Principal Component Analysis (PCA), Correlation 
Analysis, Power Analysis and False Discovery Rate and Q-values) (Figure 8) and verification of 
the results obtained was subsequently conducted using SPSS v15 and v16. No missing values 
were yielded by Progenesis SameSpots and Progenesis Stats used univariate and multivariate 
statistical techniques to further interrogate this complex data in a continuous work-flow.  
Principal Component Analysis (PCA) is a statistical technique not too dissimilar to 
factor analysis used to find common variation patterns in multiple data sets. This is achieved 
by simplifying the observed variables into a smaller number of artificial variables called 
principal components. These components account for a high proportion of the variance in the 
observed variables. The underlying assumption being that some of the information yielded is 
redundant as they are purported to measure the same construct. PCA was thus performed to 
provide a simplified representation of the multidimensional data by grouping individual images 
and to identify potential outliers.  
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Correlation Analysis is another multivariate unsupervised approach that provides a 
summary of protein activity and assist in identifying features pertaining to the same biological 
processes and pathways. Power analysis is calculated based on the sample size and is useful in 
pilot studies to verify the number of replicates needed to obtain 80% statistical power. False 
Discovery Rate and Q-values give an indication of the number of the expected proportion of 

















































2.7. Protein identification (LC/MS/MS) 
Gels were stained with modified Plus One silver stain kit (Amersham, UK) to make silver 
staining compatible with MS procedures and selected spots were manually excised from 2-DGE 
preparatory gels containing 300 µg of protein.  
The spots were identified independently by the author and two experienced 
postdoctoral researchers and excised carefully using a retroillumination and a 200 or 1000 l 
pipette tip with its end cut off. The gel fragments were suspended in ddH2O and subsequently 
taken to King’s Proteomics Facility and processed by Steve Lynham.  
The gel matrix was subjected to in-gel reduction, alkylation and digestion with trypsin. 
Cysteine residues were reduced with DTT and derivatised by treatment with iodoacetamide to 
form stable carbamidomethyl derivatives. Trypsin digestion was carried out overnight at room 
temperature after initial 1 h incubation at 37C. Peptides were extracted from the gel pieces 
by a series of acetonitrile and aqueous washes. The extract was pooled with the initial 
supernatant and lyophilised. Each sample was then re-suspended in 23 l of 50 mM 
ammonium bicarbonate prior to performing peptide mass fingerprinting, in where a series of 
peptides obtained from native proteins using residue-specific enzymes have their individual 
masses measured by spectrometric techniques and then examined against theoretical peptide 
libraries, yielding a list of likely protein identifications, and analysed by liquid chromatography 
tandem mass spectrometry (LC/MS/MS). 
Chromatographic separations were performed using an Ultimate LC system (Dionex, 
UK). Peptides were resolved by reversed phase chromatography on a 75 m C18 PepMap 
column using a three-step linear gradient of 0-48% acetonitrile/0.1% formic acid over 30 
minutes at a flow rate of 200 nl/min. Peptides were ionised by electrospray ionisation using a 
Z-spray source fitted to a QTof-micro (Waters Corp.) operating under MassLynx v4.0. The 
instrument was set to run in automated switching mode, selecting precursor ions based on 
their intensity, for sequencing by collision-induced fragmentation. The MS/MS analyses were 
conducted using collision energy profiles that were chosen based on the m/z and the charge 
state of the peptide. 
The mass spectral data was processed into peak lists using ProteinLynx Global Server 
V2.2.5 with the following processing parameters: smoothing by Savitzky-Golay method, 2 
iterations, 4 channels; peak centroiding top 80%, no deisotoping or background subtraction. 
Proteins were identified by searching the peak lists against the Uniprot database (version 
Aug_2011) using Mascot software V2.2 (Matrix Science, UK). Parameter specifications for 
database searching were as follows: Precursor ion mass tolerance 1.2 Da, fragment ion mass 
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tolerance 0.6 Da, up to three missed cleavages (trypsin), variable modifications: cysteine 
carbamidomethylation, methionine oxidation and pyroglutamisation of N-terminal glutamine 
residues. Sequence information was obtained for all the peptides included in the results. 
 
2.7.1. Bioinformatics 
The mass spectral data was processed into peptide peak lists and searched against the Swiss 
Prot Database (current as of June 2005) using Mascot software (Matrix Science, UK). 
Assumptions included peptide mass tolerance of 1 Da and fragmentation tolerance of 0.5 Da, a 
maximum of two mis-cleavages and MOWSE algorithm score of 95% confidence. Where 
reported peptide matches are below 95% confidence limits, each peptide was visually verified 
before inclusion. Proteins with 3 or more peptides above the confidence limit are considered 
to be real and not a false positive. Proteins with less than 3 significant peptides were subjected 
to a search in a reverse sequence database (Swiss Prot in reverse). To add further confidence 
the peptide sequence for each protein were submitted to an NCBI protein-protein BLAST 
search to ascertain that the peptide sequence is unique to that protein. Carbamidomethylation 
and oxidation were set as variable modifications within the searching parameters.   
For the statistical analysis raw integrated optical density (IOD) spot data from each of 
the images into SPSS (v 11) and Progenesis Stat package. Normalized spot data is obtained by 
Progenesis. The OD of individual spots was normalized by the software using the background 
density as a measure of exposure and developing time. 
 
2.7.2. Identification of proteins that differentiate between 
cases and controls 
Statistical analysis was performed using SPSS (v11), and Progenesis SameSpots packages. It is 
known that biological protein expression data obtained from a 2-DGE is generally not 
distributed normally. Therefore integrated optical densities of spots on 2D gels were tested for 
normality using the Shapiro-Wilko test. Spots examined were not normally distributed 
therefore non-parametric tests (Mann-Whitney) combined with false discovery rate analysis as 
correction for multiple comparison testing was applied. The assessed mean difference 
between patients and controls was applied to each spot using Mann-Whitney. The p-values for 
the null hypothesis of no mean differences were saved sorted by increasing p value and 
ranked. By ranking the significant protein abundances it allowed the application of a further 
test False Discovery Rate (FDR). False discovery rate or FDR is a calculation of the proportion of 
false positives among all positives. This test was first introduced by Benjamini and Hochberg in 
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1995. For example if the choice of threshold is set at FDR of 0.05 (5%), one would expect, 5% 
falsely induced protein spot expression. In addition it was expected that 95% of the rejected 
protein change to be truly induced (Benjamini et al., 2001). Following this, the proteins in the 
selected spots were then identified using tandem liquid mass spectrometry (LC/MS/MS) as 
described earlier. 
   
2.8. Validation 
 
2.8.1. Serotonin ELISA in rat plasma and brain 
In order to establish that the surgical procedure had successfully delivered the antipsychotic 
and antidepressant agents, it was decided to measure serotonin levels in brain and plasma as 
both agents are known to affect serotonergic transmission. We used the Serotonin ELISA Fast 
Track (Labor Diagnostika Nord) to measure serotonin levels in plasma and the Serotonin 
Research ELISA (Labor Diagnostika Nord) to measure the levels of serotonin in brain. Plasma 
samples were stored at -80°C were thawed on ice until they reached room temperature (RT) 
prior to being used. A volume of 25 µl per sample was used in the assay. Brain samples, which 
were preserved at -80°C were thawed on ice, eluted in lysis buffer and diluted 1:10 prior to 
use. A volume of 100 µl per sample was used. 
 
2.8.2. Western blot in human plasma 
Western blot (protein immunoblot) was used to detect the specific proteins of interest in an 
independent sample of subjects. Briefly, the Western blot method is used to separate proteins 
according to molecular weight by means of gel electrophoresis. The separated proteins are 
then transferred to a membrane where they are incubated with specific antibodies. Plasma 
proteins were resolved in 10% (w/v) polyacrylamide SDS-PAGE using the Gel unit vertical 
complete for precast or handcast gels up to 200mm x 100mm (Fisherbrand, FB69602). Plasma 
was diluted at 1:50 in PBS (loading volume was 10 l per well). Gels were run at constant 
voltage (200V, 3.00 A and 300 W) with a Bio-Rad PowerPac 300 until the dye reached the 
bottom end of the gel (1-2 hours).Once protein separation occurred in the acrylamide gels, the 
proteins were transferred to 17x6 cm pieces of 0.45 µm nitrocellulose membrane (Schleicher 
& Scheull) in order to be probed with specific antibodies. A Trans-Blot Electrophoretic Transfer 
Cell (Bio-Rad) (Fig3) was used and the following sequence was assembled in the vertical 
panels: cathode (black cover) (the terminal from where the current flows out, usually the 
negative pole)/6 Whatman 3MM filter papers soaked in transfer buffer/Gel-Nitrocellulose 
membrane-6 Whatman 3MM filter papers soaked in transfer buffer/anode (transparent cover) 
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(the terminal where the current flows in from the outside, usually the positive pole). Proteins 
migrate from the gel into the nitrocellulose membrane as they are negatively charged as a 
result of the SDS. 
A current of constant voltage of 100 V was then applied for 1 hour. Following the 
transfer, the membrane was incubated with Ponceau solution for 1 min to determine the 
efficiency of the protein transfer and subsequently blocked to reduce non-specific binding by 
using a 5% non-fat milk 0.01 M PBS solution. 
Membranes were then incubated overnight at 4C in blocking buffer with the primary 
antibody at an optimized dilution for detection based on manufacturer’s protocol.  
The following morning, the membranes were washed in 0.1% PBS-Tween (3x5 min) 
and placed in a white, non-transparent box containing 10 ml of 0.1% PBS Tween + 5% milk for 
30 min at room temperature. Secondary antibodies were diluted in 5% Milk PBSTween 
solution (1:6000) in a Falcon tube protected from light with foil paper. The 0.1% PBSTween+5% 
milk of the boxes containing the membranes was replaced with the secondary AB solution and 
the boxes were placed in an orbital rocker for 1 hour at RT. The membranes were washed on 
PBSTween 3x 5 minutes and scanned using a LI-Cor Odyssey scanner and proprietary software 
was used for fluorescence detection. 
The blots were run in triplicate. Fluorencence signal intensities were individually measured (K 
counts). The average was calculated and normalised as follows: individual samples were 
performed across three gels. Mean optical density was calculated per each subject and a total 
average was calculated for the entire group (i.e. cases and controls). Subsequently, the group 
average value was used to correct the measure of the individual average mean. An 
independent samples t-test for equality of means was applied using SPSS v16.0.  
 
2.8.3. S100B ELISA 
S100B was measured using Merck/EMD Millipore’s Human S100B ELISA kit (Cat. No. 
EZHS100B-33K) designed to allow to measure levels of S100B in cerebrospinal fluid (CSF), 
serum or plasma (heparin or EDTA). This kit was validated in human samples, but the assay is 
cross-reactive in multiple species, including bovine, hamster, horse, monkey, mouse, pig, 
rabbit and rat.  
The ELISA assay was performed in a 96-well plate according to the manufacturers 
instructions supplied with Human S100B ELISA 96-well plate (Cat. #EZHS100B-33K). All plasma 
samples were used as neat as no prior dilution was required. Briefly, the plate was rinsed with 
300 µl diluted wash buffer. Subsequently, 50 µl of controls and standards were added to the 
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appropriate wells. 50 µl plasma samples were added to the appropriate wells, with 50 µl of 
assay buffer alone to the blank wells. Plate was sealed and incubated 2hr on an orbital shaker 
at room temperature (RT).  
The plate was washed 5 times with wash 300 µl buffer; 100 µl detection antibodies 
was added to all wells and incubated for 1.5 hr on an orbital shaker at RT. Again, the plate was 
washed 5 times with wash 300µl buffer; 100µl enzyme solution added and incubated for 
30min at RT on a shaker. Once more the plate was washed 5 times with wash 300µl buffer; 
100µl substrate solution was added to all wells incubated for 5-25min depending on colour 
change. The reaction was stopped with 100µl stop solution and absorbance read in a plate 
reader set at 450nM. All plasma samples were performed in duplicate. 
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CHAPTER 3: Examining the effects of DISC1 
knockdown on the proteome of human 




3.1. Rationale and aims 
It is widely accepted that SCZ is a polygenic disorder for which the underlying biological 
pathways remain at best speculative. A (1;11)(q42;q14.3) chromosomal translocation affecting 
the disrupted-in-schizophrenia-1 (DISC1) gene has been found to co-segregate with SCZ and 
other major psychiatric disorders in a large Scottish pedigree (Blackwood et al.  2001; Hennah 
et al.  2003). Linkage and association studies suggest that variation in DISC1 may also confer 
risk for psychiatric disorders in general populations (Ekelund et al.  2001; Hamshere et al.  
2005; Hennah et al.  2003; Hodgkinson et al.  2004; Macgregor et al.  2004; Schosser et al.  
2010; Schumacher et al.  2009). DISC1 is highly expressed in the cerebral cortex, hippocampus 
and amygdala (Millar et al.  2000) and has been shown to be involved in neural progenitor cell 
proliferation and differentiation, via interaction with glycogen synthase kinase 3 (GSK3) (Mao 
et al.  2009), as well as neural migration and neurite outgrowth (Duan et al.  2007; Ishizuka et 
al.  2011; Kamiya et al.  2005).  
In this study, 2DPAGE and MS was used to determine protein expression changes 
resulting from DISC1 knockdown in human cortical neural progenitor cells (CTXOE03) using 
RNA interference (RNAi). This was intended to model the haploinsufficiency of DISC1 that is 
thought to mediate the pathogenic effects of the t(1;11)(q42;q14.3) translocation (Millar et al.  
2005).  
The aim of this study was to explore, using a classical proteomic approach, the 
molecular and cell signalling pathways that may contribute to the signalling alterations that are 
thought to be responsible for the varied array of symptoms of SCZ. 
The culture, transfection and harvesting of CTXOE03 cells was done by Sinead Kinsella, 
an MSc in Neuroscience student in Dr N. Bray’s lab in the Department of Neuroscience, 
Institute of Psychiatry, who used some of these data for her dissertation.  
 
3.1.1. DISC1 
Long- term psychiatric follow up studies of this Scottish family showed that 18 of 29 carriers of 
the (1;11)(q42;q14.3) chromosomal translocation were diagnosed with a major mental illness 
(Blackwood and Muir, 2004; Chubb et al.  2008). Association studies have linked DISC1 to SCZ 
(Hennah et al.  2003) and a genomewide screen performed in an isolated Finnish population 
revealed several putative loci in four chromosomal regions (one of them was 1q32.2-q41) 
predisposing to SCZ (Hovatta et al.  1999), although  it is unlikely that common DISC1 SNP 
alleles account for a substantial proportion of the genetic risk of SCZ, according to recent study 
in a large (837 cases and 1473 controls) Scandinavian case-control sample (Saetre et al.  2008). 
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A second gene, named disrupted-in-SCZ-2 (DISC2), encoding an RNA gene antisense to DISC 1 
was also found to be affected by this translocation (Chubb et al.  2008). 
DISC1 encodes a scaffold protein with multiple coiled coil motifs which is located in the 
nucleus, cytoplasm and mitochondria and is highly expressed during brain development. This 
protein is likely to have multiple function (Brandon et al.  2009; Chubb et al.  2008) and three 
isoforms have been identified so far within molecular weight range of 70-85 kDa (James et al.  
2004). The DISC1 protein may play a role in nucleus-centrosome association, neuronal 
proliferation, differentiation and migration, hippocampal formation and cortical layering, all of 
which are affected in SCZ (Brandon et al.  2004; Millar et al.  2005). DISC1 has been shown to 
interact with a range of cytoskeletal proteins some of which, like NudeE-like (NUDEL) are 
associated with cortical development and linked to the lissencephaly gene (LIS-1), responsible 
for a rare cortical developmental disorder in which abhorrent neuronal migration in uterus 
results in lack of development of brain gyri and sulci conferring it a smooth aspect 
macroscopically (Ozeki et al.  2003). 
In addition, DISC1 appears to be a component of the microtubule-associated dynein 
motor complex and is essential for maintaining the complex at the centrosome (Kamiya et al.  
2005). As a result, depletion of DISC1 protein impairs neurite outgrowth. This cellular 
alteration leads to abhorrent cortical circuitries. It has been shown that mice displayed 
behavioural abnormalities post-puberty when DISC1 was knockdown in pyramidal neurons in 
the prefrontal cortex in utero (Niwa et al.  2010). 
DISC1 deficiency could be mediated by two different mechanisms: 1) haplo-
insufficiency, by which two functional copies of the gene are required for the normal 
expression levels of the protein; and 2) dominant-negative, by which the abnormal product 
derived from the mutant allele inhibits the wild-type product. Based on this, genetically 
engineered transgenic mice have been used to study the downstream effects of DISC1 
depletion in mammals. 
A strand of transgenic mice generated using a bacterial artificial chromosome (BAC) 
and expressing 2 copies of truncated DISC1 exhibited increased immobility and reduced 
vocalization in depression-related tests, and impairment in conditioning of latent inhibition. 
The animals had enlarged lateral ventricles, reduced cerebral cortex, partial agenesis of the 
corpus callosum, and thinning of layers II/III with reduced neural proliferation at 
midneurogenesis. In addition, parvalbumin GABAergic neurons were reduced in the 
hippocampus and medial prefrontal cortex. It was also shown that cultured transgenic neurons 
grew fewer and had shorter neurites (Shen et al.  2008). 
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Since expression of dominant-negative proteins has been frequently used in animal 
models to achieve partial loss of function for other proteins (Oike et al.  1999), in another 
animal model, a dominant-negative form of DISC1 (DN-DISC1) was expressed under the control 
of the promoter for the α-isoform of calcium/calmodulin-dependent kinase II (αCaMKII). The 
resulting transgenic mice were shown to display abnormalities consistent with findings in 
severe SCZ like enlarged lateral ventricles, particularly on the left side, selective reduction of 
parvalbumin (a marker for interneuron deficit) in the cortex, and behavioural abnormalities 
including hyperactivity, disturbance in sensorymotor gating and olfactory-associated behaviour 
and an anhedonia/depression-like deficit (Hikida et al.  2007). 
DISC1 has shown to have a role in the regulation of synapse maturation (Brandon et al.  
2009; Camargo et al.  2007) and of spine density, which had been previously reported to be 
decreased in the dorsolateral prefrontal cortex layer 3  pyramidal neurons of patients with SCZ 
(Glantz and Lewis, 2000). 
Despite all this evidence, the mechanism by which DISC1 confers its susceptibility to 
psychosis remains largely unknown. It has recently been suggested that DISC1 interacts with 
Phosphodiesterase 4B (PDE4B) and that elevation of cAMP leads to dissociation of TPDE4B 
from DISC1 and an increase in its activity, which in turn inactivates cAMP (Millar et al.  2005). 
DISC1 is involved in the Wnt receptor signaling pathway (Figure 10), which also contains DRD2 
and GSK3-β. This signalling pathway is a target for lithium and it is involved in carcinogenesis, 
neurodevelopment, and axon guidance, regulation of cytoskeleton and of intracellular calcium 
levels. Downregulation of DISC1 has been shown to lead to a decrease in the cytosolic level of 
β–catenin (Brandon et al.  2009; Mao et al.  2009) which is involved in the maintenance of 
adherens junctions in epithelial cells and in anchoring the actin cytoskeleton, transmitting the 
contact inhibition signal that causes cells to stop dividing. β–catenin is a transcription factor 
and a substrate of GSK3-β, which is a crucial node for mediating neurogenesis, neuronal 
polarization and axon growth during brain development (Hur and Zhou, 2010). 
There is evidence to suggest that through physical interaction with GSK3- β, DISC1 
prevents GSK3-β from phosphorylating β–catenin (Mao et al.  2009). The inhibition of GSK3- β-
mediated-phosphorylation of β–catenin allows β–catenin to enter the cell nucleus, interact 








In a study on patients diagnosed with Major Depressive Disorder (MDD), DISC1 
knockdown resulted in suppression of phosphorylation of ERK and Akt and reduction brain 
gray matter volume in cingulate cortex in individuals carrying it compared to Ser/Ser704 
subjects (Hashimoto et al.  2006). 
Thus, DISC1 was selected for this study with the purpose of examining the underlying 
molecular pathways mediating symptomatology in SCZ as it has provided the most pragmatic 
findings for determining etiologic mechanisms and understanding of SCZ. Discovery-phase 
experiments using two dimensional gel electrophoresis (2DPAGE) and mass spectrometry-
based proteomic analysis of plasma were performed as they had been successfully conducted 
by our group previously to study Alzheimer’s disease (Hye et al.  2006), and also more recently 
in the context of non-demented subjects (Guntert et al.  2010). 
 
3.2. Materials and methods 
 
3.2.1. Culturing of CTXOE03 cells 
All cell culture work was carried out by MS Sinéad Kinsella in Dr Nicholas Bray’s lab under the 
tissue culture hood in sterile conditions. A detailed description can be found in the Methods 
chapter.  
The CTXOE03 neural progenitor cell line were grown on laminin at 37°C with DMEM 
F12 media supplemented with human albumin serum,  transferrin, putrescine DiHCl, insulin, 
progesterone, L-glutamine, sodium selenite, bFGF, EGF, and  4-OHT. RNAi transfection was 
carried out using the NTER system (Sigma). There were 4 RNAi conditions - ‘Control RNAi’, 
‘RNAi1’, ‘RNAi2’ and ‘No RNAi’. Cells were harvested six days after initial siRNA transfection. 
RNA extraction was performed using Tri Reagent (Ambion). cDNA synthesis was carried out 
using Superscript III (Invitrogen), following DNase treatment of extracted total RNA. Analysis 
was carried out using MJ Opticon software from Bio-Rad. Average values of duplicates for 
DISC1 were divided by average of duplicate values of the POLR3C housekeeping gene for each 
cDNA sample. Expression values were compared between RNAi1 vs. Control RNAi, and RNAi2 
vs. Control RNAi using 2-tailed t-tests. 
 
3.2.2. Protein analysis 
Nanodrop (ND-1000) was used to measure protein concentration in samples. The desired 
volume, containing 50 μg of protein, was calculated for each sample from protein 
concentration measurements. Individual gels corresponded to each one of the six samples 
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(designated A-F) in each of the four RNAi conditions (RNAi1, RNAi2, Control RNAi and No 
RNAi). Twenty-four gels in total were run in 2 batches of 12 gels each to minimise 
experimental error due to the batch effect. 
The first set of gels run contained RNAi1, RNAi2, Control RNAi and No RNAi samples A-
C; and the second batch contained RNAi1, RNAi2, Control RNAi and No RNAi samples D-F. 350 
μl Rehydration buffer was added to the appropriate sample volume. Gels were run in batches 
of 12. Individual samples were dissolved in IPG rehydration buffer and 350 μl total volumes 
was loaded in 18cm Immobiline DryStrips (pH 3-11). Proteins were separated according to 
individual isoelectric point (PI) using the IPGphor (Amersham Bioscience) platform and 
subsequently equilibrated with dithiothreitol (DTT) and 2-Iodoacetamide 
The second dimension (separation of proteins by size) was performed using SDS-PAGE 
2D acrylamide gels on an electrophoresis Ettan Dalt II (Amersham Biosciences) separation 
unit. Proteins were fixed to the gel matrix and stained with an optimised and adapted version 
of the protocol described by Hochstrasser et al. (Hochstrasser et al.  1988). Gels were scanned 
immediately after being developed and the subsequent image analysis was performed using 
Progenesis SameSpots software (Nonlinear Dynamics, UK) version 3.3.3420.25059. 
Following the analysis of the images, preparatory gels were made with 300 μg protein 
and selected spots were excised from the gel matrix, suspended in ddH2O and taken to King’s 
College London Proteomics facility to be processed by Steve Lynham. The gel fragments were 
subjected to in-gel reduction, alkylation and digestion with trypsin prior to performing peptide 





3.3.1. Transfection of CTXOE03 Cells and DISC1 knockdown  
From the images taken (Figure 11) it can be seen that successful uptake of the red fluorescent 
oligonucleotide into CTXOE03 cells took place and can be assumed that the transfection of the 
samples was successful. Statistical analysis of data from the qPCR reported DISC1 to be 
successfully knocked down in the CTXOE03 cells following treatment with two different siRNAs 
specific for DISC1. Analysis of this qPCR data showed a 35% reduction in DISC1 expression for 
the samples treated with RNAi1 (p = .046, SEM = 0.09) and a 38% reduction in DISC1 
expression for the samples treated with RNAi2 (p = .05, SEM = 0.11) relative to the DISC1 
expression calculated in the Control RNAi condition.  
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3.3.2. Proteomic changes 
Protein concentrations in individual samples were determined for the four conditions RNAi1, 
RNAi2, Control RNA and No RNAi and two-dimensional gel electrophoresis (2DPAGE) was 
performed in acrylamide gels. Gel analysis software ‘Progenesis Samespots’ was used to 
determine significant abnormal protein levels in different group (condition) comparisons; 
RNAi1 vs. Control RNAi, RNAi2 vs. Control RNAi, Control RNAi vs. NoRNAi, RNAi1 vs. RNAi2, 
RNAi1 vs. NoRNAi, and RNAi2 vs. NoRNAi. The No RNAi group was used to assess the effects of 
siRNA treatment itself on protein expression (off-target effects). Statistical analyses were 
conducted between the RNAi1 and RNAi2 and Control RNA. 
 Post alignment and analysis, the software identified a number of spots and generated a report 
with < 20 protein spots in each case comparison found to be of statistical significant (p ≤ .05). 
Average fold change value and p-value (ANOVA) were used to compare common significant 
differences between RNAi1 vs. Control RNAi, and RNAi2 vs. Control RNAi. A Principal 
Component Analysis (PCA) performed with Progenesis SameSpots Statistical software on the 
groups showed a first component that accounted for 28.09% of the variance observed and a 
second component that accounted for 14.95% of the variance resulting in a clear distribution 




Figure 11. Image (x100) of CTXOE03 cells on day 3 of transfection with red fluorescent 
oligonucleotide 






Figure 12. Principal Component Analysis (PCA) on the four groups. 






3.3.3. RNAi1 vs. Control RNAi 
The comparison between the two groups yielded 8 spots with a statistically significant 
difference (Table 9). These spots were labelled as 1 (160), 2 (189), 3 (202) 4 (71), 5 (2020), 6 
(2688), 7 (293) and 8 (1305) (Figure 13). 
 
3.3.4. RNAi2 vs. Control RNAi 
In the RNAi2 vs. Control RNAi condition comparison there were 18 protein spots of significance 
reported (Table 10). For the RNAi2 comparison these spots were labelled as 1 (1276), 2 (980), 3 
(782) 4 (2020), 5 (2688), 6 (633), 7 (513), 8 (953), 9 (1282), 10 (712), 11 (1024), 12 (390), 13 
(192), 14 (1303), 15 (1185), 16 (1381), 17 (1182) and 18 (2065) (Figure 14). 
 
3.3.5. Common spots 
There was a shared common significant change in two protein spots in both RNAi conditions 
compared with Control RNAi (Table 10). For the RNAi1 comparison these spots were labelled 
number 5 (Spot No 2020, p = .041, average fold change = .62) and number 6 (Spot No 2688, p = 
.044, average fold change = 1.6). For the RNAi2 comparison these spots were labelled number 
4 (Spot No 2020, p = .004, average fold change = 0.5) and number 5 (Spot No 2688, p = .004, 
average fold change = 1.6). 
On examination of the gel it can be determined that both spots on both gels lie on the 
bottom of the gel and slightly to the right implying that these proteins both have a low 
molecular weight and a pH at the top end of the pH 3-11 spectrum examined by the isoelectric 
focussing strip used in 2-D gel electrophoresis. These spots will from now on be referred to as 





Figure 13. A representative image of 2-D gel of RNAi1 vs. Control RNAi comparison with the 
top 20 candidate spots identified and labelled. 






Figure 14. Representative Image of 2-D gel with top 20 candidate spots identified and labelled 
for RNAi2 vs. Control RNAi comparison. 






















RNAi1 Control RNAi2 Control 
160 .003 3.4 1 6.91E+04 2.03E+04 1276 .000 1.4 1 1.23E+06 1.74E+06 
189 .004 3.4 2 4.70E+04 1.37E+04 980^ .000 1.4 2 7.44E+05 1.07E+06 
202 .005 3.3 3 6.17E+04 1.87E+04 782^ .002 1.7 3 6.92E+04 4.00E+04 
71 .016 1.8 4 7.53E+04 4.20E+04 2020^* .004 2 4 2.82E+05 5.65E+05 
2020^* .041 1.6 5 3.53E+05 5.65E+05 2688^* .004 1.6 5 2.79E+06 1.75E+06 
2688^* .044 1.6 6 2.80E+06 1.75E+06 633 .005 2.5 6 1.47E+05 5.83E+04 
293 .044 1.5 7 1.58E+05 2.39E+05 513^ .012 1.8 7 1.73E+05 9.46E+04 
1305 .048 2.1 8 5.60E+05 1.17E+06 953 .012 1.6 8 3.41E+05 2.07E+05 
980^ .068 1.2 9 8.98E+05 1.07E+06 712 .014 1.7 10 7.32E+05 4.26E+05 
153 .086 2 10 9.80E+04 4.86E+04 1024^ .014 1.8 11 9.56E+05 5.31E+05 
1024^ .092 1.4 11 7.41E+05 5.31E+05 1282^ .014 2.2 9 2.69E+05 5.83E+05 
782^ .124 1.3 12 5.28E+04 4.00E+04 390 .017 2.2 12 7.99E+04 3.61E+04 
1488 .149 1.2 13 3.19E+05 2.61E+05 192 .018 1.7 13 2.65E+04 4.39E+04 
155 .153 1.6 14 1.03E+05 6.50E+04 1303 .02 1.3 14 3.90E+06 5.23E+06 
1381 .153 1.6 15 1.66E+05 2.64E+05 1185 .022 1.5 15 3.37E+05 5.08E+05 
1282^ .165 1.6 16 3.57E+05 5.83E+05 1381 .031 1.8 16 1.48E+05 2.64E+05 
1218 .187 1.7 17 1.05E+05 1.74E+05 1182 .043 1.4 17 1.91E+05 2.70E+05 
133 .203 1.5 18 5.03E+05 3.41E+05 2065 .046 1.5 18 1.50E+05 2.33E+05 
119 .214 1.5 19 1.55E+05 1.01E+05 809 .065 1.3 19 1.76E+05 1.39E+05 
513^ .221 1.3 20 1.27E+05 9.46E+04 1892 .103 2.2 20 1.79E+05 8.04E+04 
ANV = average normalised volumes. ^Common spots to both groups. * Significant spots common to 
both groups.  
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3.3.6.  LC/MS/MS 
Preparatory gels compatible with LC/MS/MS were prepared for each RNAi treatment group 
(Figure 15). A total of six gels per group with a load of 300 µg protein per gel were run in a 
single 12 gel batch. Spots A and B were excised on all 12 gels and taken to King’s College 
Proteomics Facility for digestion and LC/MS/MS analysis. 
The mass spectral data was processed into peak lists using ProteinLynx Global Server 
v2.2.5 with the following parameters: (1) MS survey – No background subtraction, SG 
smoothing 2 iterations 3 channels, peaks centroided (top 80%) no de-isotoping and (2) MS/MS 
– No background subtraction, SG smoothing 2 iterations 4 channels, peak centroiding (top 
80%) no de-isotoping. 
The peak lists was searched against the Swiss-Prot and a concatenated Swiss-Prot 
database using Mascot software v2.2 (http://www.matrixscience.com) using the following 
parameter specifications: precursor ion mass tolerance 1.2 Da, fragment ion mass tolerance 
0.6 Da, tryptic digest with up to three missed cleavages, variable modifications: acetyl (protein 
N-term), carbamidomethylation (C), Gln->pyro-glu (N-term Q), oxidation (M) and 
phosphorylation (S, T and Y). 
LC/MS/MS analysis and interrogation of the data against the Swiss-Prot database 
successfully identified proteins from the excised and digested 2D gel spots.  
The results of the analysis and database searches are given in Table 10. Database 
generated files were uploaded into Scaffold 3 (v3_00_06) software 
(www.proteomesoftware.com) to create .sfd files (PR232 RSF_NB 2D gel spots 12112010). All 
samples were aligned in this software for easier interpretation and used to validate MS/MS 
based peptide assignments and protein identifications. Peptide assignments were accepted if 
they contained at least two unique peptide assignments and were established at 100% 
identification probability by the Protein Prophet algorithm (Nesvizhskii et al.  2003). The 
Threshold Identity Score corresponds to a 5% chance of incorrect assignment. Peptides 
identified below these probabilities were accepted following manual inspection of the raw 
data to ensure that fragment ions correctly match the assigned sequence.  
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Figure 15. Protein spots common to both DISC1 RNAi1 and RNAi2 knockdowns. 
Panel A represents 2D PAGE gel of RNAi1 vs. Control whilst Panel B represents a 2D PAGE gel 
















Dihydropteridine reductase(QDPR, DHPR) Human P09417 25773 6.9 
RSF/NB B 
(2688) 
Peptidyl-prolyl isomerase A (PPIA, 
Cyclophilin A ) 
Human P62937 18001 7.7 
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3.4. Summary  
In this study, the approach to the examination of the proteome in SCZ used is a novel discovery 
approach. It is based on the examination at the protein level of a mimicked haploinsufficiency 
of DISC1 in human neural progenitor cells using classical proteomic techniques. It was 
hypothesised that as the gene that is altered in the disorder was known (and although off 
target effects must also be considered); changes at the proteomic level could be directly 
related to the effects elicited by the knockdown of DISC1.  
DISC1 was successfully knocked down in CTXOE03 cells via siRNA transfection, with 
expression reduced in both DISC1 RNAi treated groups (35% reduction in DISC1 expression for 
the samples treated with RNAi1 and a 38% reduction in DISC1 expression for the samples 
treated with RNAi2). Analysis of the cellular proteome was carried out by using 2DPAGE 
coupled to LC/MS/MS and results revealed significantly abnormal levels of several proteins 
across both DISC1 RNAi transfection groups.  
Eight significant protein changes were found in the RNAi1 vs. Control RNAi 
comparison, and there were a total of 18 significant protein changes found in the RNAi2 vs. 
Control RNAi comparison. Analysis of both set of results yielded two spots which were 
identified in this study as being regulated by both RNAi groups with a statistically significant 
difference with the control RNAi group. These spots were then excised and processed through 
LC/MS/MS for identification. These analytes were dihydropteridine reductase (DHPR) and 
peptidyl-prolyl isomerase A (cyclophilin A). It is noteworthy to mention here that a single 
analyte per spot was obtained, suggesting that discovery approaches for knockout studies 
have great potential in neuropsychiatric disorders. 
Dihydropteridine reductase (DHPR) maps to chromosome location 4p15.31 and is a 
protein present in cytoplasm, cytosol and mitochondrion that catalyzes the NADH-mediated 
reduction of quinonoid dihydrobiopterin. Dihydropteridine reductase deficiency presents as 
atypical phenylketonuria due to insufficient production of biopterin, a cofactor for 
phenylalanine hydroxylase. The product of this enzyme, tetrahydrobiopterin (BH-4), is an 
essential cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases and is therefore 
important in the biosynthesis of biogenic amines like dopamine, norepinephrin and serotonin. 
The most obvious marker of DHPR deficiency, which leads to tetrahydrobiopterin or (BH4) 
deficiency is neonatal hyperphenilanemia. DHPR activity has been measured in blood in a small 
sample of people with SCZ and healthy controls but no differences were found between the 
groups (Szymanski et al.  1985). More recently, DHPR was found to be upregulated in the 
Wernicke’s area (Martins-De-Souza et al.  2009a) and in the thalamus and CSF (Martins-De-
Souza et al.  2010) of SCZ patients. 
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Cyclophilin A (PPIA) maps to chromosomic region 7p13 and is secreted from smooth 
muscle and macrophages in response to oxidative stress, which suggests a role in inflammation 
(Jin et al.  2004). In addition, PPIA catalyzes the cis-trans isomerization of proline imidic 
peptide bonds in oligopeptides and accelerate the folding of proteins. This protein is a 
cyclosporin binding-protein and may play a role in cyclosporin A-mediated 
immunosuppression. PPIA can also interact with several HIV proteins, including p55 gag, Vpr, 
and capsid protein, and has been shown to be necessary for the formation of infectious HIV 
virions. In neuropsychiatric disorders, the role of cyclophilin A is not yet fully explored. It 
appears that it has a role in apoptosis as it augments chromatinolysis synergically with 
apoptosis inducing factor (AIF) (Cande et al.  2004), which moves from mitochondria to nuclei 
following cerebral hypoxia-ischemia (Zhu et al.  2007). A recent study showed that it was 
downregulated in the anterior cingulate cortex of schizophrenic males (Martins-De-Souza et al.  
2010) but was found in a different study by the same authors to be upregulated in the 
thalamus and CSF of SCZ patients (Martins-De-Souza et al.  2010) , which may suggest a region-
specific profile expression. In addition, cyclophilin A appears to promote atherosclerosis in 
apolipoprotein-E deficient mice (Nigro et al.  2011), an intriguing relationship which may have 
clinical significance for dementia patients. 
As a limitation of this study, significant down-regulation of dihydropteridine reductase 
and up-regulation of cyclophilin-A need to be confirmed by enzyme-linked immunosorbent 
assays (ELISAs) and work is currently being conducted in concjunction with Dr Bray to validate 
the finding.  It is equally important to take into account that not all downstream translational 
changes may be noted at the time point of this experiment, and therefore many more 
proteomic changes may take place following DISC1 knockdown than have been reported here. 
In summary, one of the strongest apparent risk factors for psychiatric illness is a 
(1;11)(q42;q14) chromosomal translocation disrupting the DISC1 gene, which co-segregates 
with psychotic and affective disorders in a large Scottish family. We have used RNA 
interference (RNAi) to model the reduction in DISC1 expression that is predicted to result from 
this translocation in cells derived from the human fetal cortex. 2-dimensional gel 
electrophoresis (2DE) and liquid chromatography–mass spectrometry (LC-MS) were used to 
identify proteins that were differentially expressed as a result of DISC1 knockdown in these 
cells. Two proteins, identified as dihydropteridine reductase and cyclophilin-A, showed 
significant expression changes that were shared by the two DISC1 RNAi conditions. 
Dihydropteridine reductase, encoded by the QDPR gene, recycles tetrahydrobiopterin (BH-4), 
an essential cofactor for tyrosine and tryptophan hydroxylases and therefore an important 
determinant of dopamine and serotonin synthesis. Cyclophilin-A, encoded by the PPIA gene, 
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has been implicated in a variety of functions, including protein folding and inflammation. 
Abnormal expression of these proteins could make a significant contribution to 








CHAPTER 4: Examining the effects on brain 
and blood proteome of antipsychotic and 





4.1. Rationale and aims 
This study was performed to examine the effects of antidepressant and antipsychotic treatment 
on protein expression in mammalian brain tissue and plasma with the intention of identifying 
molecular pathways altered by the effect of antipsychotic medication. Due to obvious ethical 
and logistic constraints that limit access to human brain samples, the study was performed 
using adult inbred F344 rats in collaboration with Dr María Jesús Arranz and Dr Sridar Natesan 
(Section of Schizophrenia, Imaging and Therapeutics, Department of Psychosis Studies, Institute 
of Psychiatry, King’s College London).  
The hallmark symptom of SCZ, psychosis, appears to be susceptible to treatment with 
antipsychotic medication which, in the majority of cases, acts by blocking dopaminergic 
receptors. This is an apparently compensatory mechanism to excessive dopaminergic release 
from the presynaptic neuron, mainly in the striatum. Dopamine D2 blockade is directly 
correlated to treatment response (Kapur and Mamo, 2003) but by which mechanism these 
compounds exert their effects is far from being fully understood. It is known nonetheless, that 
antipsychotic treatment induces changes in gene expression, leading to RNA modifications 
(Chertkow et al.  2007; Thomas, 2006) that will eventually manifest in protein expression 
variations, potentially altering cell signalling and intracellular molecular pathways in a specific 
way.  
With the underlying assumption that there are highly conserved signalling pathways 
like JAK/STAT, Notch, Wnt and Hedgehog that could be altered either by the disorder or by the 
action of these drugs, this study aimed to show that differential protein expression patterns 
induced by antipsychotic treatment could be explored using a classical proteomic approach. 
Moreover, the information obtained about modifiers of signalling pathways will be used for the 
interpretation of the results from the human studies carried out in this thesis. 
In addition, comparison of protein expression profiling patterns between different 
types of drugs (antipsychotic and antidepressants, using a vehicle as control group) may identify 
individual expression profile pharmacological signatures which will shed light on unique mode 
of actions (in the case of clozapine) or on side-effect profiles. 
A classic proteomic approach (2DPAGE/LC/MS/MS) was used in an animal model to 
identify expression changes on the proteome of mammalian plasma and striatum (a brain 
region associated with the pathophysiology of SCZ in humans) following chronic antipsychotic 
administration. 
Thus, the main hypothesis tested in this study was that antipsychotic administration 
induces a pattern of protein expression unique to antipsychotic effect (i.e. not observed with 
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other treatments such as antidepressants) and is circumscribed to certain intra and extra-
cellular pathways. 
 
4.2. Material and methods 
All experiments were conducted in compliance with the Animals Experimental Procedures Act 
(1986) and were approved by relevant local ethics committees. 
 
4.2.1. Animals 
Thirty-six adult male inbred F344 rats, weighing 225-250g on arrival, were housed in cages with 
a standard 12-hour light/dark cycle at 22oC. Access to water and food consisting on a standard 
diet for rodents were provided ad libitum. Weight gain was monitored for the 14 days of 
treatment duration (Figure 16).  
The environment including temperature, humidity, ventilation, lighting and noise was 
maintained according to standards set by the Home Office in the Code of Practice for the 
housing of animals used in scientific procedures (21/03/2005). Animals subjected to the same 
treatment (haloperidol, citalopram or control) were housed together in cages of four 
individuals each which resulted in three cages per treatment arm (each arm consisted of 12 
animals). Animals were sacrificed in three consecutive days to minimise batch effects as 
follows: four ‘test’ animals and four controls were sacrificed on day one; 12 haloperidol-
treated animals and 4 control animals on day two; and 12 citalopram-treated animals and four 
controls on day three. 
In this study, the butyrophenone haloperidol, regarded mainly as a dopamine D2, D3 
and D4 receptor blocking compound, was used to examine the downstream effects of 
antipsychotic medication in the proteome. The antidepressant citalopram, a selective 
serotonin reuptake inhibitor (SSRI), was used as a comparison to find the unique specific 
profile, specific to the antipsychotic action of haloperidol. In addition, a vehicle was also used 
as an inert compound to control for unspecific changes induced predominantly by the 
experimental design (Table 11).  
The subcutaneous implantation of chronic continuous dosing Alzet® osmotic mini-
pumps to deliver the selected treatment was performed by Dr Natesan according to the 
procedure described by Samaha et al (Samaha et al.  2007). 
 In brief, animals were anesthetised and minipumps containing vehicle (VEH; 0.5% 
glacial acetic acid/H2O solution), haloperidol, or citalopram were implanted thorough a 1.5-cm-
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wide incision in the animal's lower back and inserted between the scapulae. The dose of the 
antipsychotic was chosen based on D2/3 receptor occupancy level determined in Sprague 
Dawley rats to ensure that clinically appropriate levels were achieved (Natesan et al.  2008) 
while the dose of citalopram was adjusted according to the equivalent human dose as current 
practice in animal studies (Hesketh et al.  2007). Haloperidol was administered to the 
equivalent of 0.5 mg/kg/day and citalopram to 10 mg/Kg/day. Both agents were dissolved in 




Table 11. Drugs used on animal study, target receptor and metabolic pathway. 










D2, D3, D4 
Sigma (σ), (Antagonist) 





Sigma (σ) (Agonist), α1, H1, 
mAchR 


































14 days of continuous dosing: vehicle, haloperidol, citalopram 
 
Analysis of 
plasma and striatum 
 
72 Gels 
(36 animals and 2 tissues) 
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4.2.2.  Protein analysis 
Animal manipulations, sacrifice and relevant tissue dissections, excisions and extractions were 
performed by Dr Natesan. Animals were sacrificed by decapitation on day 14 of treatment. 
Brains were removed and the striatum area was dissected, washed on diethyl pyrocarbonate, 
snap frozen by placing them in isopentane over dry-ice and subsequently stored at -80oC. Brain 
lysates were obtained using a standard lysis buffer. The solution was stirred for 10 minutes 
before being filtered. Following filtration, 1 g CHAPS, 0.5 g DTT and protease inhibitors were 
added to 48 ml of the solution and it was then aliquoted into 1 ml and stored at -80°C until 
use. 
Brain tissue was homogenized at approximately 100mg/ml in lysis buffer using a 
manual tissue grinder. The homogenised sample was then transferred to a clean microtube 
and spun. The resulting precipitated tissue pellet was discarded and the supernatant was 
retained as the total lysate. 
Truncal blood from sacrificed animals was collected in EDTA coated tubes immediately 
after decapitation using single-use sterile funnels and EDTA tubes. The tubes were placed at 
4oC for one hour and then spun at 3000 g for 8 minutes at 4oC. Plasma was aliquoted in 0.5 ml 
eppendorf tubes and stored at -80oC until needed for proteomic analyses. 
Protein concentration of brain and plasma samples was determined according to the 
method of Bradford (Bradford, 1976) using bovine serum albumin as a standard. Fifty 
micrograms of protein were used for the proteomic analysis of striatum and plasma samples. 
In order to establish that the surgical procedure had successfully delivered the 
antipsychotic and antidepressant agents, it was decided to measure serotonin levels in brain 
and plasma as both agents are known to affect serotonergic transmission. We used an ELISA 
Serotonin Assay (Serotonin ELISA Fast Track , Labor Diagnostika Nord) to measure serotonin levels 
in plasma and the Serotonin Research ELISA (Labor Diagnostica Nord) to measure the levels of 
serotonin in brain.  
Plasma samples stored at -80°C were thawed on ice until they reached room 
temperature (RT) prior to being used. A volume of 25 µl per sample was used in the assay. 
Brain samples, which were preserved at -80°C were thawed on ice, eluted in lysis buffer and 
diluted 1:10 prior to use. A volume of 100 µl per sample was used. 
Briefly, prepared lysates and plasma samples were defrosted and centifuged prior to 
use. Gels were run in three batches of 12 gels, comprising four samples per each group 
(vehicle, haloperidol and citalopram treated animals). The volume of sample determined to 
contain 50 µg of protein was dissolved in IPG rehydration buffer and 350 μl total volume was 
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loaded in 18cm Immobiline DryStrips (pH 3-11). Proteins were separated according to 
individual isoelectric point (PI) using the IPGphor (Amersham Bioscience) platform and 
subsequently equilibrated with dithiothreitol (DTT) and 2-Iodoacetamide.  
The second dimension (separation of proteins by size) was performed using SDS-PAGE 
2D acrylamide gels on an electrophoresis Ettan Dalt II (Amersham Biosciences) separation 
unit. Proteins were fixed to the gel matrix and stained with an optimised and adapted version 
of the protocol described by Hochstrasser et al. (Hochstrasser et al.  1988). Gels were scanned 
immediately after being developed and the subsequent image analysis was performed using 
Progenesis Samespots software (Nonlinear Dynamics, UK) version 3.2. Selected spots were 
excised from 2-DGE preparatory gels containing 300 µg of protein and gels were stained with 
modified Plus One silver stain kit (Amersham, UK). The spots were excised, suspended in 
double distilled water (ddH2O) and taken to King’s College London Proteomics Facility to be 
processed by Steve Lynham. The gel fragments were subjected to in-gel reduction, alkylation 
and digestion with trypsin prior to performing peptide mass fingerprinting and analysed by 
liquid chromatography tandem mass spectrometry (LC/MS/MS). 
Image analysis was conducted using Progenesis SameSpots v3.3 software. Images were 
scanned using a Storm scanner and acquired as 12-bit .tiff files. Images were subjected to a 
process of quality control before conducting the analysis. One image per set (plasma, striatum 
and prefrontal) was selected as the reference image for the group. The reference images were: 
26 (plasma), 2 (striatum) and 14 (prefrontal). The alignment was performed step-wise using 
built-in visual tools. An average of 50 vectors per image was added manually to specific protein 
patterns. Automatic vectors were subsequently added by the software using an image 
recognition algorithm and images were then ‘aligned’. All the identified spots underwent an 
analysis process that included spot detection, background subtraction, normalisation and 
matching. The resulting spots were outlined and brought forward for the next stage of the 
image analysis. Individual images were grouped according to treatment arms (control, 
haloperidol, citalopram).  
Different comparisons were performed (3 groups ANOVA and 2 groups non-parametric 
testing (haloperidol vs. control; citalopram vs. control and haloperidol vs. citalopram).Spots 
were statistically ordered according to p-value from the one way ANOVA and fold change. The 
statistical analysis was initially performed using the built-in Progenesis Stats software (a 
statistical resource containing Principal Component Analysis (PCA), Correlation Analysis, Power 
Analysis and False Discovery Rate and Q-values) and verification of the results obtained was 





4.3.1.  Serotonin ELISA 
Levels in plasma were obtained for all subjects but brain levels were only ascertained for those 
subjects with enough tissue to run the assay without compromising the proteomic experiment 
(Table 12). 
  Brain serotonin levels, as predicted, were increased by citalopram and to a lesser 
extent by haloperidol. Plasma serotonin levels were increased in the haloperidol treated group 
but decreased following treatment with the SSRI (Figure 17). Surprisingly, the only non-
significant difference in average serotonin levels was found between the increment due to 
haloperidol (47.5 pg/mg) and citalopram (77.6 pg/mg) in the brain of the treated animals 
(Table 13). 
Thus, the ELISA results indicated that the drug reached the target tissues and 




Table 12. Serotonin levels in plasma and brain tissue in F344 animals. 
Group Animal Number ELISA plasma pg/µl ELISA brain pg/mg 
Control 1 229.8  
2 436.1  
3 418.9 19.9 
4 851.1 14.2 
5 497.5 25.3 
6 87.6 18.6 
7 333.1 38.7 
8 313.6 4.4 
9 683.6  
10 555.7  
11 563.4 6.2 
12 458.1  
Mean 452.4 18.2 
SE 58.7 4.43 
    
Haloperidol 13 540.1 52.4 
14 655.7 43.2 
15 437.0 53.1 
16 816.4  
17 860.6 63.4 
18 447.3 48.0 
19 532.1 23.5 
20 675.9 72.7 
21 550.8 34.2 
22 462.9 58.8 
23 771.3 62.1 
24 475.5 11.3 
Mean 602.1 47.5 
SE 43.3 5.53 
    
Citalopram 25 58.2 41.6 
26 50.9  
27 41.1 18.0 
28 60.1 174.4 
29 46.4 74.6 
30 53.6  
31 95.7 27.5 
32 65.6  
33 74.8 50.5 
34 37.1 105.3 
35 66.4 111.4 
36 59.0 95.0 
Mean 59.1 77.6 





Table 13. Student's t-test (two-tailed) results for serotonin levels in plasma and brain tissue in 
F344 animals. 




Control vs. Haloperidol 0.017 0.001 
Control vs. Citalopram 3.50E-05 0.007 















Figure 17. Mean serotonin levels in plasma and brain of F344 animals following treatment with 
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ELISA plasma pg/µl 










4.3.2.  Plasma 
Thirty six images, 12 per group, were selected for image analysis. The image corresponding to 
animal number 26 from the citalopram treated group was selected as the reference image 
against which the remaining 35 were aligned. Alignment of the images yielded 1724 
theoretical potential spots which were subsequently manually curated, leaving 347 spots with 
an Anova p < .05 as calculated by Progenesis Stats. Out of those, 96 of them were deemed to 
be actual spots rather than gel artefacts (Figure 18). 
Using these 96 spots, a Principal Component Analysis (PCA) was conducted and a clear 
group separation between the haloperidol treated, citalopram treated and vehicle treated 
groups was observed in the sample (Figure 19) indicating that using the combined information 
of protein expression in these selected spots, gels were correctly assigned to the treatment 
group they belonged to with very little overlap or outliers. 
To validate these results, an analysis of variance (ANOVA) was conducted to test for 
differences between the means of each spot of the three different groups in our study using 
SPSS 16.0 for windows. Spots that had a FDR (False Discovery Rate) < 3% and that could be 
unmistakably identified and excised from the gels were selected (Table 14). 
On a confirmatory statistical analysis, the values of the haloperidol and citalopram 
groups were compared individually as independent samples with the control group using a 
non-parametric test (Mann-Whitney U test) (Table 15 and 16). Accordingly, the following 19 
spots were selected from the list and sent to MS for ID: 699, 694, 668, 711, 708, 943, 661, 946, 






Figure 18. Image of rat plasma proteome corresponding to animal 26 with all the spots 




Figure 19. PCA of 96 significant plasma spots in rats included in analysis. 
Principal component 1 (27.55% of total variance). Principal component 2 (12.35% of total 
variance). Groups: Control (pink), haloperidol (blue), citalopram (purple). Number 699 is the 




Table 14. Summary of top plasma spots in rats ranked as per ANOVA results between the three 












694 19.676 2 0.000 3 0.011 0.005 0.498 
668 19.383 2 0.000 4 0.014 0.004 0.433 
708 19.059 2 0.000 5 0.018 0.004 0.407 
699 18.817 2 0.000 6 0.021 0.004 0.383 
711 18.587 2 0.000 7 0.025 0.004 0.368 
661 18.434 2 0.000 8 0.029 0.003 0.348 
946 17.416 2 0.000 10 0.036 0.005 0.463 
947 17.321 2 0.000 12 0.043 0.004 0.404 
943 16.029 2 0.000 14 0.050 0.007 0.661 
1669 15.362 2 0.000 16 0.057 0.008 0.808 
763 13.713 2 0.001 22 0.079 0.013 1.340 
985 13.383 2 0.001 24 0.086 0.014 1.448 
1681 11.815 2 0.003 38 0.136 0.020 2.003 
1126 11.596 2 0.003 40 0.143 0.021 2.123 
862 11.497 2 0.003 42 0.150 0.021 2.125 
837 10.977 2 0.004 46 0.164 0.025 2.516 
1679 10.857 2 0.004 48 0.171 0.026 2.560 
1127 10.815 2 0.004 49 0.175 0.026 2.561 
240 10.378 2 0.006 53 0.189 0.029 2.946 
These spots were present in the ANOVA list from Progenesis SameSpots and could be identified and 





Table 15. Summary of top plasma spots in rats ranked as per Mann-Whitney results in SPSS 

















No. Progenesis (p) 
  (p)   
699 0.000 2 0.001 4 p1 2.91E+06 1.45E+06 
694 0.002 1.8 0.004 10 p2 2.60E+06 1.48E+06 
708 0.006 1.7 0.008 14 p5 1.41E+06 8.46E+05 
763 0.008 1.7 0.009 20 P10 2.29E+06 1.36E+06 
1679 0.019 1.5 0.015 30 P14 5.65E+06 3.89E+06 
711 0.017 1.5 0.043 39 P4 1.44E+06 9.79E+05 
943 0.052 1.6 0.057 45 P6 1.57E+06 2.48E+06 
946 0.070 1.6 0.106 71 p8 2.83E+06 4.41E+06 
661 0.141 1.3 0.133 84 p7 1.35E+06 1.04E+06 
1669 0.108 1.5 0.149 98 P9 3.26E+06 2.24E+06 
668 0.189 1.3 0.166 103 P3 1.66E+06 1.29E+06 
These spots were present in the ANOVA list from Progenesis SameSpots and could be identified and 
excised from the gel. AVN = Average Normalised Volume.  
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Table 16. Summary of top spots ranked as per Mann-Whitney results in SPSS between the 




















946 1.35E-04 2.6 0.000 3 p8 2.83E+06 7.29E+06 
943 2.71E-05 3.2 0.000 5 P6 1.57E+06 4.99E+06 
668 2.42E-04 1.8 0.001 10 P3 1.66E+06 2.96E+06 
1127 3.01E-04 1.6 0.001 11 P16 1.46E+06 8.93E+05 
661 2.89E-04 1.8 0.001 13 P7 1.35E+06 2.46E+06 
1126 0.001 1.7 0.003 24 P13 8.84E+05 5.16E+05 
240 0.018 1.7 0.004 26 P19 1.20E+06 1.99E+06 
862 0.017 1.9 0.007 38 P17 3.63E+05 5.61E+05 
711 0.003 1.4 0.004 30 P4 1.44E+06 2.03E+06 
1669 0.004 1.6 0.008 41 P9 3.26E+06 5.38E+06 
708 0.017 1.3 0.024 62 p5 1.41E+06 1.85E+06 
694 0.004 1.4 0.028 67 p2 2.60E+06 3.62E+06 
These spots were present in the ANOVA list from Progenesis SameSpots and could be identified and 










Fold Label Control Haloperidol Citalopram 
699 5.71E-07 2.5 p1 2.91E+06 1.45E+06 3.64E+06 
694 6.92E-07 2.5 p2 2.60E+06 1.48E+06 3.62E+06 
668 5.76E-06 2.3 P3 1.66E+06 1.29E+06 2.96E+06 
711 6.04E-06 2.1 P4 1.44E+06 9.79E+05 2.03E+06 
708 1.48E-05 2.2 P5 1.41E+06 8.46E+05 1.85E+06 
943 2.93E-05 3.2 P6 1.57E+06 2.48E+06 4.99E+06 
661 1.06E-04 2.4 p7 1.35E+06 1.04E+06 2.46E+06 
946 2.09E-04 2.6 p8 2.83E+06 4.41E+06 7.29E+06 
1669 3.30E-04 2.4 P9 3.26E+06 2.24E+06 5.38E+06 
763 3.63E-04 2.3 P10 2.29E+06 1.36E+06 3.10E+06 
985 6.35E-04 1.5 P11 3.18E+06 4.78E+06 4.62E+06 
947 9.72E-04 2.1 P12 9.80E+06 1.40E+07 2.02E+07 
1126 .003 2.2 P13 8.84E+05 1.12E+06 5.16E+05 
1679 .003 1.5 P14 5.65E+06 3.89E+06 5.79E+06 
1681 .003 1.8 P15 2.13E+06 3.81E+06 2.48E+06 
1127 .005 2 P16 1.46E+06 1.80E+06 8.93E+05 
862 .006 1.9 P17 3.63E+05 2.91E+05 5.61E+05 
837 .011 1.5 P18 2.30E+06 1.85E+06 2.83E+06 





The location of the spots is shown in Figure 20. Spots p1, p2, p3, p4, p5, p7 and p9 
clustered together and were likely to correspond to isoforms of the same protein(s). Similarly, 
p6, p8 and p12 formed another distinct group, as well as p13 and p16. 
These spots were excised from the gel and taken for identification to the King’s College 
Proteomics Facility. The results obtained from the LC/MS/MS procedure are summarised in 
tables 30 and 31. The top hits for spots p1, p2, p3, p4, p5, p7 and p9 were fibrinogen α and 
beta chain in all of them, making these analytes highly likely to be responsible for the overall 
expression changes observed in this group. The normalised average volumes of spots p1, p2, 
p3 and p7 were increased in the citalopram treated animals and decreased in the haloperidol 
group compared to controls, whereas the expression of p4 and p5 was increased in the 
citalopram group but highly increased in the haloperidol treated animals. 
The other ‘group’ of proteins likely to be isoforms of the same species was formed by 
p6, p8 and p12 which yielded α-1-macroglobulin as their top hit. The expression of p6 and p8 
was increased in the citalopram treated group whereas p12 was raised in the control group. 
Spots p13 (decreased in haloperidol treated animals) and p16 (increased in citalopram 
treated animals) contained carbonic anhydrase 1 and 2, Ig kappa chain C region, A allele and Ig 
lambda-2 chain C-region. 
Spot p10 (decreased in haloperidol treated animals and increased in the citalopram 
group) contained fibrinogen gamma chain, complement C3 and fibrinogen beta chain; p11 
(decreased in controls), haptoglobin and anionic trypsin-2, p14 (decreased in haloperidol 
treated animals), α-1-antiproteinase, angiotensin, fibrinogen gamma chain and Vitamin D-
binding protein; p15 (increased in haloperidol treated animals), plasminogen and 
serotransferrin; p17 (increased in citalopram treated animals), apolipoprotein A-IV and ATP 
synthase subunit beta, mitochondrial; and p18 and p19 (both increased in citalopram treated 
animals), complement C3. 
Summarising, haloperidol increased the expression of isoforms of fibrinogen alpha and 
beta chain (p4, p5), isoforms of α-1-macroglobulin (p6, p8), haptoglobin and anionic trypsin-2 
(p11), plasminogen and serotransferrin (p15); and decreased the expression of isoforms of 
fibrinogen alpha and beta chain (p1, p2, p3, p7, p9), fibrinogen gamma chain (p10), an isoform 
of α-1-macroglobulin (p12), carbonic anhydrase 1 and 2, Ig kappa chain C region, A allele and Ig 
lambda-2 chain C-region (p13), α-1-antiproteinase, angiotensin, fibrinogen gamma chain and 
vitamin D-binding protein (p14), apolipoprotein A-IV and ATP synthase subunit beta, 
mitochondrial (p17) and complement C3 (p18). Citalopram increased the expression of 
isoforms of fibrinogen alpha and beta chain (p1, p2, p3, p4, p5, p7, p9), an isoform of α-1-
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macroglobulin (p6, p8), fibrinogen gamma chain (p10), haptoglobin and anionic trypsin-2 
(p11), carbonic anhydrase 1 and 2, Ig kappa chain C region, A allele and Ig lambda-2 chain C-
region (p16), apolipoprotein A-IV and ATP synthase subunit beta, mitochondrial (p17) and 
complement C3 (p18). Citalopram decreased the expression of an isoform of α-1-
macroglobulin (p12), carbonic anhydrase 1 and 2, Ig Kappa chain C region, A allele and Ig 
lambda-2 chain C-region (p13) (Table 18). 



























Fibrinogen alpha chain P06399 86632 5.5 44 21 29% 
Fibrinogen beta chain P14480 54201 7.9 29 15 37% 
Beta-2-glycoprotein 1 P26644 33175 8.6 6 4 16% 
Ig gamma-2B chain C region P20761 36474 7.7 3 3 17% 
Serotransferrin P12346 76346 7.1 1 1 2% 
P2 (694) 
Fibrinogen alpha chain P06399 86632 5.5 41 20 29% 
Fibrinogen beta chain P14480 54201 7.9 33 19 40% 
Beta-2-glycoprotein 1 P26644 33175 8.6 2 2 8% 
Ig gamma-2B chain C region P20761 36474 7.7 2 1 6% 
P3 (668) 
Fibrinogen beta chain P14480 54201 7.9 56 27 56% 
Fibrinogen alpha chain P06399 86632 5.5 24 15 25% 
Beta-2-glycoprotein 1 P26644 33175 8.6 5 4 11% 
Ig gamma-2B chain C region P20761 36474 7.7 1 1 5% 
Anionic trypsin-2 P00763 26211 4.8 1 1 4% 
P4 (711) 
Fibrinogen alpha chain P06399 86632 5.5 8 5 9% 
Fibrinogen beta chain P14480 54201 7.9 4 3 10% 
Ig gamma-2B chain C region P20761 36474 7.7 4 2 11% 
P5(708) 
Fibrinogen beta chain P14480 54201 7.9 49 24 55% 
Fibrinogen alpha chain P06399 86632 5.5 21 13 21% 
Ig gamma-2B chain C region P20761 36474 7.7 7 5 24% 
Beta-2-glycoprotein 1 P26644 33175 8.6 1 1 5% 
P6 (943) Alpha-1-macroglobulin Q63041 2E+05 6.5 7 7 6% 
P7 (661) 
Fibrinogen alpha chain P06399 86632 5.5 30 19 29% 
Pyruvate kinase isozymes M1/M2 P11980 57781 6.6 5 3 8% 
P8 (946) Alpha-1-macroglobulin Q63041 2E+05 6.5 8 7 5% 
P9 (1669) Fibrinogen beta chain P14480 54201 7.9 56 24 54% 
P10 (763) 
Fibrinogen gamma chain P02680 50600 5.6 36 19 60% 
Complement C3 P01026 2E+05 6.1 2 1 2% 
Fibrinogen beta chain P14480 54201 7.9 2 1 3% 
P11 (985) 
Haptoglobin P06866 38539 6.1 14 10 25% 
Anionic trypsin-2 P00763 26211 4.8 1 1 4% 
P12 (947) 
Alpha-1-macroglobulin Q63041 2E+05 6.5 15 11 8% 
Tubulin alpha-1C chain Q6AYZ1 49905 5.0 2 1 3% 
P13 
(1126) 
Carbonic anhydrase 2 P27139 29096 6.9 19 2 9% 
Ig kappa chain C region, A allele P01836 11725 5.0 6 2 25% 
Ig lambda-2 chain C region P20767 11311 5.8 4 2 32% 
Carbonic anhydrase 1 B0BNN3 28282 6.9 3 1 4% 
P14 
(1679) 
Alpha-1-antiproteinase P17475 46107 5.7 33 8 27% 
Angiotensinogen P01015 51949 5.4 5 3 9% 
Fibrinogen gamma chain P02680 50600 5.6 13 2 7% 
Vitamin D-binding protein P04276 53509 5.7 9 1 4% 
P15 
(1681) 
Plasminogen Q01177 90477 6.8 19 13 16% 
Serotransferrin P12346 76346 7.1 2 1 2% 
P16 
(1127) 
Carbonic anhydrase 2 P27139 29096 6.9 17 3 20% 
Carbonic anhydrase 1 B0BNN3 28282 6.9 6 2 11% 
Ig kappa chain C region, A allele P01836 11725 5.0 4 2 25% 
Ig lambda-2 chain C region P20767 11311 5.8 2 2 32% 
P17 (862) 
 
Apolipoprotein A-IV P02651 44429 5.1 81 16 51% 
ATP synthase subunit beta, mitochondrial P10719 56318 5.2 6 2 5% 
P18 (837) Complement C3 P01026 186342 6.1 31 3 2% 
P19 (240) Complement C3 P01026 186342 6.1 9 3 3% 
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Table 19. Summary of direccion of expression from the selected plasma spots. 
Spot label 
(number) 
Protein I.D. Haloperidol Citalopram 
P1 (699) 
Fibrinogen alpha chain 
Fibrinogen beta chain 
Beta-2-glycoprotein 1 




Fibrinogen alpha chain 
Fibrinogen beta chain 
Beta-2-glycoprotein 1 
Ig gamma-2B chain C region 
↓ ↑ 
P3 (668) 
Fibrinogen beta chain 
Fibrinogen alpha chain 
Beta-2-glycoprotein 1 




Fibrinogen alpha chain 
Fibrinogen beta chain 
Ig gamma-2B chain C region 
↑ ↑ 
P5 (708) 
Fibrinogen beta chain 
Fibrinogen alpha chain 
Ig gamma-2B chain C region 
Beta-2-glycoprotein 1 
↓ ↑ 
P6 (943) Alpha-1-macroglobulin ↑ ↑ 
P7 (661) 
Fibrinogen alpha chain 
Pyruvate kinase isozymes M1/M2 
↓ ↑ 
P8 (946) Alpha-1-macroglobulin ↑ ↑ 
P9 (1669) Fibrinogen beta chain ↓ ↑ 
P10 (763) 
Fibrinogen gamma chain 
Complement C3 








Tubulin alpha-1C chain 
↓ ↓ 
P13 (1126) 
Carbonic anhydrase 2 
Ig kappa chain C region, A allele 
Ig lambda-2 chain C region 





Fibrinogen gamma chain 







Carbonic anhydrase 2 
Carbonic anhydrase 1 
Ig kappa chain C region, A allele 




ATP synthase subunit beta, mitochondrial 
↓ ↑ 
P18 (837) Complement C3 ↓ ↑ 
P19 (240) Complement C3 ↑ ~ 
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4.3.3.  Striatum 
In a separate set of experiments, thirty six images, 12 per treatment group were selected for 
image analysis. The image corresponding to animal number 2 (Figure 21), from the control 
group was chosen as the reference image against which the remaining 35 were aligned. 
Alignment of the images yielded 1491 theoretical potential spots which were subsequently 
manually curated, leaving 234 spots with an Anova p < .05 as calculated by the program’s 
statistical package. Out of those, 106 were deemed to be actual spots rather than gel artefacts. 
Similarly to the analysis in the plasma samples, a PCA was conducted (Figure 22) using 
these 106 spots. Although the three groups are clearly visible in the graphic representation of 
the PCA, the separation is less clear than in plasma. 
SPSS 16.0 was used in parallel with the raw data on average normalised volumes for 
each one of the spots exported to calculate the ANOVA and to conduct non-parametric tests to 
compare the control group firstly to the haloperidol and then to the citalopram one.  
The ANOVA results are detailed in Appendix 2 and a summary of the values for the 
spots that were successfully identified and excised from the preparatory gels are given in Table 
32. A summary of the results from non-parametric tests are shown in tables 33 and 34, below. 
Accordingly, the following 18 spots were selected from the list and sent to MS for ID: 877, 
1159, 1228, 445, 729, 1039, 1163, 1143, 963, 1113, 595, 968, 1142, 838, 961, 1214, 908 and 





Figure 21. Image corresponding to animal 2 with the 106 significant spots included in analysis 




Figure 22. PCA of 96 significant spots included in analysis. 
Principal Component 1 (27.14% of total variance). Principal Compoenent 2 (11.87% of total 
variance). Control (pink), haloperidol (blue), citalopram (purple). 1237 is the spots which was 












Table 20. Summary of top striatum spots in rats ranked as per ANOVA results between the 
three treatment groups in SPSS.  
Spot no. 
Chi-
Square df p Rank 
Theor 
Prob FDR % 
877 13.855 2 0.001 2 0.003 0.300 29.955 
1159 12.845 2 0.002 5 0.008 0.198 19.848 
968 11.656 2 0.003 10 0.016 0.180 17.986 
1113 11.480 2 0.003 13 0.021 0.151 15.107 
1228 10.909 2 0.004 19 0.031 0.138 13.756 
1143 10.351 2 0.006 23 0.038 0.150 15.020 
1163 10.205 2 0.006 24 0.039 0.155 15.482 
595 9.769 2 0.008 29 0.047 0.159 15.932 
729 9.416 2 0.009 32 0.052 0.172 17.230 
445 9.380 2 0.009 33 0.054 0.170 17.006 
1039 8.757 2 0.013 42 0.069 0.183 18.252 
838 8.309 2 0.016 47 0.077 0.204 20.398 
963 7.984 2 0.018 53 0.087 0.213 21.281 
908 7.368 2 0.025 68 0.111 0.226 22.575 
961 7.225 2 0.027 70 0.115 0.236 23.550 
1142 7.100 2 0.029 72 0.118 0.244 24.375 
1214 7.100 2 0.029 73 0.119 0.240 24.041 
642 6.903 2 0.032 77 0.126 0.252 25.150 
These spots were present in the ANOVA list from Progenesis SameSpots and could be identified and 





Table 21. Summary of top striatum spots in rats ranked as per Mann-Whitney results in SPSS 


















877 .147 1.1 .106 2 2 4.24E+05 4.79E+05 
1159 .003 1.2 .005 5 5 2.20E+06 1.81E+06 
968 .253 1.1 .386 10 9 3.81E+06 3.60E+06 
1113 .001 1.3 .001 13 10 1.39E+06 1.07E+06 
1228 .001 1.2 .001 19 13 2.37E+06 1.98E+06 
1143 .552 1 .564 23 16 4.79E+05 4.60E+05 
1163 .006 1.2 .006 24 17 7.99E+05 6.65E+05 
595 .309 1 .184 29 18 3.79E+06 3.63E+06 
729 .182 1.1 .149 32 21 2.64E+06 2.97E+06 
445 .003 1.3 .008 33 22 7.99E+05 6.29E+05 
1039 .318 1.1 .326 42 28 1.62E+06 1.52E+06 
These spots were present in the ANOVA list from Progenesis SameSpots and could be identified and 




Table 22. Summary of top striatum spots in rats ranked as per Mann-Whitney results in SPSS 




















877 .009 1.3 .007 2 2 4.24E+05 3.29E+05 
1159 .001 1.4 .002 5 5 2.20E+06 1.63E+06 
968 4.76E-04 1.2 .000 10 9 3.81E+06 3.11E+06 
1113 .016 1.3 .014 13 10 1.39E+06 1.09E+06 
1228 .005 1.2 .016 19 13 2.37E+06 2.00E+06 
1143 6.05E-04 1.5 .001 23 16 4.79E+05 3.24E+05 
1163 .006 1.2 .010 24 17 7.99E+05 6.44E+05 
595 6.83E-04 1.2 .002 29 18 3.79E+06 3.29E+06 
729 .007 1.2 .027 32 21 2.64E+06 2.23E+06 
1039 .001 1.3 .005 42 28 1.62E+06 1.25E+06 
These spots were present in the ANOVA list from Progenesis SameSpots and could be identified and 














Control Haloperidol Citalopram 
877 3.78E-04 1.5 s1 4.24E+05 4.79E+05 3.29E+05 
1159 7.92E-04 1.4 s2 2.20E+06 1.81E+06 1.63E+06 
1228 .002 1.2 s3 2.37E+06 1.98E+06 2.00E+06 
445 .002 1.3 s4 7.99E+05 6.29E+05 7.80E+05 
729 .002 1.3 s5 2.64E+06 2.97E+06 2.23E+06 
1039 .004 1.3 s6 1.62E+06 1.52E+06 1.25E+06 
1163 .006 1.2 s7 7.99E+05 6.65E+05 6.44E+05 
1143 .008 1.5 s8 4.79E+05 4.60E+05 3.24E+05 
963 .009 1.2 s9 2.86E+06 2.54E+06 2.30E+06 
1113 .009 1.3 s10 1.39E+06 1.07E+06 1.09E+06 
595 .01 1.2 s11 3.79E+06 3.63E+06 3.29E+06 
968 .011 1.2 s12 3.81E+06 3.60E+06 3.11E+06 
1142 .013 1.2 s13 6.52E+06 5.62E+06 5.36E+06 
838 .014 1.2 s14 2.45E+06 2.00E+06 2.15E+06 
961 .018 1.2 s15 4.43E+06 3.91E+06 3.60E+06 
1214 .021 1.2 s16 7.96E+05 6.54E+05 6.38E+05 
908 .022 1.2 s17 1.51E+06 1.32E+06 1.28E+06 





The location of the spots is shown in Figure 23. These spots were excised from the gel 
and taken for identification to the King’s College Proteomics facility. The results obtained from 
the LC/MS/MS procedure are summarised in Table 24. 
Spots s1, s6, s9, s12, s15, and s17 were located very close to each other. Similarly s8, 
s2, s10 and s7 seemed to conform to another distinctive ‘group’. The remaining spots, s3, s13, 
s14, s5, s11, s4 and s18 appeared to be more widely distributed in the gel area. 
All spots were downregulated in the citalopram group with the exception of s4, which 
expression was similar to the control group and contained Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, mitochondrial (Table 25). Haloperidol upregulated the 
expression of s1 (aspartate aminotransferase, cytoplasmic; isocitrate dehydrogenase [NAD] 
subunit beta, mitochondrial; fructose-bisphosphate aldolase A; triosephosphate isomerase) 
and s5 (ATP synthase subunit α, mitochondrial). It did not alter the expression of s6 (voltage-
dependent anion-selective channel protein 1; voltage-dependent anion-selective channel 
protein 2; glyceraldehyde-3-phosphate dehydrogenase; V-type proton ATPase subunit E 1) and 
downregulated the remaining proteins identified. Trisephosphatase isomerase was identified 
in s1, s2, s7 and s8. It was downregulated in all of them except in s1 in the haloperidol treated 
group in which it appeared to be upregulated. Glyceraldehyde-3-phosphate dehydrogenase 
was also downregulated in both groups and was seen in spots s6, s9, s12 and s15. Pyruvate 
kinase isozymes M1/M2 was present in spots s3, s11, and s12. Fructose-bisphosphate aldolase 
A was identified in s1 and s17 and was downregulated in all groups with the exception of the 
haloperidol treated one where it showed an upregulation of expression. Protein DJ-1 was 
detected in s3 and s12 and its expression was downregulated by both treatments. Glutathione 
S-transferase P was present in s3 and s16 and was downregulated in both treatment groups. 
Malate dehydrogenase, mitochondrial was identified in s9 and s12 and NAD-dependent 












Table 24. MS results from the selected striatum spots. 













Aspartate aminotransferase, cytoplasmic P13221 46400 6.7 11 8 26% 
Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Q68FX0 42327 8.9 7 4 19% 
Fructose-bisphosphate aldolase A P05065 39327 8.3 4 3 11% 
Triosephosphate isomerase P48500 26832 6.9 2 2 11% 
S2 (1159) Triosephosphate isomerase P48500 26832 6.9 26 16 80% 
S3 (1228) 
Protein DJ-1 O88767 19961 6.3 52 19 90% 
Pyruvate kinase isozymes M1/M2 P11980 57781 6.6 13 8 22% 
Glutathione S-transferase P P04906 23424 6.9 3 3 25% 
Acyl-protein thioesterase 1 P70470 24692 6.1 3 2 12% 
S4 (445) 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial 
Q920L2 71570 6.8 35 21 55% 
Dihydropyrimidinase-related protein 2 P47942 62239 6.0 2 2 5% 
S5 (729) ATP synthase subunit α, mitochondrial P15999 59717 9.2 58 32 62% 
S6 (1039) 
Voltage-dependent anion-selective channel protein 1 Q9Z2L0 30737 8.6 18 11 58% 
Voltage-dependent anion-selective channel protein 2 P81155 31726 7.4 14 10 48% 
Glyceraldehyde-3-phosphate dehydrogenase P04797 35805 8.1 7 4 29% 
V-type proton ATPase subunit E 1 Q6PCU2 26112 8.4 3 3 21% 
S7 (1163) Triosephosphate isomerase P48500 26832 6.9 36 15 77% 
S8 (1143) 
Dihydropteridine reductase P11348 25536 7.7 20 12 66% 







Table 24 (continued) 
 












Glyceraldehyde-3-phosphate dehydrogenase P04797 35805 8.1 29 5 23% 
Malate dehydrogenase, mitochondrial P04636 35661 8.9 6 2 8% 
NAD-dependent deacetylase sirtuin-2 Q5RJQ4 39294 6.7 3 2 10% 
S10 (1113) 
Carbonic anhydrase 2 P27139 29096 6.9 11 7 33% 
Phosphoglycerate mutase 1 P25113 28814 6.7 3 3 22% 
S11 (595) Pyruvate kinase isozymes M1/M2 P11980 57781 6.6 92 43 74% 
S12 (968) 
Glyceraldehyde-3-phosphate dehydrogenase P04797 35805 8.1 49 11 58% 
Pyruvate kinase isozymes M1/M2 P11980 57781 6.6 8 4 13% 
Protein DJ-1 O88767 19961 6.3 6 3 26% 
Malate dehydrogenase, mitochondrial P04636 35661 8.9 4 1 6% 
S13 (1142) 
Ubiquitin carboxyl-terminal hydrolase isozyme L1 Q00981 24822 5.1 39 8 55% 
Rho GDP-dissociation inhibitor 1 Q5XI73 23393 5.1 7 2 24% 




3 2 10% 
S14 (838) 
Glutamine synthetase P09606 42240 6.6 28 6 24% 
Phosphoglycerate kinase 1 P16617 44510 8.0 22 4 18% 




4 2 5% 
Creatine kinase U-type, mitochondrial P30275 46974 8.4 7 1 4% 
S15 (961) 
Glyceraldehyde-3-phosphate dehydrogenase P04797 35805 8.1 33 7 33% 





Table 24 (continued) 
 











S16 (1214) Glutathione S-transferase P P04906 23424 6.9 15 5 30% 
S17 (908) Fructose-bisphosphate aldolase C P09117 39259 6.7 41 10 36% 
S18 (642) 
V-type proton ATPase subunit B, brain isoform P62815 56515 5.6 61 11 34% 
Tubulin beta-2C chain Q6P9T8 49769 4.8 19 2 7% 
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Table 25. Summary of direction of expression from the selected striatum spots. 
Spot label 
(number) 
Protein ID Haloperidol Citalopram 
S1 (877) 
Aspartate aminotransferase, cytoplasmic 
Isocitrate dehydrogenase [NAD] subunit beta, 
mitochondrial 
Fructose-bisphosphate aldolase A 
Triosephosphate isomerase 
↑ ↓ 
S2 (1159) Triosephosphate isomerase ↓ ↓ 
S3 (1228) 
Protein DJ-1 
Pyruvate kinase isozymes M1/M2 
Glutathione S-transferase P 
Acyl-protein thioesterase 1 
↓ ↓ 
S4 (445) 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
Dihydropyrimidinase-related protein 2 
↓ ~ 
S5 (729) ATP synthase subunit alpha, mitochondrial ↑ ↓ 
S6 (1039) 
 
Voltage-dependent anion-selective channel protein 1 
Voltage-dependent anion-selective channel protein 2 
Glyceraldehyde-3-phosphate dehydrogenase 
V-type proton ATPase subunit E 1 
~ ↓ 







Malate dehydrogenase, mitochondrial 
NAD-dependent deacetylase sirtuin-2 
↓ ↓ 
S10 (1113) 
Carbonic anhydrase 2 
Phosphoglycerate mutase 1 
↓ ↓ 
S11 (595) Pyruvate kinase isozymes M1/M2 ~ ↓ 
S12 (968) 
Glyceraldehyde-3-phosphate dehydrogenase 
Pyruvate kinase isozymes M1/M2 
Protein DJ-1 
Malate dehydrogenase, mitochondrial 
↓ ↓ 
S13 (1142) 
Ubiquitin carboxyl-terminal hydrolase isozyme L1 
Rho GDP-dissociation inhibitor 1 





Phosphoglycerate kinase 1 
Pyruvate dehydrogenase E1 component subunit alpha, 
somatic form, mitochondrial 




NAD-dependent deacetylase sirtuin-2 
↓ ↓ 
S16 (1214) Glutathione S-transferase P ↓ ↓ 
S17 (908) Fructose-bisphosphate aldolase C ↓ ↓ 
S18 (642) 
V-type proton ATPase subunit B, brain isoform 




4.3.4.  Prefrontal 
The purpose of this analysis was to show that region specific changes occurred in striatum 
following treatment with haloperidol and citalopram. This was achieved by ensuring that there 
was no overlap with the striatum analysis. Prefrontal tissue images were analysed in the same 
way that the plasma and striatum images. Spots were taken following the same procedure; 
namely, the ANOVA values for all manually curated spots were calculated using the statistical 
package from Progenesis SameSpots v3.3 and SPSS 16.0 and both list compared for 
overlapping spots.  
Non-parametric tests were conducted between the control and haloperidol treated 
groups and between control and citalopram treated groups (data not shown). Spots appearing 
on the four resulting lists were ranked according to statistical significance and fold change. 
There were 2842 identifiable spots of which 110 had an ANOVA value p < .05. All were 
manually curated and 33 were selected as being statistically significant and not an artefact of 
the gel. A summary of the spots selected and a table detailing the main characteristics of those 
is shown here (Figure 24, Table 26). The resulting spots were not sent to MS for identification. 
A PCA was also performed using those 33 spots, which showed some specific group 











Table 26. Prefrontal spots with average normalised volumes. 





Control Haloperidol Citalopram 
2708 .003 1.6 2 2.76E+05 4.34E+05 4.14E+05 
2618 .006 1.6 5 1.23E+06 1.85E+06 2.01E+06 
2621 .008 1.8 7 3.60E+05 4.37E+05 6.46E+05 
1622 .01 1.3 4 1.08E+06 8.52E+05 8.63E+05 
1829 .011 1.3 6 6.66E+06 5.22E+06 5.66E+06 
1249 .011 1.3 3 3.29E+06 3.71E+06 2.90E+06 
1587 .011 1.3 14 3.52E+06 4.53E+06 3.99E+06 
2619 .011 1.3 1 4.23E+06 5.67E+06 4.88E+06 
2729 .016 1.7 12 5.44E+05 7.82E+05 9.18E+05 
3061 .021 1.3 15 5.20E+06 6.68E+06 5.77E+06 
2650 .028 1.3 9 3.06E+06 3.86E+06 3.94E+06 
755 .028 1.5 8 9.68E+05 8.76E+05 6.48E+05 
3079 .029 1.3 16 3.26E+06 4.25E+06 3.55E+06 
2629 .033 1.5 13 1.21E+06 1.76E+06 1.79E+06 
2165 .038 1.3 20 2.89E+05 3.33E+05 3.81E+05 
2348 .039 1.3 17 6.46E+05 7.69E+05 8.54E+05 
2223 .042 1.3 19 6.70E+05 8.34E+05 8.73E+05 
2203 .050 1.3 11 6.70E+05 7.59E+05 8.74E+05 
2549 .083 1.7 18 4.07E+05 6.77E+05 6.23E+05 





Figure 25. PCA of 33 significant spots in prefrontal included in analysis. 
Principal Component 1 (27.31% of total variance). Principal Component 2 (14.40% of total 
variance). Control (pink), haloperidol (blue), citalopram (purple). 1209 is the spot which was 











This is, to the best of our knowledge, the first study conducted to explore simultaneously the 
effects of antipsychotic and antidepressant medication in the striatum and plasma proteome 
of F344 animals. 
Inbred F344 animals were chosen over outbred strains like Long Evans (LE) or Wistar 
rats as these latter groups have greater genetic variation and variability in pathological lesions 
and require larger sample sizes to show significant statistical differences than inbred 
populations. F344 are albino animals with a Wistar background and are usually labelled as 
young (3-6 months), adult, (11-18 months) and aged (22-24 months). We used adult rats for 
our study as they maintain a moderate weight as adults (around 250 g) and are for the most 
part healthy and lacking the more common health problems usually present in aged F344 rats 
like adenomas of Leydig cells, leukaemia, pituitary adenoma, bile duct hyperplasia or hepatic 
micro abscesses. 
We initially envisaged caging the animals in groups of three, one subject per treatment 
group (haloperidol, citalopram and vehicle treated) in order to minimise experimental error by 
ensuring that the same conditions of light, food, and water were provided homogenously 
throughout the cohort. Unfortunately, it was soon observed that haloperidol treated animals 
became oversedated, which rendered them unable to defend themselves from attacks from 
the other two animals in the cage, which attempted to chew on the site of the incision and 
pump implant. For that reason, we were forced to change the experimental conditions after 
the implantation of the pumps and the animals were housed according to treatment received 
in cages of 4 animals each. This resulted in having 3 cages of 4 animals each per treatment 
group and for that reason, housing conditions may have slightly differed among treatment 
groups, although we understand this is common and normal practice in many animal houses 
facilities. The sacrifice of the animals, the extraction of brain tissue and plasma as well as other 
tissues (lungs, kidneys, heart, liver, muscle and adipose tissue) was performed on 3 days to 
minimise ‘batch effect’. On day 1, 4 animals were sacrificed as ‘test’ for the procedure first and 
then 4 vehicle-treated animals were processed. On day 2, the entire haloperidol-treated 
cohort was sacrificed alongside 4 vehicle-treated animals. On day 3, the entire citalopram-
treated group and the remaining 4 vehicle treated animals were processed. 
Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-
one) is a phenyl-piperidinyl-butyrophenone used in the treatment of psychotic disorders such 
as SCZ and schizoaffective disorder, and is the drug of choice for Tourette syndrome. It also has 
sedative and antiemetic activity. Haloperidol pharmacological effects are primarily at 
subcortical level. It is a strong blocker of adrenergic receptors and dopaminergic receptors. 
161 
 
Peripherally, it exerts weaker anticholinergic activity and ganglionic blocking action. In 
addition, it weakly blocks histamine and serotonergic receptors. 
The precise mechanism whereby the therapeutic effects of haloperidol are produced is 
not precisely known. It is a CNS depressor at the subcortical level of the brain and seems to act 
at the caudate nucleus inhibiting the ascending reticular activating system of the brain stem 
interrupting the impulse between the diencephalon and the cortex. Inhibition of 
catecholamine receptors may also contribute to haloperidol's mechanism of action. 
Citalopram is a furancarbonitrile (1-[3-(dimethylamino)propyl]-1 (4-fluorophenyl)-1,3-
dihydro-2-benzofuran-5-carbonitrile), and an antidepressant of the serotonin uptake 
inhibitors’ class. The therapeutic effect of citalopram is presumed to be linked to its inhibition 
of neuronal serotonin uptake at the serotonin reuptake pump of the presynaptic neuronal 
membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. citalopram has also 
very weak effects on norepinephrine and dopamine neuronal reuptake and no significant 
affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, 
serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors. We predicted that due to 
these therapeutic profiles, some of the pathways that will be highlighted would be altered by 
the effect of both agents whereas others will be exclusively affected by either one of them. 
In order to verify that the medication reached the target tissues, an ELISA assay was 
conducted to determine serotonin plasma and striatum levels in the entire cohort. A serotonin 
ELISA was used as both agents were known to alter serotonergic pathways and it was expected 
that striatum serotonin levels in the citalopram treated animals far exceeded those in the 
other groups. The fact that the haloperidol treated group showed an increase in serotonin 
levels with respect to controls also demonstrates that haloperidol was also effectively 
delivered via the implanted mini-pumps.  
Brain serotonin levels were increased by citalopram and haloperidol, in the two 
treated groups despite early evidence of haloperidol not having an effect on the synthesis of 5-
hydroxytryptophan (5-HTP), a precursor of serotonin (Carlsson et al.  1977). This effect could 
possibly be mediated by the indirect effect of haloperidol on dopa decarboxylase (Buckland et 
al.  1992) (Figure 26); whereas plasma serotonin levels were increased in the haloperidol 
treated group and markedly decreased in the plasma of the citalopram treated animals. 
The reasons for this were not explored further in this study but remain a subject of 
interest and further analysis since serotonin is synthesised in serotonergic neurons throughout 
the nervous system (although principally in the raphe nuclei in the brain) and in 
enterochromaffin cells of the gastrointestinal tract. Tryptophan, an essential amino acid, is the 
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precursor to serotonin synthesis occurring by the sequential action of tryptophan hydroxylase 
to 5-hydroxytryptophan and decarboxylation into 5-HT by 5-hydroxytryptophan decarboxylase. 
The availability of tryptophan influences the circadian levels of serotonin in the brain and 
plasma (Mateos et al.  2009).  
Serotonin is stored mainly as a peripheral pool in platelet granules and at lower levels 
in plasma. The principal metabolite of serotonin is 5-hydroxyindoleacetic acid generated by 
monoamine oxidase in hepatic and lung endothelial cells. Thus 5-HT plasma levels reflect 
equilibrium between synthesis, catabolism, platelet storage capacity, uptake and release 
kinetics and ability. It is plausible that citalopram and haloperidol have opposing effects only in 
































Figure 26. Metabolic pathway of dopamine, serotonin, and BH4. 
5-hydroxyindole acetic acid is formed initially from tryptophan in a reaction catalysed by 
tryptophan hydroxylase○2 to form 5-hydroxytryptophan (5HTP), which requires molecular 
oxygen and tetrahydrobiopterin (BH4) for its activity. 5-hydroxytryptophan is decarboxylated 
by pyrimidine dependent aromatic L-amino acid decarboxylase○3 to form the active 
neurotransmitter serotonin. Serotonin is catabolised by monoamine oxidase○4 to form 5-
hydroxyindole acetic acid (5HIAA). Tyrosine is metabolised by tyrosine hydroxylase○1 to L-
dopa. Aromatic L-amino acid decarboxylase○3 is also required for the decarboxylation of L-
dopa to dopamine, which is then catabolised to homovanillic acid by monoamine oxidase and 
catechol O-methyl-transferase○5. GTP = Guanosine triphosphate. DHNP = Dihydroneopterin 
triphosphate. 6-PT = 6-Pyruvoyl-tetrahydropterin. DHPR = Dihydropteridin reductase. qBH2 = 







A classical proteomic approach was used to examine the two target tissues (plasma 
and striatum) as well as the control tissue (prefrontal). Twenty two different proteins were 
identified in 19 plasma spots (Table 27): α-1-antiproteinase; α-1-macroglobulin; 
angiotensinogen; anionic trypsin-2; apolipoprotein A-IV; ATP synthase subunit beta, 
mitochondrial; beta-2-glycoprotein 1; carbonic anhydrase 1; carbonic anhydrase 2; 
complement C3; fibrinogen α chain; fibrinogen beta chain; fibrinogen gamma chain; 
haptoglobin; Ig gamma-2B chain C region; Ig kappa chain C region, A allele; Ig lambda-2 chain C 
region; plasminogen; pyruvate kinase isozymes M1/M2; serotransferrin; tubulin α-1C chain 
and vitamin D-binding protein. 
And 30 were identified in 18 striatum spots (Table 27): acyl-protein thioesterase 1; 
aspartate aminotransferase, cytoplasmic ; ATP synthase subunit α, mitochondrial; carbonic 
anhydrase 2; creatine kinase U-type, mitochondrial; dihydropteridine reductase; 
dihydropyrimidinase-related protein 2; fructose-bisphosphate aldolase A; fructose-
bisphosphate aldolase C; glutamine synthetase; glutathione S-transferase P; Glyceraldehyde-3-
phosphate dehydrogenase; isocitrate dehydrogenase [NAD] subunit beta, mitochondrial ; 
malate dehydrogenase, mitochondrial; NAD-dependent deacetylase sirtuin-2; NADH 
dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial; phosphoglycerate kinase 1; 
phosphoglycerate mutase 1; protein DJ-1; pyruvate dehydrogenase E1 component subunit α, 
somatic form, mitochondrial; pyruvate kinase isozymes M1/M2; Rho GDP-dissociation inhibitor 
1; succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial; triosephosphate 
isomerase; tubulin beta-2C chain; Ubiquitin carboxyl-terminal hydrolase isozyme L1; voltage-
dependent anion-selective channel protein 1; voltage-dependent anion-selective channel 








Table 27. Proteins identified in plasma and striatum of F344 rats. 
Proteins in plasma 
Accession 
No. 
Proteins in striatum 
Accession 
No. 
Alpha-1-antiproteinase p17475 Acyl-protein thioesterase 1 p70470 
Alpha-1-macroglobulin q63041 Aspartate aminotransferase, cytoplasmic p13221 
Angiotensinogen p01015 ATP synthase subunit α, mitochondrial p15999 
Anionic trypsin-2 p00763 Carbonic anhydrase 2 p27139 
Apolipoprotein A-IV P02651 Creatine kinase U-type, mitochondrial p30275 
ATP synthase subunit beta, mitochondrial p10719 Dihydropteridine reductase p11348 
Beta-2-glycoprotein 1 p26644 Dihydropyrimidinase-related protein 2 p47942 
Carbonic anhydrase 1 b0BNN3 Fructose-bisphosphate aldolase A p05065 
Carbonic anhydrase 2 p27139 Fructose-bisphosphate aldolase C p09117 
Complement C3 p01026 Glutamine synthetase p09606 
Fibrinogen alpha chain p06399 Glutathione S-transferase P p04906 
Fibrinogen beta chain p14480 Glyceraldehyde-3-phosphate dehydrogenase p04797 
Fibrinogen gamma chain p02680 Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial q68FX0 
Haptoglobin p06866 Malate dehydrogenase, mitochondrial p04636 
Ig gamma-2B chain C region p20761 NAD-dependent deacetylase sirtuin-2 q5RJQ4 
Ig kappa chain C region, A allele p01836 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial p19234 
Ig lambda-2 chain C region p20767 Phosphoglycerate kinase 1 p16617 
Plasminogen q01177 Phosphoglycerate mutase 1 p25113 
Pyruvate kinase isozymes M1/M2 p11980 Protein DJ-1 o88767 
Serotransferrin p12346 Pyruvate dehydrogenase E1 component subunit α, somatic form, mitochondrial p26284 
Tubulin alpha-1C chain q6AYZ1 Pyruvate kinase isozymes M1/M2 p11980 
Vitamin D-binding protein p04276 Rho GDP-dissociation inhibitor 1 q5XI73 
 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial q920L2 
Triosephosphate isomerase p48500 
Tubulin beta-2C chain q6P9T8 
Ubiquitin carboxyl-terminal hydrolase isozyme L1 q00981 
Voltage-dependent anion-selective channel protein 1 q9Z2L0 
Voltage-dependent anion-selective channel protein 2 p81155 
V-type proton ATPase subunit B, brain isoform p62815 
V-type proton ATPase subunit E1 q6PCU2 
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Antagonistic effects between haloperidol and citalopram were observed in both 
plasma and striatum. 
In plasma, haloperidol decreased the expression of fibrinogen alpha, beta and gamma 
chains; beta-2-glycoprotein 1; Ig gamma-2B chain C region; serotransferrin; anionic trypsin-2; 
pyruvate kinase isozymes M1/M2; complement C3; apolipoprotein A-IV and ATP synthase 
subunit beta, mitochondrial; while citalopram increased it. The expression of α-1- 
mocroglobulin was increased by haloperidol and decreased by citalopram in plasma (Table 28). 
In striatum, haloperidol increased the expression of aspartate aminotransferase, 
cytoplasmic; isocitrate dehydrogenase [NAD] subunit beta, mitochondrial; fructose-
bisphosphate aldolase A; triosephosphate isomerise and ATP synthase subunit α, 
mitochondrial; while citalopram decreased it (Table 29). 
The main pathways in which haloperidol and citalopram showed opposing expression 
effects are glucose and lipid metabolism, mitochondrial function, immune response, 















Belongs to the protease inhibitor I39 (α-2- 
macroglobulin) family. 
Anionic trypsin-2 p00763 Prss2 Calcium ion binding, peptidase activity. 
Apolipoprotein A-IV P02651 Apoa4 Antioxidant, cholesterol transporte and lipid binding 
ATP synthase subunit 
beta, mitochondrial 
p10719 Atp5b MHC class 1 protein , calcium ion and ATP binding 
Beta-2-glycoprotein 1 p26644 Apoh 
Glycoprotein and lipid binding. May prevent 
activation of intrinsic blood coagulation cascade by 
binding to phospholipids on the surface of damaged 
cells 
Complement C3 p01026 C3 





Blood coagulation, platelet activation, response to 
calcium ion 




Inflammatory and calcium ion response, platelet 
activation 
Haptoglobin p06866 Hp 
Inflammatory response, haemoglobin binding, 
apoptosis 
Ig gamma-2B chain C 
region 




Glucose metabolic processes, apoptosis, response to 
hypoxia 
Serotransferrin p12346 Tf 
























p05065 Aldoa Glycolisis and gluconeogenesis, scaffolding protein 
Isocitrate 
dehydrogenase 
[NAD] subunit beta, 
mitochondrial 
q68FX0 Idh3B 













5.1. Rationale and aims 
Proteome-based plasma biomarkers for neuropsychiatric conditions have been identified in 
disorders such as Alzheimer’s (Hye et al.  2006) and Parkinson’s disease (Chen et al.  2011) 
using classical proteomic approaches such as 2DPAGE and immunoblotting. The aim of this 
pilot study was to test the viability of using proteomic techniques, namely 2DPAGE coupled 
with LC/MS/MS, to search for biomarkers in plasma in a small, yet well characterised and 
matched case-control sample of patients with schizophrenia. 
 
5.2. Material and methods 
The Genetics and Psychosis (GAP) study is an infrastructure project supported by the Maudsley 
Charitable Fund and the National Institute of Health Research (NIHR) Biomedical Research 
Centre (BRC) for Mental Health. It was approved by the local ethics committee and aims to 
recruit all patients with a first onset psychosis attending the South London and Maudsley 
Mental Health National Health Service (NHS) Foundation Trust, the largest mental health trust 
in the UK. 
Patients aged 18–65 years with a clinical diagnosis of psychosis who presented for the 
first time to the Lambeth, Southwark and Croydon adult in-patient units of the South London 
and Maudsley Mental Health National Health Service (NHS) Foundation Trust between 2005 
and 2008 were approached for inclusion in the study. Written consent to provide biological 
samples and to allow the use of those for proteomic studies was obtained in all of those who 
agreed to take part.  
 
5.3. Subjects and samples 
Cases with a diagnosis of organic psychosis, learning disability, head injury, or with poor 
command of English language were excluded. Those who met ICD–10 criteria for a diagnosis of 
psychosis (codes F20–F29 and F30–F33) (World Health Organization. The ICD–10 Classification 
of Mental and Behavioural Disorders. Clinical Description and Diagnostic Guidelines. WHO, 
1992) were invited to participate in the study. Controls were recruited over the same period of 
time from the local communities from where the cases lived were recruited by means of 
advertisements in the local press, and leaflet distribution at train stations, shops and 
job centres. The control sample was selected to match as much as possible the patient sample 
in age, gender, ethnicity, educational qualifications and employment status. Potential control 
subjects were excluded if they met criteria for psychosis, either by means of reporting past 
psychiatric history of a psychotic disorder or by being identified as possibly having one by the 
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Psychosis Screening Questionnaire (Bebbington PE, Nayani T. The Psychosis Screening 
Questionnaire. Int J Methods Psychiatr Res 1995; 5: 11 –9).  
Systematic assessments on all patients were made by trained researchers to collect 
clinical variables using standardised research scales. All medication and non-prescription drugs 
used were carefully noted. Subjects were drawn from the GAP sample on the basis of having a 
control matched as close as possible for ethnicity, age, gender, current use of alcohol, tobacco 
and cannabis. Potential cases were further selected according to the antipsychotic treatment 
they were receiving at the time their blood sample was obtained.  
For this study, 30 cases and 30 matched controls were selected for the discovery 
phase. There were no statistically significant differences between the groups in terms of 
gender, age, ethnicity, alcohol, and tobacco and cannabis use (Table 30). A more detiled 
description of the sample is provided in Table 31. 
Blood samples were collected using a 23G butterfly needle and a vacutainer needle 
holder following standard venipuncture in the cubital region, in the area of anastomosis 
between the radial and the ulnar veins, or in the brachial vein proximal to this area. To avoid 
coagulation of the sample, a 9ml K3EDTA tube (Greiner Bio-One, Cat # 455036X - EDTA tube, 
lavender lid) was used. Samples were kept at +4C until being processed, with the time 
between collection and processing of the sample never exceeding two hours. Tubes were 
labelled with the subject barcode only. Blood samples were centrifuged at 3000 rcf (xg), 8 
minutes at +4C and plasma was aliquoted in 0.5 ml eppendorf tubes and immediately frozen 
at -80C.  
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Table 30. Summary of demographic details for the subjects used for the pilot study.  
M = Male, F = Female, C = Caucasian, B = Black.  
 
 Cases Group 
(N = 30) 
Control Group 
(N = 30) 
 
  
  Mean SD Mean SD U z p 
Age 32.83 9.128 33.43 9.673 440.000 -.148 .882 
  N % N % χ
2
 df p 
Female 6 20 7 23.3 .098 1 .754 
Ethnicity 
White 16 53.3 19 63.3 
.868 3 .833 
Black African 5 16.6 3 10 
Black Caribbean 5 16.6 4 13.3 
Other 4 13.3 4 13.3 
Alcohol Use 20 66.6 24 80 1.364 .243 .382 
Tobacco Use 16 53.3 15 50 .067 1 .796 
Cannabis Use 19 63.3 19 63.3 .000 1 1 
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Table 31. Subjects from the GAP sample used for the pilot study.  
Case 
Control 





































































































































































































































































































































































































































































BA = Black African, WB = White British, BC = Black Caribbean; OC = Other Caucasian. 
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5.4.  Protein analysis 
Since protein concentration is chiefly due to albumin content and differences in its 
concentration had not been reported in SCZ, loading the same protein quantity, rather than 
the same volume was favoured. Protein concentrations of plasma samples were determined 
according to the method of Bradford (Bradford, 1976) using bovine serum albumin as a 
standard. In brief, samples (2 l) were mixed with Bradford reagent (1 ml) and the optical 
density (OD) was read after 20 minutes at 595 nm. 
Samples were defrosted on ice to minimise protein degradation and then mixed 
(vortex) and centifuged to homogenize the contents. The volume of plasma determined to 
contain 50 µg of protein (approx. 1 l) was dissolved in IPG rehydration buffer containing 15 μl 
IPG Buffer (pH3-11 NL). For running 18cm Immobiline DryStrips, 350 μl total volume was 
required per strip. The sample comprised no more than 100 μl of the total volume and hence, 
eppendorfs containing 350 μl – Xsample volume of IPG rehydration buffer + Xsample volume were 
prepared and left at room temperature for 30 min to allow protein denaturation, followed by a 
5 min spin at 13000 rpm. 
Immobiline pH gradient strips of 18 cm length (pH 3-11) were then focused to 
immobilise individual proteins according to their isoelectric point, completing the first step of 
the process of separating the complex biological mixture. The strips were rehydrated and 
focused using the IPGphor (Amersham Bioscience) platform.  
The strips were taken off the strips holders and frozen overnight at -80C prior to the 
second dimension separation. Immobiline strips were taken off the freezer and thawed at RT 
before being equilibrated in order to re-solubilise the proteins and to reduce -S-S- bonds. 
Equilibration took place in an orbital shaker where they were individually placed in cylindrical 
glass tubes. SDS-PAGE 2D Acrylamide gels were made in-house using the Ettan Dalt II gel caster 
system (Amersham biotech, UK) and electrophoresis plates. A 10% acrylamide solution was 
made immediately before use and poured into the caster. The gels were allowed to polymerise 
overnight. 
The IPG gel strips were cut to size at both ends, taking care not to alter the hydrated 
gel and inserted between the two glass sheets of each plate and gently slid down until 
reaching the upper surface of the polymerise gel where they were sealed in place using a 
solution containing agarose. Electrophoresis was performed using the Ettan Dalt II 
(Amersham Biosciences) separation unit. The gels were kept at a constant current of 5 watts 
per gel for 1h and then subjected to a current of 80 watts per gel for up to 10-12 h or until the 
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bromophenol dye used in the sealing solution had completed its run across the vertical axis of 
the gel. The electrophoresis separation unit was kept at RT. 
Gels were stained using the silver staining procedure with an optimised and adapted 
version of the protocol described by Hochstrasser et al. (Hochstrasser et al.  1988). For 
preparative mass spectrometry silver staining was performed using a separate staining kit with 
slight modifications (Silver Plus one, Amersham Biosciences). Gels were scanned immediately 
after being developed using a Bio-Rad GS-710 Calibrated Imaging Densitometer and 
proprietary software (Bio-Rad, Seoul). Images of individual gels were cropped and saved in .tiff 
format for posterior image analysis which was performed using Progenesis Samespots 
software (Nonlinear Dynamics, UK) version 3.0. 
Statistical analysis was performed using SPSS (v15). The mean integrated optical 
densities of spots on 2D gels were analysed using Student’s t-test or non-parametric tests 
(Mann-Whitney) if not normally distributed. False Discovery Rate (FDR) correction for multiple 
testing was applied. Spots were selected according to significance level (p) and fold change. 
Validation by immunoblotting was performed on an extended sample of cases and controls. 
Samples were run in triplicate and the optical densities were normalized using the average 
density of the membrane. Average values for the repeated measures of the same sample were 
obtained and Student’s t-test was applied in normally distributed variables, otherwise the 
Mann-Whitney test was used. 
Selected spots were excised from 2-DGE preparatory gels containing 300 µg of protein 
gels and stained with modified Plus One silver stain kit (Amersham, UK) to make silver staining 
compatible with MS procedures. A reference image with the selected spots was printed using 
Progenesis SameSpots software and used as template for manual picking. The gel fragments 
were subsequently taken to Proteome Science plc and processed by Steve Lynham. Gel 
fragments were subjected to in-gel reduction, alkylation and digestion with trypsin. The 
MS/MS analyses were conducted using collision energy profiles that were chosen based on the 
m/z and the charge state of the peptide. The mass spectral data was processed into peak lists 
and searched against the Swiss Prot or NCBI non-redundant databases using Mascot software 
(Matrix Science, UK). The data was searched using specific amino acid modification 
parameters, ie. Variable cysteine carbamidomethylation modification (resulting from reduction 
and alkylation reaction) and variable methionine oxidation modification. Sequence information 
was obtained for all the peptides included in the results. Protein assignments were based on 
the matching of MS/MS spectra to the protein sequence. All results were visually verified to 
ensure that the fragment ions correctly matched the assigned sequence.  
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The sequence coverage for each identified protein is given in Appendix 3. Four 
proteins were identified with two peptides matched to the protein sequence and for a further 
four proteins, identification was based on a single matched peptide. In these cases, the 
observed MW (molecular weight) and pIs (Isoelectric points) of the protein spot can be taken 
into account to give extra confidence to the protein sequence. From assessing the theoretical 
MW and pIs of the proteins to the observed values, all proteins appeared to fall within 
acceptable ranges. To add extra confidence to the observed results, the peptide sequence for 
each protein identification was subjected to an NCBI protein-protein BLAST search to ascertain 
that such sequences were unique to that protein. In all cases the peptides were unique to the 
protein indicated. 
To add even further confidence to the assignments and give an indication of the false-
positive rate within the dataset, each dataset was searched against a database containing the 
Swiss-Prot database in reverse sequence. No false-positives were assigned within the datasets 
indicating a high confidence in the genuine assignments. 
 
5.5. Immunoblotting and validation of targets 
Western blot was used to detect proteins of interest in an independent sample of subjects. 
Western blot is used to separate proteins according to molecular weight by means of gel 
electrophoresis. The separated proteins are then transferred to a membrane where they are 
incubated with specific antibodies. The validation sample was drawn from the GAP study. 
Plasma proteins were resolved in 10% (w/v) polyacrylamide SDS-PAGE using the Gel 
unit vertical complete for precast or handcast gels up to 200mm x 100mm (Fisherbrand, 
FB69602). Sample loading volume was 10 l and gels were run at constant voltage (200V, 3.00 
A and 300 W) with a Bio-Rad PowerPac 300 until the dye reached the bottom end of the gel (1-
2 hours). Once protein separation occurred in the acrylamide gels, the proteins were 
transferred to 17x6 cm pieces of 0.45 µm nitrocellulose membrane (Schleicher & Scheull) in 
order to be probed with specific antibodies. A Trans-Blot Electrophoretic Transfer Cell (Bio-
Rad) was used. A current of constant voltage of 100 V was then applied for 1 hour. Following 
the transfer, the membrane was incubated with Ponceau solution for 1 min to determine the 
efficiency of the protein transfer and subsequently blocked to reduce non-specific binding by 
using a 5% non-fat milk 0.01 M PBS solution. 
Membranes were then incubated overnight at 4C in blocking buffer with the primary 
antibody at an optimized dilution for detection based on manufacturer’s protocol. The 
following morning, the membranes were washed in 0.1% PBS-Tween (3x5 min) and place in a 
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white, non-transparent box containing 10 ml of 0.1% PBS Tween + 5% milk for 30 min at room 
temperature. Secondary antibodies were diluted in 5% Milk PBSTween solution (1:6000) in a 
Falcon tube protected from light with foil paper. The 0.1% PBSTween+5% milk of the boxes 
containing the membranes was replaced with the secondary AB solution and the boxes were 
placed in an orbital rocker for 1 hour at RT. The membranes were washed on PBSTween 3x 5 




Image analysis of the gels using Progenesis SameSpots yielded 1481 differentially expressed 
spots. Out of those 77 were significantly different according to p value and fold change. 
Principal Component Analysis (PCA) is a multivariate analysis related to factor analysis which 
was used to transform the observations (spots identified) in a set of uncorrelated variables 
(Principal Components). The first component account for as much of the variability as possible. 
Subasequent ones have the highest possible variance as long as they remain uncorrelated with 
the preceding component. Following PCA, a group distribution was observed in the sample 
(Figure 27) showing that cases and controls could be discriminated on the basis of the selected 
significantly differentially expressed spots. Eight spots (60, 61, 67, 72, 92, 94, 1286 and 1847) 
were selected for LC/MS/MS according to their level of significance and fold change (Figure 










Figure 28. Image of a preparatory human plasma gel with the selected spots highlighted and 
excised for LC/MS/MS.   
A preparatory gel, rather than an ‘analytical gel’ has been used here for illustration purposes. 

























60 928.01 670.06 .02 1.4 
Hemoglobin subunit beta 








61 2415.93 1824.78 .02 1.4 










67 824.49 584.70 .03 1.4 
Protein S100-A8 (S100 




72 1343.12 2053.97 .05 1.3 
Serum albumin precursor P02768 69321 5.9 
Gelsolin precursor (Actin-




92 10960.74 12721.52 .03 1.1 
Ig kappa chain C region P01834 11602 5.6 
Ig kappa chain V-II region TEW P01617 12308 5.7 
94 9663.57 8713.63 .01 1.1 
Ig kappa chain C region P01834 11602 5.6 
Ig lambda chain C regions P01842 11230 6.9 










Complement C4-A precursor 






Thus, six spots containing hemoglobin subunit beta; peroxiredoxin-1; complement 
factor I precursor; clusterin precursor; S100-A8; Ig kappa chain C region; Ig lambda chain C 
regions; afamin precursor; complement C1r subcomponent precursor and complement C4-A 
precursor appeared to be increased in cases whereas the expression of serum albumin 
precursor; gelsolin precursor; Ig kappa chain C region and and Ig kappa chain V-II region TEW 
was decreased. 
Commercial antibodies (Table 33) were obtained for afamin, S100A8, gelsolin, clusterin 
and peroxiredoxin-1 and validation was performed for these proteins. 
Antibodies were tested and optimized according to manufacturer’s instructions. 
S100A8 and gelsolin showed clear distinction bands at the correct molecular weight and 
therefore were selected for further analysis (Figure 29). 
Immunoblots for gelsolin were performed in triplicate. Fluorencence signal intensities 
were individually measured (K counts) and normalised. An independent Samples t-test for 
equality of means was applied using SPSS v15. 
Gelsolin levels were quantified in triplicate for 87 controls and 125 cases. The S100A8 
validation was done in a sample of 58 controls and 82 cases. The S100B ELISA in human plasma 
samples was done in a sample of 75 cases and 75 matched controls. 
Individual measures were normalized and the mean of the three quantifications was 
obtained. Student’s t-test was used as the variable appeared to be normally distributed. A 
significant difference between cases and controls was observed. The figures presented here 
are the average normalised volumes for each subject. Equal variances were not assumed 
following a non-significant result on the Levene’s Test (0.292) and the p value was calculated 




Table 33. Antibodies used for Western blot in human plasma samples. 








































The antibody is directed against an 
epitope located on the 47 kD peptide 
derived from a chymotryptic cleavage of 
gelsolin. This peptide contains the 



















Table 34. Results of gelsolin quantification.  
Gelsolin N Mean SD p MD SED 
95% CI 
Lower Upper 
Controls 87 0.44 0.15 
.01** 0.52 0.20 0.11 0.09 
Cases 125 0.39 0.13 
SD = Standard deviation; MD = Mean difference; SED = Standard error of the difference. 















Figure 30. Gelsolin mean average values (p = .009). 























S100A8 levels were also determined in the same validation sample. Student’s t-test 
was used as the variable appeared to be normally distributed. Equal variances were not 
assumed following a non-significant result on the Levene’s Test (0.457) and the p value was 
calculated at p = .9 (Table 35).  
As no difference was obtained, no further validation on S100A8 was performed. 
Nonetheless, S100A8 is one protein of a family of 25, all of which are involved in Ca2+ 
regulation and thus, it was decided to test another protein from the same family, S100B, 
instead. To examine the expression levels of S100B we utilised the Millipore Human S100B 
ELISA 96-Well Plate (Cat. #EZHS100B-33K). The ELISA allowed the detection of S100B with 
excellent sensitivity with a mean CV of 7.35% between duplicates. The inter assay was 
calculated from the QC 1&2 across all plates (mean 9.2%). Standard curves were generated 
using a 5-parameter logistic (5-PL) regression fit (Sigma Plot, Sysstat Software Inc) with a linear 
range from S7-S5 for all analytes. 
Quantified data from Sigma Plot was inputted into SPSS (v15), Shapiro-Wilk test for 
normality was performed (p > .05) indicating the data was not normally distributed. We 
therefore used nonparametric test (Mann–Whitney).  
Comparison of the means showed a large increase in S100B levels in the schizophrenia 





Table 35. Results of S100A8 quantification.  
S100A8 N Mean SD SED p MD 
95% CI 
Lower Upper 
Controls 58 0.68 0.13 0.02 
.96 .00 -0.04 0.04 
Cases 82 0.68 0.13 0.01 







Table 36. Results of S100B ELISA quantification in human plasma samples.  
S100A8 N Mean SD SED p MD 
95% CI 
Lower Upper 
Controls 75 56.49 40.65 4.69 
.007** -53.11 -91.61 -14.60 
Cases 72 109.60 163.56 19.27 
SD = Standard deviation; MD = Mean difference; SED = Standard error of the difference. ** 













Figure 31. S100B average plasma levels (p = .007). 





















This study intended to examine whether classical proteomic approaches could be used to 
canvass the plasma of patients suffering from psychotic symptoms for disease biomarkers. 
Samples were collected, processed and stored in accordance with a standard operational 
protocol (SOP) (Hochstrasser et al.  1988) which has been optimised at the Lovestone lab and 
is routinely employed for biomarker studies in plasma in AD (Hye et al.  2006; Thambisetty et 
al.  2010b).  
Fifteen subject pairs were selected from the GAP sample. Patients belonged to three 
treatment groups: (1) medication free; (2) treated with olanzapine; or (3) treated with 
risperidone. Controls were selected on the basis of being the closest match to the case for 
gender, age, ethnicity, smoking, alcohol and cannabis use.  
Plasma was extracted from whole blood in EDTA coated tubes; samples were 
subjected to less than 3 freeze-thaw cycles prior to entering electrophoresis. Gels were 
obtained, scanned and analysed and the top eight spots yielding significant p-value and fold 
change following multiple corrections (FDR) were excised from MS-compatible gel matrixes 
and subjected to mass spectrometry. As a result, 14 proteins and potential targets were 
identified. Ten of these proteins were upregulated in cases and 4 in controls. From the first 
group S100A8, peroxiredoxin-1, clusterin and afamin were selected and from the second group 
gelsolin was carried forward for validation and examined using Western blots with commercial 
antibodies. 
For two of those, gelsolin and S100A8, commercial antibodies were available. Gelsolin 
was found to be significantly lower in cases than in controls but no difference was observed in 
S100A8 expression levels between the groups. Failure to validate S100A8 was thought to be 
largely the result of the poor quality of the antibody. Hence, another protein of the same 
family, S100B was tested instead on the basis of 1) being a Ca2+ - binding protein of the same 
family; 2) previous reports of association with SCZ at proteomic (Lara et al.  2001; Petzold et al.  
2003; Rothermundt et al.  2004; Schmitt et al.  2005; Zhang et al.  2010b) and genetic level (Liu 
et al.  2005; Roche et al.  2007); and 3) availability of an ELISA kit. 
Gelsolin is a calcium-regulated protein that exerts its effect in the assembly and 
disassembly of actin filaments and maps to 9q33, a gene locus found to be implicated in 
modifying the clinical course and severity of SCZ (Fanous et al.  2007). Defects in this gene also 
cause familial amyloidosis finnish type (FAF), whereby systemic deposition of amyloid by the 
secreted (not cytoplasmic) form of the protein is found in most tissues resulting in a 
characteristic triad of ophthalmological, neurologic and dermatological symptoms (Kiuru, 
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1992). A recent study form the Lovestone group has shown that AD patients also displayed 
significantly lower plasma gelsolin levels compared to non-denmented controls (NDC) subjects 
and correlated with disease progression rate estimated by Mini-Mental Status Examination 
(Guntert et al.  2010).  
S100 proteins are Ca2+ - binding proteins of small molecular weight (10-12 KDa) which 
are located in chromosomes 1q21 (S100A1-A18, trychohylin, fillagranin, repetin), 21q22 
(S100B), Xp22 (S100G), 4p16 (S100P) and 5q14 (S100Z) and are present exclusively in 
vertebrates (Sedaghat and Notopoulos, 2008). S100B is the most abundant member of the 
S100 family expressed in the brain, predominantly synthesized and secreted by astrocytes. In 
addition, S100B, maps to 22q21, an area of linkage for schizophrenia and BPAD with psychosis 
(Liu et al.  2009; Roche et al.  2007) which has been identified as regulatory for presynaptic 
calcium signalling and synaptic plasticity in a mouse model of 22q11 deletion syndrome (Earls 
et al.  2010).  
Increased extracellular levels of S100B in the brain are indicative of neuronal injury or 
underlying chronic inflammation that can be subsequently measured in the peripheral 
circulation, after passing through the blood brain barrier. S100B, has previously been 
associated with SCZ in CSF (Rothermundt et al.  2004), and found to be increased in 
medication-free patients with a negative correlation with illness duration, indicating that a 
neurodegenerative process may take place in a subset of people suffering from SCZ (Lara et al.  
2001). In this study, we have used an ELISA that was designed to measure S100B in plasma, 
serum and CSF.  
The main limitations of this study are two fold. Firstly, 2DPAGE is labour intensive, 
quantification is poor, automation is difficult and cannot be coupled directly to mass 
spectrometry (Wang et al.  2002). Secondly, in this study only one protein (gelsolin) resulting 
from the discovery phase was validated. Not all the commercial antibodies obtained were 
shown to work on plasma and a signal at the predicted height corresponding to the theoretical 
molecular weight was identified in only two of them. Here, we present a retrospective study of 
samples collected from patients experiencing psychotic symptoms along with age matched 
controls on the levels of gelsolin and S100B found in the peripheral circulation. We have 
showed that classic proteomic techniques can be used for SCZ biomarker research in plasma 
and bear great promise for discovery of altered signalling pathways and molecular processes. 
The results of this study suggest that a subset of people presenting with psychotic 
symptoms might be suffering from underlying altered calcium signaling pathways.  
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6.1. Schizophrenia plasma proteomics 
The search for biomarkers in plasma in SCZ research started well over 50 years ago with the 
study of the variation in plasma aminoacids, serum lipids and proteins during psychotic 
episodes and periods of recovery (Wang et al.  2002) as well as following prefrontal lobotomy 
(Man et al.  1947a). Since then, proteomic studies have been conducted using serum, plasma, 
or cellular fractions of blood. Proteins for which two or more studies have been conducted and 
the changes in protein expression appear to be concordant and/or have been identified in 
plasma and in at least one other different tissue (brain, CSF, or serum) in schizophrenia are: 
1. Brain derived neurotrophic factor (BDNF) 
BDNF has been found downregulated in plasma in two studies in SCZ (Palomino et al.  2006; 
Tan et al.  2005) and in the plasma and CSF of drug-naïve first-episode psychotic patients (Issa 
et al.  2010; Pillai et al.  2010). In addition, it was reduced in the serum (Cunha et al.  2006) and 
plasma (Palomino et al.  2006) of bipolar patients. On the other hand, it has been shown to be 
upregulated in serum in SCZ in one other study (Jockers-Scherubl et al.  2004). BDNF promotes 
the survival and differentiation of selected neuronal populations of the peripheral and central 
nervous systems during neurodevelopment, participates in axonal growth, pathfinding, and in 
the modulation of dendritic growth and morphology. BDNF regulates synaptic transmission 
and plasticity at adult synapses and contributes to long-term potentiation (LTP), long-term 
depression (LTD) and to the homeostatic regulation of intrinsic neuronal excitability. Defects in 
BDNF are a cause of congenital central hypoventilation syndrome (CCHS), a rare disorder 
characterized by abnormal control of respiration. 
2. Neural cell adhesion molecule 1 (NCAM1) 
NCAM serum levels have been shown to be raised in plasma (Lyons et al.  1988) and in CSF of 
SCZ patients (Poltorak et al.  1997; Vawter et al.  2001) and also in the plasma of AD patients 
(Todaro et al.  2004). It is a cell adhesion molecule involved in cell-to-cell interactions as well as 
cell-matrix interactions during development and differentiation and also in neurite 
fasciculation and outgrowth. NCAM1 is involved in development of the nervous system, and in 
the expansion of T cells and dendritic cells, which play an important role in the immune 
surveillance of the CNS. 
3. Transthyretin (TTR) 
TTR was downregulated in plasma of SCZ patients in two studies (Wan et al.  2006; Yang et al.  
2006) and in CSF of SCZ patients (Huang et al.  2006a; Wan et al.  2006). It was also reduced in 
the serum of patients with AD (Elovaara et al.  1986). TTR probably transports thyroxine from 
the bloodstream to the brain. TTR defects are a cause of (1) hyperthyroxinemia 
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dystransthyretinemic euthyroidal (HTDE), a condition characterized by raised levels of total 
and free thyroxine in euthyroid subjects and (2) carpal tunnel syndrome type 1. 
4. Nerve Growth Factor (NGF) 
NGF expression has been found to be downregulated in plasma, serum, and in CSF of SCZ 
patients (Kale et al.  2009; Xiong et al.  2010), in plasma of BPAD patients (Barbosa et al.  
2010), and in serum of PD patients (Lorigados et al.  2002). NGF is important for the 
development and maintenance of the sympathetic and sensory nervous systems. It stimulates 
division and differentiation of sympathetic and embryonic sensory neurons. Defects in NGF are 
the cause of hereditary sensory and autonomic neuropathy type 5 (HSAN5). HSAN5 patients 
manifest loss of pain perception and impaired temperature sensitivity, ulcers, and in some 
cases self-mutilation. 
5. Interleukin-2 (IL2) 
IL2 expression was upregulated in the plasma and serum of patients with SCZ (Ganguli and 
Rabin, 1989; Maes et al.  1995b), and in their CSF (Licinio et al.  1993; McAllister et al.  1995), in 
the plasma of BPAD patients (Maes et al.  1995a), in serum of PK patients (Brodacki et al.  
2008) and in mononuclear cells of AD patients (Huberman et al.  1994). Reduced levels were 
found in peripheral blood mononuclear cells (PBMC) of PD (Bessler et al.  1999), and AD 
patients (Beloosesky et al.  2002). IL2 is type-1 secreted cytokine involved in the proliferation 
of lymphocites T and B. 
6. Interleukin-6 (IL6) 
IL6 levels were upregulated in the serum of SCZ patients according to 2 studies (Maes et al.  
1995a; Naudin et al.  1996) and in the CSF of patients with SCZ (Garver et al.  2003; van 
Kammen et al.  1999). The expression of its receptor (IL6R) was also upregulated according to 
another one (Muller et al.  1997). IL6 has also been found upregulated in the plasma of BPAD 
(Maes et al.  1995a) and AD patients (Swardfager et al.  2010). IL6 is a pro-inflammatory 
cytokine (type-1) which has been shown to be an endogenous pyrogen. The IL6 gene is 
implicated in a wide variety of inflammation-associated disease states including susceptibility 
to diabetes and systemic juvenile rheumathoid arthritis. 
 These data suggest alterations in plasma in schizophrenia indicative of disfunction in 
the regulation of synaptic transmission, nervous system development and thyroid function. In 
addition, they may have sensory and autonomic deficits (loss of pain perception and impaired 
temperature sensitivity), susceptibility to diabetes and alterations in their immune response. 
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In a recent paper, a serum protein signature of 34 analytes was identified in a cohort of 
closely matched first onset SCZ patients (n = 71) and controls (n = 59) (Schwarz et al.  2011a). 
These analytes were: α-1-antitrypsin (a1AT), α-2-macroglobulin (A2M), angiopoietin 2 (ANG2), 
BDNF, betacellulin, bone morphogenic protein (BMP6), carcinoembryonic antigen (CEA), CD40 
ligand (CD40L), cortisol, connective tissue growth factr (CTGF), epidermal growth factor (EGF), 
eotaxin 3, factor VII, follicle stimulating hormone (FSH), granulocyte macrophage colony 
stimulating factor (GM-CSF), gluthathione S transferase (GST), haptoglobin (HPT), intercellular 
adhesion mollecule 1 (ICAM 1), insulin-like growth factor binding protein (IGFBP 2), IL10, IL17, 
IL5, luteinizing hormone (LH), macrophage migration inhibitory factor (MIF), NCAM, pancreatic 
polypeptide (PP), prostatic acid phosphatise (PAP), RANTES (C-C motif chemokine 5), resistin, 
serum glutamic oxaloacetic transaminase (SGOT), sortilin, stem cell factor (SCF), 
thrombopoietin (TPO), and thrombospondin 1 (TSP1). 
Most of these proteins are involved in immunoregulation, cardiovascular diseases, and 
metabolic alterations, and in cellular migration and proliferation. Caution should be exercised 
when interpreting these results, as some of them, like haptoglobin and α-1-macroglobulin 
were shown in Chapter 4 of this thesis to be upregulated by haloperidol and citalopram in 
plasma, whereas glutathione S transferase was downregulated in the striatum of the F344 rats. 
 
6.2. Summary of my findings 
6.2.1. Examining the effects of DISC1 knockdown on the 
proteome of human progenitor cells 
The DISC1 affected Scottish pedigree included 23 members who met Research Diagnostic 
Criteria (RDC) for mental disorders, out of which 3 were cases of SCZ, 2 of schizoaffective 
disorder, 6 of major depressive disorder, 3 of generalised anxiety disorder, 1 of minor 
depressive disorder and 3 of alcoholism. There were also 3 who attempted suicide and 2 who 
completed it. A further 5 members were being treated for severe conduct disorder, learning 
disabilities, bizarre behaviour, and emotional disorders (St et al.  1990) . Since then, DISC1 has 
been associated with chronic fatigue syndrome (Fukuda et al.  2010), autism and mental 
retardation (Crepel et al.  2010), Asperger syndrome (Kilpinen et al.  2008), depression 
(Hashimoto et al.  2006), and bipolar disorder (Maeda et al.  2006). 
The approach used in this study to examine the proteome in SCZ is a novel discovery 
approach. A mimicked haploinsufficiency of DISC1 in human neural progenitor cells was 
investigated at a protein expression level. DISC1 expression was reduced in both DISC1 RNAi 
treated groups (35% reduction with RNAi1 and a 38% reduction for the samples treated with 
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RNAi2). Analysis of the cellular proteome was carried out by using 2DPAGE coupled to 
LC/MS/MS and two spots containing one single analyte each, were identified in this study as 
being regulated by both RNAi groups with a statistically significant difference with the control 
RNAi group. Dihydropteridine reductase (DHPR) was downregulated and peptidyl-prolyl 
isomerase A (cyclophilin A) was upregulated by both RNAi treatment groups.  
The DHPR gene locates to 4p15.31. Deletions in this area have been associated to 
development of cervical cancer (Singh et al.  2007), basal-like breast tumours (Horlings et al.  
2010), lung cancer (Davidson et al.  2010) and bladder cancer (Tatarano et al.  2011). In 
neuropsychiatric disorders, comparative gains in copy number variations have been found in 
Parkinson’s disease (Kim et al.  2008). DHPR reached gene-wide significance in bipolar affective 
disorder (Shi et al.  2008) but failed to survive correction for multiple testing. In addition, a SNP 
located on 4p15.31, was associated with a reduced risk of increasing suicidal ideation during 
treatment with escitalopram (Perroud et al.  2010). 
DHPR can be found in cytoplasm, cytosol and mitochondrion. It catalyzes the NADH-
mediated reduction of quinonoid dihydrobiopterin. The product of this enzyme, 
tetrahydrobiopterin (BH4), is an essential cofactor for phenylalanine, tyrosine, and tryptophan 
hydroxylases and is therefore important in the biosynthesis of dopamine and serotonin (Figure 
32).  
A marker of DHPR deficiency, which leads to tetrahydrobiopterin or (BH4) deficiency 
and impaired biogenic amines synthesis, is neonatal hyperphenilanemia. BH4 is an essential 
cofactor of aminoacid hydroxylases which are the rate-limiting enzymes in phenylalanine 
(Phe), tyrosine (Tyr), and tryptophan (Trp) catabolism and in biosynthesis of the 
neurotransmitters dopamine and serotonin. BH4 enhances the release of dopamine and 
serotonin in neurons (Liang and Kaufman, 1998) and is a neuroprotective factor via the nitric 
oxide (NO) synthase pathway (Thony et al.  2000). BH4 deficiencies have been associated with 
Alzheimer’s disease, Parkinson’s disease, autism, and depression (Thony et al.  2000).  
More recently, DHPR was found to be upregulated in the Wernicke’s area (Martins-De-
Souza et al.  2009a) and in the thalamus and CSF (Martins-De-Souza et al.  2010) of SCZ 
patients. On the other hand, DHPR activity has been measured in blood in a small sample of 
people with SCZ and healthy controls but no differences were found between the groups 
(Szymanski et al.  1985).  
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Figure 32. Biosynthesis and regeneration of tetrahydrobiopterin including possible metabolic 
defects and catabolism of phenylalanine. 
1.1 = phenylalanine-4-hydroxylase (PAH); 1.2/1.6 = GTP cyclohydrolase I (GTPCH), 1.3 = 6-
pyruvoyl-tetrahydropterin synthase (PTPS), 1.4 = dihydropteridine reductase (DHPR), 1.5 = 
pterin-4-a-carbinolamine dehydratase (PCD), 1.7 = sepiapterin reductase (SR), carbonyl 
reductase (CR), aldolase reductase (AR), dihydrofolate reductase (DHFR), aromatic aminoacid 






The cyclophilin A (PPIA) gene maps to chromosomic region 7p13 and has been weakly 
linked to mood-incongruent psychosis in bipolar affective disorder (Hamshere et al.  2009). 
Cyclophilin A (PPIA) catalyzes the cis-trans isomerization of proline imidic peptide bonds in 
oligopeptides and accelerate the folding of proteins.  
Cyclophilin A is a proinflammatory cytokine that activates endothelial cells and is the 
main target of cyclosporine A (Jin et al.  2004). PPIA is secreted from smooth muscle and 
macrophages in response to oxidative stress (Jin et al.  2004). This protein is a cyclosporin 
binding-protein and may play a role in cyclosporin A-mediated immunosuppression. The 
complex cyclosporin-PPIA inhibits calcineurin, a calcium/calmodulin dependent phosphatase. 
The protein can also interact with several HIV proteins, including p55 gag, Vpr, and capsid 
protein, and has been shown to be necessary for the formation of infectious HIV virions, 
regulating HIV-1 and hepatitis C infectivity (Braaten and Luban, 2001; Liu et al.  2009). 
Cyclophilin A is upregulated in endometrial carcinoma (Li et al.  2008) and is involved 
in the progression of human breast cancer (Zheng et al.  2008), being necessary for the 
prolactin (PRL)-induced activation of the Janus-activated kinase 2 tyrosine kinase (Jak2/STAT) 
signaling pathway by interacting with the human prolactin receptor (Syed et al.  2003). 
Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signaling (Yang et al.  
2007). In neuropsychiatric disorders, the role of PPIA is not yet fully understood. It appears 
that it has a role in apoptosis as it augments chromatinolysis synergically with apoptosis 
inducing factor (AIF) (Cande et al.  2004), which moves from mitochondria to nuclei following 
cerebral hypoxia-ischemia (Zhu et al.  2007). A recent study showed that PPIA was 
downregulated in the anterior cingulate cortex of schizophrenic males (Martins-De-Souza et al.  
2010) but was found in a different study by the same authors to be upregulated in the 
thalamus and CSF of SCZ patients (Martins-De-Souza et al.  2010) , which may suggest a region-
specific profile expression. In addition, PPIA appears to promote atherosclerosis in 
apolipoprotein-E deficient mice (Nigro et al.  2011). 
In this study, a classical proteomic approach has been used to show that DISC1 
haploinsuficiency results in downregualtion of DHPR and thus, alteration in the synthesis of 
dopamine and serotonin as well as upregulation of PPIA. These alterations are likely to act 
synergistically inducing the molecular alterations responsible for the emergence of 
psychopathology in terms of affective and psychotic symptoms, as well as some of the 
cytostructural alterations frequently observed in people with schizophrenia such as reduced 






6.2.2. Examining the effects on brain and blood proteome 
of antipsychotic and antidepressant medication on F344 inbred 
rats 
A classical proteomic approach was used to examine two target tissues (plasma and striatum) 
as well as the control tissue (prefrontal) from F344 inbred rats treated with haloperidol, 
citalopram and a control (vehicle) solution through surgically implanted osmotic mini-pumps. 
Serotonin levels were measured in plasma and prefrontal cortex to verify that medication 
reached target organs and 2DPAGE coupled to LC/MS/MS was used to examine differential 
proten expression in plasma and striatum. Following analysis of the gels using Progenesis 
SameSpots software, 19 spots from plasma and 18 from striatum were selected on the bases 
of their p-value, fold change and FDR.  
Twenty-two different proteins were identified in 19 plasma spots: α-1-antiproteinase;  
α-1-macroglobulin; angiotensinogen; anionic trypsin-2; apolipoprotein A-IV; ATP synthase 
subunit beta, mitochondrial; beta-2-glycoprotein 1; carbonic anhydrase 1; carbonic anhydrase 
2; complement C3; fibrinogen α chain; fibrinogen beta chain; fibrinogen gamma chain; 
haptoglobin; Ig gamma-2B chain C region; Ig kappa chain C region, A allele; Ig lambda-2 chain C 
region; plasminogen; pyruvate kinase isozymes M1/M2; serotransferrin; tubulin α-1C chain 
and vitamin D-binding protein.  
And 30 in 18 striatum spots: acyl-protein thioesterase 1; aspartate aminotransferase, 
cytoplasmic ; ATP synthase subunit α, mitochondrial ; carbonic anhydrase 2; creatine kinase U-
type, mitochondrial; dihydropteridine reductase; dihydropyrimidinase-related protein 2; 
fructose-bisphosphate aldolase A; fructose-bisphosphate aldolase C; glutamine synthetase; 
glutathione S-transferase P; glyceraldehyde-3-phosphate dehydrogenase; isocitrate 
dehydrogenase [NAD] subunit beta, mitochondrial ; malate dehydrogenase, mitochondrial; 
NAD-dependent deacetylase sirtuin-2; NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial; phosphoglycerate kinase 1; phosphoglycerate mutase 1; protein DJ-1; pyruvate 
dehydrogenase E1 component subunit α, somatic form, mitochondrial; pyruvate kinase 
isozymes M1/M2; Rho GDP-dissociation inhibitor 1; succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial; triosephosphate isomerase; tubulin beta-2C chain; 
ubiquitin carboxyl-terminal hydrolase isozyme L1; voltage-dependent anion-selective channel 
protein 1; voltage-dependent anion-selective channel protein 2; V-type proton ATPase subunit 
B, brain isoforms and V-type proton ATPase subunit E1. 
A list of upregulated proteins and another one of downregulated proteins was 
prepared and inputed to generate biological networks. A system biology analysis was 
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performed using GeneGo (www.genego.com). GeneGo provided data mining analysis to 
identify and prioritise the most relevant pathways, networks and cellular processes altered by 
the effect of the drug. The main parameters for the analysis were (a) relative enrichment with 
the uploaded data, and (b) relative saturation of networks with canonical pathways. Networks 
were then prioritized based on the number of fragments of canonical pathways present on 
them. 
Three proteins were present in both lists and were mostly downregulated in plasma 
and striatum by haloperidol and citalopram: carbonic anhydrase 2, pyruvate kinase isozymes 
M1/M2 and tissue-specific chains of tubulin, in plasma (alpha-1C) and in brain (beta-2C). 
Carbonic anhydrase (CAH2) was downregulated in both treatment groups in plasma 
and in striatum. CAH2 is an enzyme with carbonate dehydratase activity (H2CO3 = CO2 + H2O) 
and metal, protein and zinc ion binding properties. It is involved in carbon dioxide transport, 
response to pH, response to stress, response to steroid hormone stimulus, regulation of bone 
resorption, odontogenesis and kidney development mainly. It is extremely ubiquitous and can 
be found in the apical part of the cell, the axon, the basolateral plasma membrane, the 
cytoplasm and cytosol, the extracellular space, the microvillus and the nucleus. CAH2 is 
involved in osteoporosis and its transcription is regulated (activated) by the vitamin D3 
Receptor (VDR) in monocytic cells (Quelo and Jurdic, 2000). 
Its Homo sapiens homolog is a 29246 Da protein coded by the CA2 gene, located in 
8q21.3-q22, and partakes in similar cell signalling pathways and molecular processes. This 
chromosomal region has been recently shown to have a weak linkage to SCZ (Wiener et al.  
2009) and a possible association with juvenile bipolar disorder phenotype (Doyle et al.  2010). 
Evidence of alteration in this protein in SCZ has been suggested by Martins-De-Souza and 
colleagues recently (Martins-De-Souza et al.  2009b), who found it to be down regulated in the 
anterior temporal lobe of post-mortem samples of SCZ patients. Nonetheless, given the 
cellular mechanisms this protein is involved in and the fact that it was downregulated as a 
result of medication in an animal model of healthy rodents, it is probably safer to assume that 
the finding of Martins-de-Souza and colleagues was due to the effect of medication rather 
than being part of the etiopathological process of the disorder. 
A second protein that appeared in both lists was the mitochondrial pyruvate kinase 
isozymes M1/M2 (KPYM_RAT). It was downregulated in both plasma and brain in the 
haloperidol treated group and in the striatum of the citalopram treated group, whereas it was 
upregulated in the plasma of the citalopram treated animals. KPYM_RAT is a glycolytic enzyme 
located in the cytoplasm, cytosol, flagellum, mitochondrion, nucleus and plasma membrane of 
the cell as well as having a soluble fraction. It catalyzes the transfer of a phosphoryl group from 
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phosphoenolpyruvate (PEP) to ADP, generating ATP. It is involved in ATP metabolism, G-
protein signalling, glycolisis and gluconeogenesis and pyruvate metabolism (Sugden and 
Holness, 2002). It participates in insulin signal transduction and potassium ion transport. It is 
also involved in the organism response to hypoxia, liver development and programmed cell 
death (Kietzmann et al.  2002). 
The human homolog of this protein, KPYM maps to gene PKM2, located on 15q22 
which has been shown to be an area of linkage in SCZ (Stone et al.  2004). Moreover, a 
decrease in the levels of pyruvate, the final product of glycolisis, has been previously reported 
in the mediodorsal thalamus but not in the CSF of SCZ patients (Martins-De-Souza et al.  2010). 
Whether this alteration is a medication effect or integral part of the pathophysiology of SCZ 
remains to be determined. The expression of the enzyme is induced by insulin mediated 
activation of PI3K and MAPK signalling pathways (Mazurek, 2011). Activation of PI3K/Akt 
signalling promotes phosphorylation/inactivation of GSK-3, suppresses GSK-3-dependent 
phosphorylation of tau at residues overphosphorilated in AD and prevents apoptosis of 
confluent cells and may prevent development of AD pathology (Baki et al.  2004).  
Downregulation of PKM2 may thus alter GSK3-beta signalling which has been speculated to be 
altered in SCZ patients (Souza et al.  2008). 
Lastly, the third altered protein, tubulin, is involved in microtubule-based movement 
and protein polymerization and is an integral component of cytoplasm, cytosol, microtubules 
and cytoskeleton. It plays a crucial role in cell division, vesicle formation and exosomal 
release, as well as in maintaining effective intracellular transport of organelles, such as 
mitochondria from the soma to the synapse, and in stabilising the synapse by establishing 
intersynaptic filaments that attach the synaptic bulbs from the axon of the presynaptic 
neuron to the plasma membrane of the opposing neuron. This dimer of alpha and beta 
chains, had its α-1C chain (Tuba1c) downregulated in plasma in both treatment groups, and 
its beta-2C chain (Tubb2c), which is expressed exclusively in neurons, was downregulated as 
well in both groups relative to vehicle treated animals in the striatum samples.  
Tuba1c (7q36) has nucleotide binding activity and GTPase activity. The homolog 
human gene is TUBA1C, located in 12q13.12; a gene associated with human lissencephaly and 
cerebellar hypoplasia (Lecourtois et al.  2010) and thus, suspected of playing a crucial role in 
neurodevelopment. TUBA1C was identified as a unique candidate DTNBP1-interacting protein 
in HEK293 human cell line using SDS polyacrylamide gel electrophoresis and HPLC/MS/MS 
recently (Mead et al.  2010), suggesting that impairments in vesicle formation could be part of 
a pathogenic mechanism in SCZ. 
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Tubb2c (3p13) has similar activity, molecular function and structural roles to Tuba1c. 
The human homolog gen, TUBB2C, is located in 9q34, an area recently linked to SCZ which also 
contains the dopamine β-hydroxylase (DβH) gene (DBH) (Cubells et al.  2011). 
In addition, deletions of the TUBA1C gene have been linked to oestrogen receptor 
negativity in breast cancer patients (Pierga et al.  2007). Tubulins are known targets for ‘vinca 
alkaloid’ drugs such as vinblastine and vincristine in oncology and also for colchicine, an anti-
gout agent that binds to tubulin, inhibiting microtubule formation and neutrophil motility, 
reducing inflammation. The observed haloperidol-induced downregulation of tubulin may have 
similar effects to these agents. In fact, an antiproliferative effect of a haloperidol metabolite 
has been recently reported in prostate cancer cells (Marrazzo et al.  2011). 
 GeneGo (www.genego.com) was used to examine the pathways likely to be altered by 
haloperidol and citalopram using the candidate protein lists yielded by the Mann-Whitney 
tests. In order to simplify the network analysis, only the first two top candidates per spot were 
used as these were considered to be the ones more likely to be accountable for the differences 
in expression observed in the individual spots. Networks were then prioritized based on the 
number of fragments of canonical pathways present on the network. 
The main networks altered by haloperidol in plasma were: 
1. Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway 
2. Angiotensin II, fibrinogen gamma, iC3b, fibrinogen α, C3a  
3. C3, PZP (pregnancy zone protein or α-1-macroglobulin), fibrinogen (fibrin), 
angiotensinogen, fibrinogen beta. 
4. Angiotensin (1-7), MAS1. 
5. Alpha 1-antitrypsin, PZP (pregnancy zone protein or α-1-macroglobulin), kallikrein 12, 
kallikrein 3 (prostate specific antigen, PSA), kallikrein 5. 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway 
or cascade is involved in growth hormone signaling pathway, response to wounding and 
positive regulation of response to external stimulus. JAK activation stimulates cell proliferation, 
differentiation, migration and apoptosis. This pathway was suppressed in plasma by the effects 
of haloperidol. 
Angiotensin II is an inhibitory factor of PRL secretion (Leite et al.  2008), and the 
downregulation of this inhibition may mediate dopamine regulated hyperprolactinemia 
amongst other things.  
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Alpha-1-macroglobulin is a protease inhibitor that acts as regulator of neuronal 
development and function. Its active form depresses dopaminergic and cholinergic 
transmission (Hu et al.  1998). Hence, an excess of dopaminergic transmission could be the 
result of a deficit in the active form of this protein. The downregulation of this pathway by 
haloperidol may be suggestive of a non-synaptic therapeutic effect of the medication or of a 
primary defect in its regulation, which may be central to the appearance of psychotic 
disorders.  
MAS1 is the receptor for angiotensin 1-7 and when activated, it modulates a critical 
component in a growth-regulating pathway to bring about oncogenic effects. It is also involved 
in maintaining blood pressure and in intracellular signaling probably through Akt 
phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase 
inhibition (Iwai and Horiuchi, 2009). The downregulation of this pathway by haloperidol in 
plasma is another example of its antiproliferative activity (Marrazzo et al.  2011), which has 
only recently started to be ascertained, and may be mediated by its antagonism to the σ 
receptor subtype (Vilner et al.  1995). 
In the striatum, the following signalling pathways where mainly altered by haloperidol: 
1. CRMP2 (collapsing response mediator protein 2), ATP5A (ATP synthase subunit α, 
mitochondrial), succinate dehydrogenase, MPTP (mitochondrial permeability transition 
pore) complex, SDHA (Succinate dehydrogenase subunit A). 
2. VDAC 1 (voltage-dependent anion-selective channel protein 1), PKM2 (pyruvate kinase 
isozyme M1/M2), VDAC 2, DHPR (Dihydropteridine reductase), TPI1. 
3. G3P2 (glyceraldehyde-3-phosphate dehydrogenase), DJ-1 (Parkinson disease autosomal 
recessive, early onset 7, PARK7), CAR-2 (carbonic anhydrase II), VDAC 1, p53. 
4. DJ-1, G3P2 (glyceraldehyde 3PO4 dehydrogenase), androgen receptor, p53, c-Myc. 
CRMP2 (also known as dihydropyrimidinase related protein, DRP) plays a critical role in 
axon outgrowth and axon-dendrite specification (Uchida et al.  2005). It is a physiological 
target of GSK-3-beta (Soutar et al.  2010). This signaling pathway was shown to be 
downregulated by haloperidol in this thesis. A recent study examining the effects of 
antipsychotics (haloperidol and clozapine), mood stabilisers (lithium and valproic acid) and 
antidepressants (imipramine and fluoxetine) on GSK-3, Akt and Wnt in the rat prefrontal cortex 
and striatum found that only antipsychotic treatment regulated Wnt pathway and enhanced 
the association of GSK-3 at the dopamine D2 receptor (Sutton and Rushlow, 2011). 
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ATP5A is the gene coding for the subunit of the soluble catalytic core (F1) of 
mitochondrial ATP synthase. The other component (F0) is a membrane-spanning proton 
channel. During oxidative phosphorylation mitochondrial ATP synthase produces ATP from 
ADP in the presence of a proton gradient across the inner membrane. It appears to be 
upregulated by haloperidol, which may explain the therapeutic action on decreased oxidative 
metabolism found in SCZ brains (Benitez-King et al.  2010) but be equally responsible for the 
neuronal damage observed following chronic treatment, leading to extrapyramidal symptoms 
and neurocytoskeletal disorganization (Benitez-King et al.  2010). 
Succinate dehydrogenase (SDH) is a crucial enzyme of the Krebs cycle as an electron 
transferring protein in the mitochondrial respiratory chain where most cell energy is obtained 
through oxidative phosphorylation. Consistent with previous findings (Streck et al.  2007), it 
was found to be downregulated in this study, suggesting that long term treatment with 
haloperidol worsens a pre-existing pathological state of deficient cell energy generation. This 
may explain the appearance of cognitive dysfunction, negative symptoms and extrapyramidal 
side-effects known to be associated with the chronic administration of typical antipsychotics. 
The MPTP (mitochondrial permeability transition pore) complex is a protein pore formed by 
multiple macromolecular components (voltage-dependent anion-selective channel proteins 1 
and 2, amongst others) in the membranes of mitochondria under certain conditions such as 
traumatic brain injury or stroke and that can lead to mitochondrial swelling and subsequent 
cell death.  
TPI1 is an enzyme on the glycolisis/gluconeogenesis pathway that catalyzes the 
isomerisation of glyceraldehyde 3-phosphate (G3P) and dihydroxy-acetone phosphate (DHAP). 
It was downregulated by haloperidol, consistent with the notion of iatrogenic decrease in cell 
energy production and has recently been shown to be increased by clozapine (Baig et al.  
2010), raising the speculation that this pathway might explain the metabolic syndrome seen 
patients treated with atypical antipsychotics. 
Pathway 3 appears entirely downregulated by haloperidol. G3P2 catalyzes the sixth 
step of glycolisis, adding up evidence to the detrimental effect haloperidol exerts on cellular 
energy metabolism. DJ-1 is a neuroprotective transcriptional co-activator, which reduced 
expression by haloperidol leaves dopaminergic neurons vulnerable to apoptosis and may 
contribute to the emergence of extrapyramidal symptoms (Xu et al.  2005). Carbonic 
anhydrase II is a metalloenzyme that catalyzes the reaction of CO2 and H2O to HCO3
− and H+ 
and vice-versa and is stimulated by Vitamin D3. A downregulation on this enzyme will have a 
similar effect to carbonic anhydrase inhibitors such as acetazolamide, dorzolamide and 
topiramate which are used as antiglaucoma agents, antidiuretics, antiepileptics, and in the 
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management of altitude sickness. In addition, lack of carbonic anhydrase result in a reduction 
of hydrogen ions causing increased levels of free radicals leading ultimately to cell death. 
Pathway 4, downregulated by haloperidol in striatum, contains p53, a tumour 
suppressor protein activated by Akt1, and c-Myc, a transcription factor that inhibits Akt1. 
Haloperidol downregulation of these proteins alters the cell cycle leading to apoptosis and 
supports its antiproliferative activity in cancer cells (Marrazzo et al.  2011).  
Citalopram affected mainly the following networks in plasma: 
1. C3, fibrinogen, fibrinogen gamma, fibrinogen α, iC3b. 
2. ATP5B (ATP synthase subunit beta, mitochondrial), TCR (T cell (lymphocyte) receptor) 
gamma/delta. 
3. CAR, CXADR (coxsachie virus and adenovirus receptor), CAR/RXR-α (androstane receptor 
(CAR, NR1I3)/retinoid X receptor α), ESR1 (nuclear), c-Jun. 
4. CAR/RXR- α, PKM2 (pyruvate kinase isoenzymes M1/M2), PZP, ESR1 (nuclear), c-Jun. 
5. PZP, C3a, c-Jun, c-Src (proto-oncogen tyrosine-protein kinase Src), annexin II. 
6. CAR, MKK7 (MAP2K7, Mitogen activated protein kinase kinase 7), PNRC2 (proline-rich 
nuclear receptor coactivator 2), RAR (retinoic acid receptor), Ephrin-B receptors. 
The observed upregulation of proteins in pathway 1, most of which are involved in 
blood coagulation, hemostasis, wound healing and regulation of body fluid levels, may explain 
the weak effect favouring abnormal hemostasis observed in patients treated with SSRIs 
(Alderman et al.  1996; Layton et al.  2001). Alternative explanations for SSRI-induced bleeding 
have been attributed to excess secretion of gastric acid and offered elsewhere (Andrade et al.  
2010). 
Alterations in pathway 2 indicate abnormal lipid metabolism as a result of citalopram 
treatment, resulting in release of glycerol and free fatty acids into the blood stream. ATP5B is 
the gene that codes mitochondrial ATP synthase subunit beta, which is responsible for 
catalyzing ATP synthesis during oxidative phosphorylation. TCR gamma/delta is a surface 
receptor present in a subset of lymphocyte T cells located in the gut mucosa which are thought 
to be involved in the recognition of lipid epitopes. These findings are consistent with previous 
reports of citalopram-induced generalized lipidosis in rats (Lullmann-Rauch and Nassberger, 
1983) and phospholipidosis in U937 cells (Hutchinson et al.  2008), adding strength to the 
potential perturbed lipid metabolism observed in citalopram treated subjects (Flechtner-Mors 
et al.  2008). 
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The human gene CXADR codes a cell adhesion protein called coxsackievirus and 
adenovirus receptor (CAR) which is expressed during development in the CNS. The human 
constitutive androstane receptor/retinoid x receptor α (CAR/RXR-α) regulates transcription of 
target genes and modulates cytochrome P-450 genes function (Honkakoski et al.  1998), 
variations of which have been reported to be associated with tolerance and remission in 
patients treated with citalopram (Mrazek et al.  2011). C-Jun forms the early response 
transcription factor AP-1 with c-Fos, which has been shown to be altered by citalopram 
previously (Jensen et al.  1999), and to be responsible for modulation of HPA axis activity. 
SMADs are intracellular proteins that act as transcription factors regulating the 
expression of certain genes by activating downstream transforming growth factor beta (TGF-β) 
gene transcription which is involved in cell growth, differentiation, apoptosis and cellular 
homeostasis. These are also the functions in which PKM2 and c-Jun are involved in, suggesting 
a role of citalopram in apoptosis. This role has already been reported as SSRI-induced 
apoptosis on Burkitt lymphoma cells (Serafeim et al.  2003). C-Jun, c-Src and Annexin II are 
linked by the S100 pathway. S100A6 interacts with Annexin 2 (Nedjadi et al.  2009), S100A7 
with c-Jun (Emberley et al.  2005) and c-Src with S100A4 (Watanabe et al.  1993); which 
indicates an effect of citalopram in calcium-regulated processes, such as vesicle generation 
and exocytosis, microfilament assembly, cardiac and skeletal muscle signalling, for instance.  
Mitogen activated protein kinase kinase 7 (MKK7, MAP2K7) is a kinase involved in 
mediating cell response to proinflammatory cytokines and regulates JNK signalling. Proline-rich 
nuclear receptor coactivator 2 (PNRC2) modulates transcriptional activation of nuclear 
receptors including estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor 
(GR), progesterone receptor (PR), thyroid hormone receptor (TR), retinoic acid receptor (RAR), 
and retinoid X receptor (RXR) in a ligand-dependent manner (Zhou and Chen, 2001). Ephrin 
(Eph) receptors are the largest subfamily of receptor tyrosine kinases and are of particular 
importance in late-stage nervous system development, where they are involved in cell 
positioning and morphology modulation (segmentation, axon guidance, cell migration, 
angiogenesis, limb development and cancer). Ephrin receptors have been implicated in 
antidepressant treatment response (Ising et al.  2009) and has been shown to regulate neural 
plasticity in the hippocampus (Yamaguchi and Pasquale, 2004). 
Lastly, the following were networks downregulated by citalopram in the striatum: 
1. Carbonic anhydrase II, VDAC 1, ATP5A, DHPR, MPTP complex. 




3. G3P2, DJ-1, p53, androgen receptor, c-Myc. 
Downregulation of pathway 1 signals an alteration in mitochondrial enzymes induced 
by citalopram which is different to the one observed in the brain of haloperidol treated 
animals. The expression of carbonic anhydrase II was reduced in the brain of citalopram and 
haloperidol treated animals, whereas voltage-dependent anion selective protein 1 and ATP5A 
were decreased in the citalopram group but not in the haloperidol one. This difference may 
explain the somewhat opposing effects antipsychotics and antidepressants have on neuronal 
plasticity, synaptogenesis and architecture.  
Downregulation of pathway 2 may indicate an alteration in energy (glucose) 
metabolism since phosphoglycerate mutase 1 catalyzes step 8 of glycolisis (3-
phosphoglycerate to 2-phosphoglycerate); TPI1 is an enzyme on the glycolisis/gluconeogenesis 
pathway that catalizes the isomerisation of glyceraldehides 3-phosphate (G3P) and dihydroxy-
acetone phosphate (DHAP); and IDH3B is an enzyme of the Krebs cycle that catalyzes the 
oxidative decarboxylation of isocitrate to 2-oxoglutarate. Lower baseline cerebral metabolism 
and greater decrease following citalopram treatment has recently been reported as predictor 
of good response to chronic treatment in the elderly (Smith et al.  2011). 
In pathway 3, downregulation of glyceraldehyde-3-phosphate dehydrogenase (G3P2); 
DJ-1 (a neuroprotective transcriptional co-activator); p53 (a tumour suppressor protein); the 
androgen receptor and c-Myc (a transcription factor) suggests a role in regulation of cell cycle, 
gene expression and induction (prevention if downregulated) of apoptosis, which may explain 
the neurogenesis observed with SSRI treatment. 
Thus, in plasma haloperidol decreased the expression of fibrinogen, piruvate kinase 
M1/M2, angiotensinogen and C3 while citalopram increased it; and increased plasminogen 
while citalopram did not alter its expression. Whereas in striatum, haloperidol increased 
aspartate amino transferase, isocitrate dehydrogenase and ATP synthase subunit α, 
mitochondrial while citalopram decreased their expression. Haloperidol also decreased the 
expression of succinate dehydrogenase and of dihydropyrimidinase-related protein 2, both of 
which were not altered in the striatum of citalopram treated animals. citalopram increased the 
expression of carbonic anhydrase 2 and 1 in plasma, an effect not observed with haloperidol; 
and decreased the expression of piruvate kinase M1/M2 and voltage dependent anion 
selective channel proteins 1 and 2 in striatum despite the lack of effect of haloperidol in those. 
Haloperidol and citalopram appear to affect protein and ion binding, insulin signalling 
and glucose metabolism, response to hypoxia and apoptosis. 
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Haloperidol’s main effect in plasma was seen on dopaminergic and cholinergic 
transmission, cell proliferation, migration and apoptosis, whereas in striatum, it appeared to 
modify mitochondrial function, glucose metabolism, cell cycle and apoptosis. 
In plasma, citalopram altered hemostasis, lipid metabolism, mitochondrial function, 
modulation of HPA axis, apoptosis and calcium-signalling, whereas in striatum, it affected 
mitochondrial function, glucose metabolism, cell cycle and gene expression, maybe conferring 
an anti-apoptotic effect. 
Human homologs of most of the proteins identified in this study had been reported as 
being altered in SCZ proteomic studies. For instance, the levels of apolipoprotein A-IV were 
significantly decreased in the CSF of schizophrenic patients compared to controls and the 
levels of haptoglobin, fibrinogen, complement C3 were also altered in the disease group 
according to one study (Jiang et al.  2003). Equally, dihydropyrimidinase-related protein 2 
(detected in the striatum analysis), had been reported as being decreased in the brains of SCZ 
and bipolar disorder patients (Johnston-Wilson et al.  2000), triosephosphate isomerase has 
been reported as decreased in bipolar disorder (Behan et al.  2009) and is altered by clozapine 
treatment (Baig et al.  2010), phosphoglycerate mutase 1, has been found to be decreased in 
postmortem prefrontal cortex of SCZ patients (Novikova et al.  2006) and ubiquitin carboxyl-
terminal hydrolase isozyme L1 was found to be decreased in SCZ (Prabakaran et al.  2004) and 
in bipolar disorder (Behan et al.  2009). These differences, which were considered attributable 
to the pathophysiology of the disorder, could be better explained as being the effect of 
medication. 
As a result, caution should be taken when interpreting proteomic results from studies 
involving patients on medication. In addition, these results illustrate the importance of using 
animal and cellular models in SCZ research. 
 
6.2.3. Finding biomarkers for psychosis in plasma 
In this chapter, plasma samples from 30 cases presenting for the first time with psychosis to 
the South London and Maudsley NHS Foundation Trust’s psychiatric services were compared 
to 30 well-matched controls from the local catchment-area population using 2DPAGE and 
LC/MS/MS. Proteins found to be differentially expressed between cases and controls were 
S100A8, afamin, peroxiredoxin 1, clusterin and gelsolin. Validation was performed using 
immunoassay detection methods on gelsolin and S100B in an independent sample from the 
same population. Gelsolin levels were found to be decreased in cases, while S100B appeared 
to be upregulated.  
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The gelsolin gene is located in 9q33, in a locus reported to be implicated in modifying 
the clinical course and severity of SCZ (Fanous et al.  2007). Defects in this gene also cause 
familial amyloidosis Finnish type (FAF), whereby systemic deposition of amyloid by the 
secreted (not cytoplasmic) form of the protein is found in most tissues resulting in a 
characteristic triad of ophthalmological, neurologic and dermatological symptoms (Fanous et 
al.  2007). DISC1, a well-established and studied schizophrenia risk gene as discussed 
previously, has been recently shown to act downstream of the amyloid precursor protein to 
regulate cortical precursor cell migration (Young-Pearse et al.  2010) and a reduction in its 
function induces perturbed mitochondrial calcium dynamics (Park et al.  2010).  
A recent study from the Lovestone group has shown that AD patients also displayed 
significantly lower plasma gelsolin levels compared to non-denmented controls (NDC) subjects 
and correlated with disease progression rate estimated by Mini-Mental Status Examination 
(Guntert et al.  2010). Interestingly, gelsolin (a calcium-regulated protein that exerts its effect 
in the assembly and disassembly of actin filaments) expression, has been shown to be 
increased in prefrontal cortices of people affected with Down syndrome (Ji et al.  2009), which 
are known to have an increased risk of AD. 
S100 proteins are Ca2+ -binding proteins which are located in chromosomes 1q21, 
21q22, Xp22, 4p16 and 5q14 and are present exclusively in vertebrates (Sedaghat and 
Notopoulos, 2008). These proteins localize in cytoplasm and/or nucleus of a wide range of cells 
and are involved in cellular processes such as contraction, motility, cell growth and 
differentiation, cell cycle progression, transcription, structural organisation of membranes, 
dynamics of cytoskeleton constituents, protection from oxidative cell damage, protein 
phosphorylation and secretion (Santamaria-Kisiel et al.  2006). S100A8 is a calcium-binding 
protein whose gene is located in 1q21, an area in which microdeletions have been linked to 
SCZ in a recent study (Li et al.  2011). This specific protein may inhibit the enzyme casein 
kinase, which regulates signal transduction pathways including the phosphorylation of 
Dishevelled (Dsh) in the Wnt signalling pathway (Davidson et al.  2005) and acts in a molecular 
pathway that regulates circadian rhythm (Eide et al.  2005). Abnormalities of Wnt signalling in 
SCZ have already been suggested (Cotter et al.  1998) and circadian rhythm alterations in these 
patients have been well documented since the 1960s (for a recent review, see (Lamont et al.  
2010)). S100A8 regulates cellular chemotaxis and has been implicated in cystic fibrosis, 
rheumatoid arthritis, inflammation and asthma. Asthma has been claimed to be 
underrepresented in people with SCZ compared to patients suffering from affective disorders 
(Nasr et al.  1981); and there is a long-observed inverse correlation between rheumatoid 
arthritis and SCZ (Eaton et al.  1992; Mellsop et al.  1974; Mohamed et al.  1982).  
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S100A8 levels were initially measured using a commercial antibody but no differences 
were found between cases and controls. This negative result was attributed to the poor quality 
of the antibody and a measurement of another one of these 25 proteins, S100B, in plasma was 
conducted using an ELISA kit from MERCK. S100B is a recognized biomarker for traumatic brain 
injury, several chronic neurological diseases (schizophrenia, bipolar disorder, Alzheimer’s 
disease) plus may have utility as a biomarker in other disease states, such as cerebral palsy, 
Down syndrome, multiple sclerosis and metastatic melanoma. S100B is the most abundant 
member of the S100 family expressed in the brain, predominantly synthesized and secreted by 
astrocytes. In addition, S100B, maps to 22q21, an area of linkage for Schizophrenia and BPAD 
with psychosis (Liu et al.  2005; Roche et al.  2007) which has been identified as regulatory for 
presynaptic calcium signalling and synaptic plasticity in a mouse model of 22q11 deletion 
syndrome (Earls et al.  2010). Increased extracellular levels of S100B in the brain are indicative 
of neuronal injury or underlying chronic inflammation that can be subsequently measured in 
the peripheral circulation, after passing through the blood brain barrier. S100B, has previously 
been associated with SCZ in CSF (Rothermundt et al.  2004), and found to be increased in 
medication-free patients with a negative correlation with illness duration, indicating that a 
neurodegenerative process may take place in a subset of people suffering from SCZ (Lara et al.  
2001). 
Thus, classic proteomic techniques can be effectively used in SCZ research and have 
great promise for discovery of altered signalling pathways and molecular processes. The 
results of this study suggest that a subset of people presenting with psychotic might be 
suffering from underlying altered calcium signaling.  
 
6.3. Thesis main findings 
A consistent classical proteomic approach has been used to examine the proteome of a 
molecular model of the disease, the effects of medication in vivo in the plasma and striatum of 
F344 rats and in the plasma of SCZ patients. 
1. Converging evidence implicates DHPR in SCZ. DISC1 downregulation in progenitor neural 
cells resulted in reduced enzyme expression. DHPR deficiency manifests itself by BH4 
deficiency, leading to impaired biosynthesis of dopamine and serotonin. Haloperidol 
reduced the expression of this enzyme in the striatum of F344 rats, showing that the 
enzyme is a therapeutic target of the drug, which would act by reducing the synthesis of 
dopamine in an attempt to compensate for excessive dopaminergic transmission.  
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2. PPIA, the protein found upregulated in the DISC1 study, indicated a potential dysregulation 
of calcium signalling pathways which was confirmed by the validation of gelsolin and 
S100B levels in the plasma of SCZ patients. Gelsolin and S100B levels were altered in the 
plasma of a subset of patients experiencing psychotic symptoms. This peripheral signal 
may indicate a disease process linked to calcium signalling dysregulation that can be 
detected in plasma using proteomic techniques. Nevertheless, this signal may not be 
specific to SCZ as gelsolin levels have been shown to be reduced in the plasma of patients 
with AD and to correlate with disease progression (Guntert et al.  2010), and were 
increased in brain by the effect of age and also in prefrontal cortex of individuals with 
Down syndrome (Ji et al.  2009). S100B, a calcium-binding protein produced and secreted 
by astrocytes has also been previously associated with SCZ (Lara et al.  2001; Rothermundt 
et al.  2004) and with primary insulin resistance in SCZ (Steiner et al.  2010), but also with 
AD (Peskind et al.  2001), with multi-trauma patients without head injury (Anderson et al.  
2001) , brain injury in children (Berger et al.  2002), bipolar disorder patients (Machado-
Vieira et al.  2002), SSRI response and depression (Tramontina et al.  2008).  
3. Antagonistic effects between haloperidol and citalopram were observed in both plasma 
and striatum of the treated rats. The main pathways in which haloperidol and citalopram 
showed opposing expression effects are glucose and lipid metabolism, mitochondrial 
function, immune response, coagulation, calcium signalling and apoptosis. 
4. The proteins identified in the plasma of people with SCZ could be classified as belonging to 
one of the following groups: protease inhibitors, lipid transport, inflammation, 
cytoskeletal, cell cycle, neurotrophic factors, glucose metabolism and apoptosis. Several of 
the proteins identified in this thesis in the plasma of patients with SCZ are consistent with 
previous reports although they do appear to be common to other neuropsychiatric 
disorders. For instance, clusterin which was identified in the plasma of people with SCZ 
had its gene recently reported as being linked to SCZ (Zhou et al.  2010), has also been 
associated with the severity, pathology and progression of AD (Thambisetty et al.  2010a). 
Afamin, α-1-microglobulin, APOE, transthyretin, α-1-antitrypsin were upregulated while 
clusterin was downregulated in the plasma of pregnant mothers carrying Down syndrome 
foetuses (Kolialexi et al.  2008). 
Taken together, these findings suggest that schizophrenia could be better understood as a 
heterogeneous group of disorders in which abnormal neurotransmitter synthesis, glucose and 
lipid metabolism, mitochondrial dysfunction, immune system disregulation, pro-apoptotic 
events and intracellular cell signalling systems result in a deficient synaptic transmission. It is 
known that synaptic transmission is dependent on a number of factors such as (1) the Bell-
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Magendie law (which asserts that synaptic transmission occurs in one direction) that relay on 
membrane integrity and adequate transmembrane ion-exchange for the action potential to 
travel along the axon; (2) synaptic fatigue, by which a synapse will cease functioning if its 
transmitter release is quicker than its synthesis (a process that may occur if NT synthesis is 
impeded by the downregulation of certain crucial enzymes); (3) Ca2+ and Mg2+ concentrations, 
by which a reduction in the former or an increment in the latter will reduce the amplitude of 
the synaptic potential, thus affecting NT release in the synapse; and (4) alterations in pH, by 
which alkalosis (pH increment) increases neurotransmision and acidosis (pH reduction) 
decreases it. Acidosis is frequently seen in dysregulation of glucose metabolism, such as in 
untreated diabetes. 
This dysfunction at the level of the synapse is ultimately responsible for a deficient 
neuronal transmission, leading to abhorrent sensorial input, which eventually leads to the 
emergence of psychopathology. 
Schizophrenia is a useful concept when applied to convey clinically relevant 
information about the quality and severity of psychopathology, prognosis and recommended 
treatment algorithms for the symptomatic relief of behavioural manifestations of a series of 
unknown brain disorders. The phenotypes that clinicians identify with this diagnostic category 
are likely to be phenocopies resulting from complex interactions between diverse, albeit 
probably convergent molecular pathways and environmental influxes.  
At the core of this abnormality there may be an undetermined number of genes, 
spread throughout the genome and coding for proteins with structural or functional roles, 
which additive effect disrupt brain development largely by altering the delicate interplay 
existing at the core of molecular and signalling events. This in turn may lead to aberrant 
cytostructure and cellular physiology, rendering neuronal transmission largely inefficient. In 
order to investigate these signalling pathways and establish their effects on the aberrant 
synaptic transmission, it is crucial to determine downstream effects from the gene to the 
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There are several limitations to this study. Some of them are inherent to the nature of the 
analyte (protein), the sample under study from which those were extracted (cell line, brain 
tissue and plasma of F344 animals), and human plasma; others are limitations imposed by the 
techniques used for the analysis (2DPAGE, Progenesis Samespots, LC/MS/MS); and lastly there 
are limitations to the inferences that can be drawn from comparing data emerging from the 
different studies in this thesis.  
1. Proteins: Proteins are complex analytes to study. They have different isoforms, are 
secreted and metabolised in different ways, they may form complexes when binding to 
other proteins or other substrates such as lipids, and they have active and inactive forms 
and a potentially large number of post-translational modifications. In addition, 
degradation of the sample inevitably occurs through the process of sampling, processing, 
storing and analysing. Proteins are subjected to anticoagulants, preservers, protease 
inhibitors, extreme cold temperatures and thawing processes and denaturation prior to 
being analysed. This experimental error that inevitably occurs in laboratory experiments 
can be minimised by ensuring that the sampling, processing, storing and analysis of the 
sample is equal for cases and the controls. This was attempted by always running 
combined (i.e. cases and controls at the same time) batches in all experiments. 
2. Cell lines: Human cortical neural progenitor cells (CTXOE03) are not neurons. Moreover, 
they are not ‘schizophrenic’ neurons despite having had their DISC-1 gene knock down by 
RNAi. It is clear that most cases of SCZ are not due to DISC-1 haploinsufficiency and it could 
be argued that the changes observed do not give an accurate picture of what the protein 
expression is like in the brain of people with SCZ.   However, the human neural stem cell 
line, CTXOE03, is derived from human somatic stem cells following genetic modification 
with a conditional immortalizing gene, c-mycERTAM. This transgene generates a fusion 
protein that stimulates cell proliferation in the presence of a synthetic drug 4-hydroxy-
tamoxifen (4-OHT). The cell line is clonal, expands rapidly in culture (doubling time 50-60 
h) and has a normal human karyotype (46 XY). In the absence of growth factors and 4-OHT, 
the cells undergo growth arrest and differentiate into neurons and astrocytes (Pollock et 
al.  2006). The information obtained form this experiment is limited to ascertaining 
molecular pathways that may be altered as a result of DISC-1 dysfunction. Nevertheless, if 
said pathways were found to be affected by antipsychotic medication in the case of the 
animal study, or to differ from cases and controls in the case of the human plasma study, 
there will be a strong argument to advocate for their involvement in the aetiology of a 
subset of psychotic disorders. 
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3. Animals: The Fischer F344 inbred rat is a standard laboratory animal strain that has been 
used in toxicology, immunology, ophthalmology, oncology, aging, and neurology and 
psychiatry research extensively. The animals were housed in a purpose-built animal house 
and were bred, treated and sacrificed according to current practices by skilled researchers. 
Following the implantation of the mini-pumps, the animals had to be relocated to prevent 
control-treated animals attacking the ones that were sedated by medication. By doing this, 
cages went from housing one specimen of each treatment group (as would ideally have 
been the case) to housing specimens from the same experimental arm. Although the 
general conditions of the animal house ensured that each cage was exposed to the same 
conditions, inevitably each case had its own individual set of circumstances that were not 
shared between the groups. In addition, rodents will establish a hierarchy between them 
when housed together. Dominance in rodents has been linked to variation in serotonin 
levels (Kostowski et al.  1984) and to influence neurogenesis in the dentate gyrus of 
Sprague Dawley rats (Kozorovitskiy and Gould, 2004). However unlikely these are to have 
affected the overall outcome of the experiment (it was also an inevitable circumstance), in 
future studies, more attention should be paid to these factors. Thus, the protein analysis 
performed in this study attempted to examine molecular changes induced by the effects of 
medication. There is an obvious difference between the physiology of a rodent and that of 
humans, but there are also well preserved common molecular pathways that are 
homologous and examining those in an animal model is an established research approach. 
The information obtained, though had to be carefully contextualised and thought of as 
guidance for the human study, not as a validation of their results. 
4. Plasma: Plasma is that it has a large dynamic range, exceeding 1010 (from albumin at 
around 45 mg/mL to some cytokine at 1-10 pg/mL), whereas proteomic techniques have a 
narrower level of detection 104 to 106 and candidate biomarkers are likely to be low 
abundant. In addition, alterations in plasma protein expression are inevitable during the 
experimental design. Plasma samples were kept on ice and carefully processed within a 
few hours of venipuncture. They were thawed on ice and never subjected to more than 3 
freeze-thaw cycles. Nonetheless, when aliquots were taken from the principal EDTA tube, 
several smaller Eppendorf tubes were filled with plasma and immediately frozen. These 
Eppendorf tubes were labelled 1,2,…,and 7. The first tubes contained plasma that was in 
the top section of the tube and the last ones contained plasma that was in close contact 
with the Buffy coat and the RBC fraction.  It is possible that different protein fractions are 
present at different levels in plasma the primary tube. And thus, analysis of plasma sample 
should have taken this into account.  
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5. 2DPAGE: This technique was selected over DIGE as our lab did not have the capabilities or 
the expertise to use it. SILAC couldn’t be used for human studies because it is performed in 
cell cultured media and it was felt that it was important to keep the same experimental 
design throughout. The limitations of this technique are that it is labour intensive, time 
consuming, and mostly not automated, requiring a high level of laboratory skills. A 
relatively large amount of sample (>300 µg of total protein) is needed to be able to excised 
it from the gel and analysed by mass spectrometry. It has limited reproducibility, and a 
smaller dynamic range than some other separation methods. However, the strength of 2-D 
electrophoresis has been also recognized: improved robustness and unique ability to 
analyze complete native proteins with all modifications. Better results with 2DPAGE will be 
obtained with samples with a limited range of protein expression (i.e. an organelle, 
subcellular fractions, protein complex, or cerebrospinal fluid). 2DPAGE is good for looking 
at proteins within the mass range of 20 - 250 kDa and pI of 3 - 11. All the experiments in 
this thesis were run using the same equipment, the same protocol and were all performed 
by me. Each run had a mixture of cases and controls, so that experimental error could be 
minimised. However, differences in the length of the second run were noticeable between 
the warmer months and during in winter as the room temperature in our lab was not 
controlled.  
6. Progenesis SameSpots: SameSpots still estimates spot boundaries, eliminates missing 
data, and reduces technical variability in the spot quantifications. The spot detection 
algorithm utilized by the SameSpots interface in the Progenesis package appears, at times, 
to have difficulty splitting overlapping spots in dense regions of the gel.  
7. Spot picking: Manual spot picking involved certain amount of subjective identification by 
two experienced researchers. The template used for the identification was always an 
analytical gel, whereas the spots were picked from a preparatory gel, which was 
overloaded to ensure ulterior protein identification. The use of preparatory gels was 
needed as glutaraldehyde, which is incompatible with LC/MS/MS, was used to improve 
focusing on the analytical gels. This was necessary to optimise image analysis. It is 
reasonable to consider that certain keratin contamination from human skin and hair 
occurred. 
8. Mass spectrometry: All experiments were performed at the core facility by an experienced 
researcher (Steve Lynham) using LC/MS/MS as better identification and better sequence 
coverage is obtained than by using MALDI-MS. The general limitations of this technique 
are centred on the following, interacting aspects of clinical LC-MS/MS: highly manual 
workflows, complexity of operation and maintenance of instrumentation, sample 
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throughput limits, insufficient detection sensitivity for some analytes and problems with 
detection specificity. Nonetheless, standard operational procedures have been optimised 
at the core facility and these caveats had been previously addressed. 
9. Interpreting data: Inferring information across studies performed in different samples (i.e. 
cell culture, animal model and human samples) is possible but by no means straight 
forward. Caution should be used when making inferences from the results of those 
experiments as the changes observed in protein expression may not be found ‘in vivo’. It is 
possible to imagine a situation by which proteins more easily detectable because of their 
quantity and the scope of detection of current techniques, are also the ones subject the 
most to modifications and degradations though the experimental design. 
Analysing the protein expression of a knock down genetic model in a cell line, the effects of 
antipsychotic treatment in an animal model and the plasma of people with schizophrenia with 
2DPAGE showed that the technique works best with ‘simpler’ samples such as cell culture or 






6.5. Future directions 
We are closer to finding the molecular alterations underlying psychotic symptomatology as 
well as clarifying the mechanisms of antipsychotic action. The task nonetheless, is a complex 
and multifaceted one in which combined approaches using different techniques should be 
used in order to fully understand the intricacies of the disease pathway leading from genetic 
predisposition to the behavioural manifestation of psychotic symptoms. In order to do so, a 
linear step-wise approach such as the one detailed below could be used (Figure 45). 
1. Proteomic analysis of genetic models of the disease. Schizophrenia has a strong genetic 
component (Gottesman and Shields, 1967; Sullivan et al.  2003) and GWAS studies are 
being conducted under the underlying assumption of ‘common disease, common 
variant’ hypothesis in an attempt to find the disease genes. Most variants identified so 
far confer relatively small increments in risk and explain only a small proportion of 
familial clustering (Manolio et al.  2009). Candidate genes prioritised according to GWAS 
significance could be downregulated in neuronal progenitor and glial cell lines using 
RNAi and their protein expression examined using proteomic techniques. The author 
and co-authors of the DISC1 study have received funding to conduct these experiments 
for ZNF804A and TCF4 in CTXOE03 cells. 
2. Examining the effects of current antipsychotic treatment in vitro. In vitro models for 
schizophrenia are currently being developed using stem cells (Brennand et al.  2011), 
astrocytes (Martins-De-Souza et al.  2011; Quincozes-Santos et al.  2010) and neuronal 
cultured cell lines (Ono et al.  2010). The effects of medication or psychosis inducing 
agents such as cannabis or amphetamines could be further examined using proteomic 
techniques. 
3. Drosophila models could be employed to study the effects of risk genes (van and van, 
2011) (Figure 44) and have been routinely used in human neurodegeneration research 
(Hirth, 2010). This approach has been successfully applied to assert the regulatory effect 
of dysbindin over synaptic homeostasis (Dickman and Davis, 2009). DISC1 has already 
been successfully model in flies and up to 3 disease genes could be examined for 
epigenetic interactions simultaneously (Furukubo-Tokunaga, 2009). In addition, 
behavioural, anatomical and physiological studies can be performed in this system. 
4. In vivo mammalian studies. If the candidate gene is shown to (1) alter cellular 
morphology/physiology of neuronal or glial cell lines; (2) alter fly brain morphology for 
which a homolog alteration in patients with schizophrenia has been shown; (3) alter fly 
behavioural patterns; (4) modify synaptic transmission or (5) alters signalling pathways 
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previously identified in schizophrenia, an animal mammalian model such as inbred rats 
or mice, would be helpful in establishing morphological, physiological and behavioural 
alterations. Proteomic techniques could be used to examine the brain (including specific 
isolation and analysis of the synaptosome), blood and other tissues of genetically 
altered animals. Animal models have already been succesfully used to clarify complex 
mechanisms (Baker, 2011) and to study the interplay between biological, behavioural 
and environmental influences in schizophrenia and autism (Nagai et al.  2011; Tordjman 
et al.  2007). In addition, tissue from antipsychotic treated mice has already been used 
to discriminate protein changes resulting from the disease process from those being 
induced by medication (Focking et al.  2011). Dysbindin-1 mutant mice have shown 
deficits in auditory-evoked response adaptation and prepulse inhibition of startle similar 
to patterns seen in SCZ (Carlson et al.  2011). This suggests a potential underlying 
mechanism that could be further explored using proteomic approaches. This approach 
has recently shown that reduced p35 expression in mice synapses results in protein 
changes similar to SCZ post mortem-brain (Engmann et al.  2011).  
5. Signalling pathways will be identified, followed downstream and annotated using 
pathway analysis (English et al.  2011). A targeted proteomics approach could then be 
used used to identify targets in human brain tissue. A 2-PAGE proteomic reference map 
for the prefrontal cortex region of the human brain has recently been published 
(McManus et al.  2010) and contain most of the analytes identified in this thesis in the 
animal study, suggesting that inferences from animal models to human brain can be 
made.  
6. Lastly, potential plasma candidates could be explored using high-throughput targeted 
proteomics in human plasma. This guided proteomic approach has already been 
successfully employed in SCZ. Multiplex molecular profiling approaches have started to 
appear in plasma studies in SCZ research (Schwarz et al.  2011a) and more recently, 
multiplex immunoanalyses carried out in the serum of SCZ and BPAD patients suggested 
that there are distinct alterations in the prodromal stages of the disorder (Schwarz et al.  
2011b). 
Proteomic research in neuropsychiatric disorders in general and in psychotic disorders 
in particular holds great promise for the future. Since the introduction of classic proteomic 
techniques to study psychiatric disorders and the commencement of SWISS-2DPAGE (a 
database holding data on proteins identified on 2DPAGE maps) in 1993 (Appel et al.  1993), 
these techniques have shown alterations at the protein level in the plasma, serum, CSF and 
brain of patients with SCZ and psychotic disorders. Most of the proteins identified are involved 
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in cytoskeletal functions, energy metabolism, cell signalling, and synaptic transmission, 
suggesting that a basic cell dysregulation operates at the core of the etiological disease process 
leading to psychotic disorders. 
Proteomic techniques will continue being applied to investigating disease associated 
pathways through modelling the disorder in vitro and in vivo models and with the use of 
automated throughput targeted approaches in human samples. This newly acquired 
knowledge could eventually lead to a re-classification of mental illness that could leap across, 
not only to other neuropsychiatric disorders such as Alzheimer’s or Parkinson’s disease but 
possibly even encompass systemic disorders such as diabetes mellitus or rheumatoid arthritis, 
which may share very similar molecular alterations in a different target organ/tissue, resulting 
in the different disease phenotypes observed. 
In addition, proteomic techniques will also play a major role in clarifying the 
mechanisms of action of medication as well as their side-effect profiles, contributing to 
stratified medicine by improving the management of groups of patients with shared molecular 
baseline characteristics. These patients would be screened using molecular markers and 
available therapeutic options could be selected on the basis of their predicted response and 
tolerability, ending the trial and error process that clinicians and their patients currently have 
to endure in the hope of finding a medication that, at best, will alleviate some of the 






Figure 33. Strategies for using Drosophila in the study of disease. 
Entry points are genetic screen, candidate genes and modelling theories about the aetiology or 
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LC/MS/MS Analysis of 2D gel spots: Examining the effects of 

































RSF/NB A Dihydropteridine reductase Human P09417 25773 6.9 3 2 104.0 55.1 12% MTDSFTEQADQVTAEVGK 
        47.0 52.7  EGGLLTLAGAK 
RSF/NB B Peptidyl-prolyl cis-trans isomerase A Human P62937 18001 7.68 10 4 90.9 55.0 32% VNPTVFFDIAVDGEPLGR 
        68.8 53.5  VSFELFADKVPK 
        58.1 53.3  EGMNIVEAMER 




LC/MS/MS Analysis of 2D gel spots: Examining the effects of 



































Rat P06399 86632 5.51 44 21 43.9 35.1 29% AQQIQVLQK 
        47.4 35.6  DVRDQLIDMK 
        57.5 35.5  EINLKDYEGQQK 
        47.9 34.4  ETDWPFCSDEDWNHK 
        103.1 34.2  EVVKEVVTSDDGSDCGDGMDLGLTHSFSGR 
        70.2 34.2  EVVTSDDGSDCGDGMDLGLTHSFSGR 
        56.1 35.8  FGSLTSNFK 
        59.8 35.5  FGSLTSNFKEFGSK 
        141.7 34.9  GDFANANNFDNTFGQVSEDLR 
        60.2 35.1  GDFANANNFDNTFGQVSEDLRR 
        45.8 35.7  GDKELLIGNEK 
        77.9 35.3  GLIDEANQDFTNR 
        65.6 35.6  LVTSKGDKELLIGNEK 
        71.0 35.1  MHPELGSFYDSR 
        57.2 35.5  MKGLIDEANQDFTNR 
        65.0 35.7  MSPVPDLVPGSFK 
        23.9 34.2  NIMEYLR 
        33.9 35.1  NSLFDFQK 
        52.8 35.4  QLEQVIAK 
        46.8 35.3  SQLQEGPPEWK 
        83.2 34.5  TSDSDIFTDIENPSSHVPEFSSSSK 
 
Fibrinogen beta 
chain Rat P14480 54201 7.90 29 15 48.5 35.6 37% ECEEIIR 
        73.1 34.5  QDGSVDFGR 
        57.3 35.4  KGFGNIATNEDTKK 





        57.0 35.1  GFGNIATNEDTK 
        54.7 35.6  DNDGWVTTDPR 
        69.6 35.7  TENGGWTVIQNR 
        45.9 35.3  GFGNIATNEDTKK 
        66.3 35.5  GGETSEMYLIQPDTSSKPYR 
        49.5 35.4  YCGLPGEYWLGNDKISQLTR 
        53.0 35.4  KGGETSEMYLIQPDTSSKPYR 
        90.8 35.1  YYWGGLYSWDMSK 
        65.2 35.6  IGPTELLIEMEDWK 
        104.1 35.6  LYIDETVNDNIPLNLR 
        143.3 35.2  DNENVINEYSSILEDQK 
 
Beta-2-
glycoprotein 1 Rat P26644 33175 8.59 6 4 38.0 35.3 16% ATVLYQGQR 
        43.3 35.6  ITCPPPPIPK 
        71.3 35.4  CTEEGKWSPELPVCAR 
        79.4 35.6  VCPFAGILENGVVR 
 
Ig gamma-2B 
chain C region Rat P20761 36474 7.70 3 3 77.5 35.6 17% CPVPELLGGPSVFIFPPKPK 
        80.1 34.8  NTEPVMDSDGSFFMYSK 
        39.6 35.5  APFVCSVVHEGLHNHHVEK 
 Serotransferrin Rat P12346 76346 7.14 1 1 53.1 35.5 2% TAGWNIPMGLLFSR 
694 
Fibrinogen 
alpha chain Rat P06399 86632 5.51 41 20 50.8 35.6 29% DVRDQLIDMK 
        63.1 35.5  EINLKDYEGQQK 
        54.9 35.3  ETDWPFCSDEDWNHK 
        130.2 35.3  EVVKEVVTSDDGSDCGDGMDLGLTHSFSGR 
        92.5 35.3  EVVTSDDGSDCGDGMDLGLTHSFSGR 
        59.2 35.8  FGSLTSNFK 
        128.3 35.7  GDFANANNFDNTFGQVSEDLR 
        59.3 35.6  GDFANANNFDNTFGQVSEDLRR 
        59.9 35.6  GDKELLIGNEK 





        66.9 35.1  LVTSKGDKELLIGNEK 
        41.3 36.0  MELERPGK 
        42.2 35.6  MELERPGKDGASR 
        70.5 35.3  MHPELGSFYDSR 
        69.6 35.7  MSPVPDLVPGSFK 
        34.0 34.2  NIMEYLR 
        37.7 35.1  NSLFDFQK 
        65.2 35.4  QLEQVIAK 
        43.1 35.3  SQLQEGPPEWK 
        71.0 35.4  TSDSDIFTDIENPSSHVPEFSSSSK 
 
Fibrinogen beta 
chain Rat P14480 54201 7.90 33 19 135.6 35.4 40% DNENVINEYSSILEDQK 
        42.4 35.6  ECEEIIR 
        56.5 35.6  ECEEIIRK 
        56.6 35.6  GFGNIATNEDTK 
        53.9 35.7  GGETSEMYLIQPDTSSKPYR 
        75.3 35.6  IGPTELLIEMEDWK 
        66.1 35.2  KEEPPSLRPAPPPISGGGYR 
        98.9 35.3  KGFGNIATNEDTK 
        76.0 35.3  KGFGNIATNEDTKK 
        69.5 35.5  KGGETSEMYLIQPDTSSKPYR 
        102.5 35.4  KPPDAGGCVHGDGDMGVLCPTGCELR 
        124.0 35.2  LYIDETVNDNIPLNLR 
        82.5 35.3  QAQVKDNENVINEYSSILEDQK 
        62.7 34.5  QDGSVDFGR 
        55.8 35.1  QTLLNHERPIK 
        57.0 34.9  RKEEPPSLRPAPPPISGGGYR 
        51.4 35.6  VYCDMKTENGGWTVIQNR 
        49.2 35.7  YCGLPGEYWLGNDK 
        65.6 35.7  TENGGWTVIQNR 
 
Beta-2-





        42.2 35.6  ITCPPPPIPK 
 
Ig gamma-2B 
chain C region Rat P20761 36474 7.70 2 1 62.0 34.8 6% CPVPELLGGPSVFIFPPKPK 
668 Fibrinogen beta 
chain 
Rat P14480 54201 7.90 56 27 150.0 35.4 56% DNENVINEYSSILEDQK 
       46.1 35.6  ECEEIIR 
       58.2 35.6  ECEEIIRK 
        57.1 34.9  EDGGGWWYNR 
        57.8 35.1  EEPPSLRPAPPPISGGGYR 
        58.7 35.1  GFGNIATNEDTK 
        53.3 35.7  GGETSEMYLIQPDTSSKPYR 
        72.0 35.5  IGPTELLIEMEDWK 
        45.8 35.0  KEEPPSLRPAPPPISGGGYR 
        98.9 35.3  KGFGNIATNEDTK 
        62.5 35.3  KGFGNIATNEDTKK 
        76.9 35.4  KGGETSEMYLIQPDTSSKPYR 
        94.4 35.4  KPPDAGGCVHGDGDMGVLCPTGCELR 
        85.4 35.5  KQCSKEDGGGWWYNR 
        44.7 35.1  KYCGLPGEYWLGNDKISQLTR 
        113.2 35.2  LYIDETVNDNIPLNLR 
        119.6 35.2  QAQVKDNENVINEYSSILEDQK 
        55.7 35.5  QCSKEDGGGWWYNR 
        61.6 34.5  QDGSVDFGR 
        39.4 34.9  QDGSVDFGRK 
        58.5 35.0  QTLLNHERPIK 
        48.4 34.7  RKEEPPSLRPAPPPISGGGYR 
        61.5 35.7  TENGGWTVIQNR 
        43.8 35.6  VYCDMKTENGGWTVIQNR 
        68.1 35.7  YCGLPGEYWLGNDK 
        45.1 35.3  YCGLPGEYWLGNDKISQLTR 









chain Rat P06399 86632 5.51 24 15 38.7 34.9 25% AQQIQVLQK 
        47.0 35.6  DVRDQLIDMK 
        48.0 35.3  ETDWPFCSDEDWNHK 
        84.7 35.3  EVVKEVVTSDDGSDCGDGMDLGLTHSFSGR 
        61.9 35.3  EVVTSDDGSDCGDGMDLGLTHSFSGR 
        144.9 35.7  GDFANANNFDNTFGQVSEDLR 
        58.5 35.6  GDFANANNFDNTFGQVSEDLRR 
        80.1 35.4  GLIDEANQDFTNR 
        71.3 35.6  MADEAASEAHQEGDTR 
        33.0 35.6  MELERPGKDGASR 
        60.2 35.3  MHPELGSFYDSR 
        64.7 35.6  MSPVPDLVPGSFK 
        56.4 35.4  QLEQVIAK 
        45.3 35.3  SQLQEGPPEWK 
        80.4 35.4  TSDSDIFTDIENPSSHVPEFSSSSK 
 
Beta-2-
glycoprotein 1 Rat P26644 33175 8.59 5 4 53.7 35.2 11% ATVLYQGQR 
        55.8 35.6  ITCPPPPIPK 
        48.2 35.2  KATVLYQGQR 
        62.8 35.5  VCPFAGILENGVVR 
 
Ig gamma-2B 
chain C region Rat P20761 36474 7.70 1 1 52.8 35.5 5% NTEPVMDSDGSFFMYSK 
 
Anionic trypsin-
2 Rat P00763 26211 4.77 1 1 52.5 35.6 4% TLNNDIMLIK 
708 
Fibrinogen beta 
chain Rat P14480 54201 7.90 49 24 43.7 35.6 55% DNDGWVTTDPR 
        130.8 35.2  DNENVINEYSSILEDQK 
        57.2 34.6  DNENVINEYSSILEDQKLYIDETVNDNIPLNLR 
        48.7 35.6  ECEEIIR 
        45.6 35.6  ECEEIIRK 
        57.2 34.6  EDGGGWWYNR 





        58.2 35.6  GGETSEMYLIQPDTSSKPYR 
        68.5 35.6  IGPTELLIEMEDWK 
        62.1 35.6  KEEPPSLRPAPPPISGGGYR 
        65.0 35.4  KGFGNIATNEDTKK 
        81.9 35.5  KGGETSEMYLIQPDTSSKPYR 
        78.8 34.6  KPPDAGGCVHGDGDMGVLCPTGCELR 
        103.6 35.6  LYIDETVNDNIPLNLR 
        144.4 35.3  NSIAELNSNINSVSETSSVTFQYLTLLK 
        66.1 35.4  QAQVKDNENVINEYSSILEDQK 
        68.4 34.5  QDGSVDFGR 
        44.4 35.6  QTLLNHERPIK 
        51.1 35.4  RKEEPPSLRPAPPPISGGGYR 
        59.4 35.7  TENGGWTVIQNR 
        39.5 35.5  YCGLPGEYWLGNDK 
        51.0 35.4  YCGLPGEYWLGNDKISQLTR 
        40.7 34.4  YQVSVNK 
        77.7 35.2  YYWGGLYSWDMSK 
 
Fibrinogen alpha 
chain Rat P06399 86632 5.51 21 13 43.7 35.1 21% AQQIQVLQK 
        46.2 35.6  DVRDQLIDMK 
        80.9 34.3  EVVKEVVTSDDGSDCGDGMDLGLTHSFSGR 
        60.4 34.1  EVVTSDDGSDCGDGMDLGLTHSFSGR 
        138.5 35.1  GDFANANNFDNTFGQVSEDLR 
        62.9 35.2  GDFANANNFDNTFGQVSEDLRR 
        53.9 35.7  GDKELLIGNEK 
        76.4 35.4  GLIDEANQDFTNR 
        62.4 35.2  MHPELGSFYDSR 
        64.7 35.7  MSPVPDLVPGSFK 
        45.0 35.7  RLEVDIDIK 
        45.3 35.3  SQLQEGPPEWK 









chain C region Rat P20761 36474 7.70 7 5 41.7 35.5 24% APFVCSVVHEGLHNHHVEK 
        54.0 35.5  CPTCPTCHK 
        54.9 35.5  VVSALPIQHQDWMSGK 
        78.2 35.5  CPVPELLGGPSVFIFPPKPK 
        73.3 34.9  NTEPVMDSDGSFFMYSK 
 
Beta-2-
glycoprotein 1 Rat P26644 33175 8.59 1 1 67.4 35.6 5% VCPFAGILENGVVR 
711 
Fibrinogen alpha 
chain Rat P06399 86632 5.51 8 5 181.3 32.6 9% GDFANANNFDNTFGQVSEDLR 
        48.5 32.3  GDFANANNFDNTFGQVSEDLRR 
        76.3 32.8  GLIDEANQDFTNR 
        42.6 33.0  MSPVPDLVPGSFK 
        54.4 31.7  TSDSDIFTDIENPSSHVPEFSSSSK 
 
Fibrinogen beta 
chain Rat P14480 54201 7.90 4 3 94.3 32.4 10% DNENVINEYSSILEDQK 
        43.3 32.9  IGPTELLIEMEDWK 
        83.5 32.8  LYIDETVNDNIPLNLR 
 
Ig gamma-2B 
chain C region Rat P20761 36474 7.70 4 2 71.3 32.8 11% CPVPELLGGPSVFIFPPKPK 
        53.9 31.8  NTEPVMDSDGSFFMYSK 
661 
Fibrinogen alpha 
chain Rat P06399 86632 5.51 30 19 38.9 35.1 29% AQQIQVLQK 
        46.0 35.5  DVRDQLIDMK 
        47.7 35.5  EINLKDYEGQQK 
        48.6 34.1  ETDWPFCSDEDWNHK 
        91.7 34.0  EVVKEVVTSDDGSDCGDGMDLGLTHSFSGR 
        60.1 33.9  EVVTSDDGSDCGDGMDLGLTHSFSGR 
        61.8 35.8  FGSLTSNFK 
        66.8 35.5  FGSLTSNFKEFGSK 
        136.3 34.9  GDFANANNFDNTFGQVSEDLR 
        52.2 35.0  GDFANANNFDNTFGQVSEDLRR 





        98.2 35.3  GLIDEANQDFTNR 
        71.1 34.5  MADEAASEAHQEGDTR 
        45.6 35.1  MHPELGSFYDSR 
        64.8 35.7  MSPVPDLVPGSFK 
        33.8 35.1  NSLFDFQK 
        57.6 35.4  QLEQVIAK 
        43.8 35.3  SQLQEGPPEWK 
        58.9 34.4  TSDSDIFTDIENPSSHVPEFSSSSK 
 Pyruvate kinase 
isozymes 
M1/M2 
Rat P11980 57781 6.63 5 3 74.2 35.5 8% FGVEQDVDMVFASFIR 
       40.1 35.6  LDIDSAPITAR 
       71.9 35.7  NTGIICTIGPASR 
946 
Alpha-1-
macroglobulin Rat Q63041 2E+05 6.46 8 7 60.8 32.2 5% DLSSSDLTTASK 
        67.2 32.9  KLQDQSNIQR 
        42.0 33.0  LADLPGNYITK 
        50.3 32.1  LLLQEVR 
        72.2 33.1  LQDQSNIQR 
        60.9 32.6  QQNSHGGFSSTQDTVVALQALSK 
        51.5 32.9  YNILPEAEGEAPFTLK 
947 
Alpha-1-
macroglobulin Rat Q63041 2E+05 6.46 15 11 60.8 32.2 8% DLSSSDLTTASK 
        57.6 32.6  KLQDQSNIQR 
        54.3 32.6  LADLPGNYITK 
        50.2 31.6  LLLQEVR 
        75.4 33.0  LQDQSNIQR 
        39.2 31.0  NLKPAPVK 
        77.5 31.0  NLKPAPVKVYDYYETDEFAIEEYSAPFSSDSEQGNA 
        86.7 32.2  TEVNTNHVLIYIEK 
        95.7 31.6  VYDYYETDEFAIEEYSAPFSSDSEQGNA 
        69.5 33.3  YGAATFTK 
        81.6 32.4  YNILPEAEGEAPFTLK 
 
Tubulin alpha-1C 







Rat Q63041 2E+05 6.46 7 7 67.2 32.2 6% DLSSSDLTTASK 
       56.3 32.8  LADLPGNYITK 
       43.4 31.7  LLLQEVR 
        58.2 33.1  LQDQSNIQR 
        80.2 32.3  QQNSHGGFSSTQDTVVALQALSK 
        68.6 32.3  TEVNTNHVLIYIEK 
        86.5 32.6  YNILPEAEGEAPFTLK 
1669 Fibrinogen beta 
chain 
Rat P14480 54201 7.90 56 24 135.2 32.0 54% DNENVINEYSSILEDQK 
       48.6 33.0  ECEEIIR 
       40.1 33.0  ECEEIIRK 
        57.2 31.4  EDGGGWWYNR 
        77.3 32.4  GFGNIATNEDTK 
        54.6 32.2  GGETSEMYLIQPDTSSKPYR 
        74.2 32.1  HGTDDGVVWMNWK 
        76.2 32.7  IGPTELLIEMEDWK 
        50.1 32.9  KEEPPSLRPAPPPISGGGYR 
        75.7 32.5  KGFGNIATNEDTK 
        77.6 32.5  KGFGNIATNEDTKK 
        71.7 32.1  KGGETSEMYLIQPDTSSKPYR 
        44.0 31.4  KPPDAGGCVHGDGDMGVLCPTGCELR 
        66.9 31.9  KQCSKEDGGGWWYNR 
        95.9 32.7  LYIDETVNDNIPLNLR 
        107.2 31.9  QAQVKDNENVINEYSSILEDQK 
        89.4 32.0  QDGSVDFGR 
        72.2 32.6  QTLLNHERPIK 
        57.1 32.7  RKEEPPSLRPAPPPISGGGYR 
        62.2 33.0  TENGGWTVIQNR 
        48.6 31.3  TMTIHNGMFFSTYDRDNDGWVTTDPR 
        50.9 32.1  YCGLPGEYWLGNDK 
        38.8 32.2  YCGLPGEYWLGNDKISQLTR 








Rat P02680 50600 5.62 36 19 37.2 32.0 59% AIQVYYNPDQPPKPGMIEGATQK 
       69.5 31.9  ATQQFLVYCEIDGSGNGWTVLQK 
       54.0 31.6  CHAGHLNGVYYQGGTYSK 
       64.4 31.6  DNCCILDER 
        72.8 31.7  EGFGHLSPTGTTEFWLGNEK 
        41.2 32.5  ESGLYFIRPLK 
        102.1 30.3  FGSYCPTTCGISDFLNSYQTDVDTDLQTLENILQR 
        63.6 31.9  IHDTTGKDCQDIANK 
        56.7 33.3  KMVEEILK 
        51.1 31.8  LDGSVDFK 
        70.6 32.3  LSIGDGQQHHMGGSK 
        104.8 32.4  MVEEILKYEALLLTHESSIR 
        52.8 32.0  SSTPNGYDNGIIWATWK 
        61.6 32.3  TSTADYAMFR 
        79.0 31.7  VAQLEAQCQEPCK 
        59.8 32.0  VAQLEAQCQEPCKDSVR 
        85.7 32.4  VGPESDKYR 
        70.6 32.9  YEALLLTHESSIR 
        61.1 32.8  YLQDIYTSNK 
 Complement C3 
Fibrinogen beta 
chain 
Rat P01026 2E+05 6.12 2 1 76.6 32.5 2% ILLQGTPVAQMAEDAVDGER 
 Rat P14480 54201 7.90 2 1 43.1 32.6 3% IGPTELLIEMEDWK 
985 Haptoglobin Rat P06866 38539 6.10 14 10 64.7 32.8 25% ATDLKDWVQETMAK 
        51.8 32.8  ATDLKDWVQETMAKN 
        74.7 32.7  DIAPTLTLYVGK 
        33.4 32.5  DWVQETMAKN 
        63.6 32.3  GAVSPVGVQPILNK 
        48.5 33.1  IIGGSMDAK 
        62.4 32.2  MGYVSGWGR 
        53.2 33.0  NQLVEIEK 
        43.7 32.5  SVVDIGLIK 







2 Rat P00763 26211 4.77 1 1 51.1 32.9 4% TLNNDIMLIK 
1681 Plasminogen Rat Q01177 90477 6.79 19 13 57.7 32.0 16% CEGETDFICR 
        52.9 32.7  CTTPPPPPGPTYQCLK 
        40.8 33.1  DVILFEKR 
        36.4 32.3  EAQLPVIENK 
        83.7 32.4  EQQCVIMAENSK 
        45.2 32.9  IFTPQTNPR 
        89.6 32.5  ILGSDVQQIAVTK 
        55.8 32.5  LKEAQLPVIENK 
        35.3 31.7  NLEENYCR 
        79.6 33.1  QLAAGSIADCLAK 
        64.7 32.7  TPENFPCK 
        43.5 31.7  YSPSTHPSEGLEENYCR 
        33.0 32.4  YVNWIER 
 Serotransferrin Rat P12346 76346 7.14 2 1 74.5 32.5 2% EGVCPEGSIDSAPVK 
1126 Carbonic 
anhydrase 2 Rat P27139 29096 6.89 19 2 31.7 33.1 9% EFPIANGDR 
       34.7 32.8  EPITVSSEQMSHFR 
Ig kappa chain C 
region, A allele Rat P01836 11725 4.99 6 2 30.9 32.6 25% DGVLDSVTDQDSK 
       51.3 32.6  DSTYSMSSTLSLTK 
Ig lambda-2 
chain C region Rat P20767 11311 5.76 4 2 41.8 32.6 32% ANGAPISQGVDTANPTK 
       36.6 32.8  NSFTCQVTHEGNTVEK 
Carbonic 
anhydrase 1 Rat B0BNN3 28282 6.86 3 1 43.1 32.2 4% YSSAAEAISK 
862 Apolipoprotein 
A-IV 
Rat P02651 44429 5.12 81 16 42.8 33.0 51% VSTNIDQLQK 
       52.2 32.5  LAPLAEGVQEK 
       33.0 32.4  VSQMFGDNVQK 
       32.3 32.9  QLDQQVEVFR 





       40.7 32.3  NLAPLVEDVQSK 
       35.7 32.6  EKVSSFMSTLQK 
       47.6 31.1  RAVEPLGDKFNMALVQQMEK 
       31.5 32.9  LGNINTYADDLQNK 
       62.8 32.5  FRQQLGSDSGDVESHLSFLEK 
       47.4 32.2  TDVTQQLNTLFQDK 
       41.6 32.8  QQLGSDSGDVESHLSFLEK 
       42.4 31.2  TDVTQQLNTLFQDKLGNINTYADDLQNK 
       38.6 31.7  AVEPLGDKFNMALVQQMEK 
       49.2 31.3  KGSPDQPLALPLPEQVQEQVQEQVQPKPLES 










837 Complement C3 Rat P01026 2E+05 6.12 31 3 47.3 32.8 2% AAVFNHFISDGVK 
        44.7 32.8  ILLQGTPVAQMAEDAVDGER 
        44.9 31.3  ILLQGTPVAQMAEDAVDGERLK 
1679 Alpha-1-
antiproteinase 
Rat P17475 46107 5.7 33 8 47.2 32.8 27% ISSNLADFAFSLYR 
       46.0 32.6  FDHPFIFMIVESETQSPLFVGK 
        41.7 32.5  KISSNLADFAFSLYR 
        57.3 32.5  VFNNDADLSGITEDAPLK 
        30.6 32.3  FLEEVKNNYHSEAFSVNFADSEEAK 
        32.4 31.8  GTEAAGATVVEAVPMSLPPQVK 
        40.5 32.8  NNYHSEAFSVNFADSEEAK 
        36.3 32.6  MQHLEQTLTK 
 Angiotensinogen Rat P01015 51949 5.37 5 3 40.5 32.6 11% GSYNLQDLLAQAK 
        52.0 32.4  SLDLSTDPVLAAQK 
        42.4 32.5  AAQVAMIANFMGFR 
 Fibrinogen 
gamma chain 
Rat P02680 50600 5.62 13 2 43.7 32.7 7% TSTADYAMFR 
        31.8 32.6  EGFGHLSPTGTTEFWLGNEK 
 Vitamin D-
binding protein 







Rat P27139 29096 6.89 17 3 51.2 32.8 20% EPITVSSEQMSHFR 
        47.4 31.3  AVQHPDGLAVLGIFLK 
        32.4 31.7  SIVNNGHSFNVEFDDSQDFAVLK 
 Carbonic 
anhydrase 1 
Rat B0BNN3 28282 6.86 6 2 34.4 32.2 11% VGPANPNLQK 
        39.2 32.5  HDSSLKPVSVSYNPATAK 
 Ig kappa chain C 
region, A allele 
Rat P01836 11725 4.99 4 2 45.5 32.8 25% DGVLDSVTDQDSK 
        37.6 32.7  DSTYSMSSTLSLTK 
 Ig lambda-2 
chain C region 
Rat P20767 11311 5.76 2 2 52.5 32.7 32% ANGAPISQGVDTANPTK 
        43.4 32.8  NSFTCQVTHEGNTVEK 
240 Complement C3 Rat P01026 2E+05 6.12 9 3 39.0 32.8 3% ILLQGTPVAQMAEDAVDGER 
        35.1 32.8  VYSYYNLEESCTR 

































reductase Rat P11348 25536 7.67 20 12 69.6 32.7 66% AALDGTPGMIGYGMAK 
        59.8 33.0  EGGLLTLAGAK 
        87.0 32.4  GAVHQLCQSLAGK 
        70.9 32.7  
LLGDQKVDAILCVAGGWAGGNA
K 
        130.2 32.8  MTDSFTEQADQVTAEVGK 
        36.5 32.0  NCDLMWK 
        95.3 32.8  
NSGMPSGAAAIAVLPVTLDTPMN
R 
        51.6 32.5  
NSGMPSGAAAIAVLPVTLDTPMN
RK 
        51.2 32.5  QSIWTSTISSHLATK 
        65.8 32.6  RPNSGSLIQVVTTDGKTELTPAYF 
        38.0 32.9  RVLVYGGR 
        60.2 32.8  VDAILCVAGGWAGGNAK 
 
Triosephosphate 
isomerase Rat P48500 26832 6.89 1 1 59.6 32.4 5% IIYGGSVTGATCK 
1163 
Triosephosphate 
isomerase Rat P48500 26832 6.89 36 15 68.5 32.8 77% AIADNVKDWCK 
        53.9 32.7  CLGELICTLNAAK 
        61.6 31.0  
CLGELICTLNAAKLPADTEVVCAPP
TAYIDFAR 
        68.3 32.5  CNVSEGVAQCTR 
        44.9 31.1  
ELASQPDVDGFLVGGASLKPEFVD
IINAKQ 
        76.2 32.5  HIFGESDELIGQK 





        81.6 32.2  IIYGGSVTGATCK 
        54.1 31.9  KFFVGGNWK 
        74.8 32.5  LPADTEVVCAPPTAYIDFAR 
        139.4 31.8  VNHALSEGLGVIACIGEK 
        75.8 31.8  VNHALSEGLGVIACIGEKLDER 
        76.3 31.4  
VNHALSEGLGVIACIGEKLDEREA
GITEK 
        84.7 32.5  VTNGAFTGEISPGMIK 




Rat P13221 46400 6.73 11 8 89.8 32.7 26% APPSFFAQVPQAPPVLVFK 
       51.8 32.9  IANDHSLNHEYLPILGLAEFR 
       59.3 33.0  IGADFLGR 
        71.0 32.6  NLDYVATSINEAVTK 
        98.0 32.8  NLDYVATSINEAVTKFQ 
        76.7 32.9  SCASQLVLGDNSPALR 
        103.9 32.5  TDDSQPWVLPVVR 




[NAD] subunit beta, 
mitochondrial Rat Q68FX0 42327 8.89 7 4 70.1 32.4 19% DMGGYSTTTDFIK 
        64.1 32.9  LGDGLFLQCCEEVAELYPK 
        111.8 33.0  NIANPTAMLLSASNMLR 






aldolase A Rat P05065 39327 8.31 4 3 46.6 32.8 11% ALANSLACQGK 
        65.7 32.9  FSNEEIAMATVTALR 
        76.5 32.9  GILAADESTGSIAK 
 
Triosephosphate 
isomerase Rat P48500 26832 6.89 2 2 60.0 32.8 11% VVLAYEPVWAIGTGK 








2 Rat P27139 29096 6.89 11 7 52.0 32.9 33% SHHWGYSK 
        48.7 32.0  
QSPVDIDTGTAQHDPSLQPLLICY
DK 
        56.9 32.1  
LNFNSEGEAEELMVDNWRPAQP
LK 
        48.0 32.3  
KLNFNSEGEAEELMVDNWRPAQ
PLK 
        41.1 32.0  ITEALHSIK 
        50.7 32.3  IGPASQGLQK 
        63.8 32.2  EGPLSGSYR 
 
Phosphoglycerate 
mutase 1 Rat P25113 28814 6.67 3 3 31.2 31.8 22% SYDVPPPPMEPDHPFYSNISK 
        57.4 32.4  YADLTEDQLPSCESLKDTIAR 







mitochondrial Rat Q920L2 71570 6.75 35 21 105.8 32.9 55% AAFGLSEAGFNTACLTK 
        39.3 32.7  ACALSIAESCRPGDKVPPIK 
        47.3 32.4  
AGLPCQDLEFVQFHPTGIYGAGCL
ITEGCR 
        52.6 32.6  AKNTIIATGGYGR 
        98.2 32.8  ANAGEESVMNLDKLR 
        62.6 32.4  
GCGPEKDHVYLQLHHLPPEQLAT
R 
        51.1 32.1  
GSDWLGDQDAIHYMTEQAPASV
VELENYGMPFSR 
        96.9 32.5  GVIALCIEDGSIHR 
        64.6 32.9  HTLSYVDTK 







        49.6 33.0  IDEYDYSKPIEGQQK 
        75.6 32.7  KHTLSYVDTK 
        35.5 32.6  KPFAEHWR 
        107.6 32.5  LGANSLLDLVVFGR 
        41.9 32.6  SMQSHAAVFR 
        74.4 32.5  TGHSLLHTLYGR 
        67.1 32.5  TYFSCTSAHTSTGDGTAMVTR 
        62.5 32.6  
VSDAISTQYPVVDHEFDAVVVGA
GGAGLR 
        65.1 32.6  VSQLYGDLQHLK 
        38.2 32.2  
VTLDYRPVIDKTLNEADCATVPPAI
R 
        39.9 32.0  WHFYDTVK 
 
Dihydropyrimidinas
e-related protein 2 Rat P47942 62239 5.95 2 2 36.7 32.2 5% QIGENLIVPGGVK 
        66.8 32.5  IVLEDGTLHVTEGSGR 
1159 Triosephosphate 
isomerase 
Rat P48500 26832 6.89 26 16 42.5 32.8 80% AIADNVKDWCK 
       52.0 32.9  CLGELICTLNAAK 
       88.8 32.1  
CLGELICTLNAAKLPADTEVVCAPP
TAYIDFAR 
        73.5 32.3  CNVSEGVAQCTR 
        75.5 32.6  DLGATWVVLGHSER 
        56.0 32.4  
ELASQPDVDGFLVGGASLKPEFVD
IINAK 
        71.6 32.7  HIFGESDELIGQK 
        55.9 32.4  IAVAAQNCYK 
        81.6 32.4  IIYGGSVTGATCK 
        58.1 32.1  KFFVGGNWK 
        104.8 32.8  LPADTEVVCAPPTAYIDFAR 
        75.1 32.9  RHIFGESDELIGQK 
        111.8 32.7  VNHALSEGLGVIACIGEK 
        73.7 32.8  VNHALSEGLGVIACIGEKLDER 
        72.6 32.8  VTNGAFTGEISPGMIK 







isozymes M1/M2 Rat P11980 57781 6.63 92 43 48.2 31.1 74% APIIAVTR 
        49.0 31.4  MQHLIAR 
        59.6 32.5  IISKIENHEGVR 
        42.7 33.0  VNLAMNVGK 
        56.1 33.2  GSGTAEVELK 
        38.8 33.2  LLFEELAR 
        41.0 33.1  GDYPLEAVR 
        39.9 33.0  EAEAAVFHR 
        44.1 32.8  TGLIKGSGTAEVELKK 
        67.4 33.0  GSGTAEVELKK 
        46.8 32.7  LNFSHGTHEYHAETIKNVR 
        56.0 32.5  GDLGIEIPAEK 
        65.2 32.7  LDIDSAPITAR 
        58.3 32.2  ITLDNAYMEK 
        65.5 32.6  SVEMLKEMIK 
        78.9 32.6  LNFSHGTHEYHAETIK 
        100.9 32.6  GADYLVTEVENGGSLGSK 
        64.2 32.8  NTGIICTIGPASR 
        70.5 32.7  EKGADYLVTEVENGGSLGSK 
        57.6 32.7  EKGADYLVTEVENGGSLGSKK 
        92.1 32.8  IYVDDGLISLQVK 
        75.7 32.4  CDENILWLDYK 
        78.2 32.8  CLAAALIVLTESGR 
        49.9 32.7  APIIAVTRNPQTAR 
        87.5 32.8  DAVLDAWAEDVDLR 
        81.3 32.6  KGVNLPGAAVDLPAVSEKDIQDLK 
        113.1 32.7  IYVDDGLISLQVKEK 
        99.7 32.1  
AEGSDVANAVLDGADCIMLSGET
AKGDYPLEAVR 
        72.8 32.7  GADYLVTEVENGGSLGSKK 
        92.6 32.7  RFDEILEASDGIMVAR 
        62.5 32.5  GDLGIEIPAEKVFLAQK 





        94.0 32.7  FGVEQDVDMVFASFIRK 
        76.7 32.8  AGKPVICATQMLESMIK 
        59.5 32.4  
AATESFASDPILYRPVAVALDTKGP
EIR 
        122.3 32.5  ASSQSTDPLEAMAMGSVEASYK 
        44.2 32.2  
GIFPVLCKDAVLDAWAEDVDLRV
NLAMNVGK 
        67.0 32.7  GVNLPGAAVDLPAVSEKDIQDLK 
        53.9 32.6  AATESFASDPILYRPVAVALDTK 
        132.4 32.6  
AEGSDVANAVLDGADCIMLSGET
AK 
        97.0 32.8  GIFPVLCKDAVLDAWAEDVDLR 
        30.8 32.8  
DAVLDAWAEDVDLRVNLAMNV
GK 
        60.3 32.8  ITLDNAYMEKCDENILWLDYK 
1228 Protein DJ-1 Rat O88767 19961 6.32 52 19 39.5 30.4 90% RALVILAK 
        59.0 33.0  EILKEQENR 
        67.3 32.7  DKMMNGSHYSYSESR 
        73.6 32.7  VEKDGLILTSR 
        69.8 32.8  GAEEMETVIPVDIMRR 
        80.1 32.4  AGIKVTVAGLAGKDPVQCSR 
        73.9 32.7  MMNGSHYSYSESR 
        52.0 32.6  DVVICPDTSLEEAK 
        120.7 32.1  KGLIAAICAGPTALLAHEVGFGCK 
        71.8 32.7  VTVAGLAGKDPVQCSR 
        35.0 32.8  GAEEMETVIPVDIMR 
        98.0 31.9  
TQGPYDVVVLPGGNLGAQNLSES
ALVK 
        56.6 30.3  
DVVICPDTSLEEAKTQGPYDVVVL
PGGNLGAQNLSESALVK 
        140.3 32.3  GPGTSFEFALAIVEALSGK 







        51.0 31.3  
VEKDGLILTSRGPGTSFEFALAIVE
ALSGK 
        101.4 32.1  GLIAAICAGPTALLAHEVGFGCK 
        42.5 31.1  
DGLILTSRGPGTSFEFALAIVEALSG
KDMANQVK 





isozymes M1/M2 Rat P11980 57781 6.63 13 8 78.8 32.4 22% IYVDDGLISLQVK 
        79.7 32.5  CLAAALIVLTESGR 
        68.0 32.4  GIFPVLCKDAVLDAWAEDVDLR 
        105.8 32.2  IYVDDGLISLQVKEK 
        89.6 32.6  RFDEILEASDGIMVAR 
        125.2 32.7  FGVEQDVDMVFASFIR 
        74.5 32.5  FGVEQDVDMVFASFIRK 





transferase P Rat P04906 23424 6.89 3 3 66.5 32.6 25% FEDGDLTLYQSNAILR 
        106.0 32.9  EAALVDMVNDGVEDLR 
        63.3 32.1  ALPGHLKPFETLLSQNQGGK 
 
Acyl-protein 
thioesterase 1 Rat P70470 24692 6.05 3 2 41.3 32.2 12% LAGVTALSCWLPLR 




dehydrogenase Rat P04797 35805 8.14 49 11 49.2 33.0 58% VGVNGFGR 
        70.4 32.7  VVDLMAYMASKE 
        51.2 32.6  GAAQNIIPASTGAAK 
        58.6 32.6  
VIISAPSADAPMFVMGVNHEKYD
NSLK 
        78.1 32.8  LTGMAFRVPTPNVSVVDLTCR 
        82.7 32.8  VPTPNVSVVDLTCR 





        67.8 32.9  LISWYDNEYGYSNR 
        87.4 32.8  IVSNASCTTNCLAPLAK 
        44.3 31.6  
AAFSCDKVDIVAINDPFIDLNYMV
YMFQYDSTHGK 
        133.3 32.6  WGDAGAEYVVESTGVFTTMEK 
 
Pyruvate kinase 
isozymes M1/M2 Rat P11980 57781 6.63 8 4 70.6 32.7 13% CLAAALIVLTESGR 
        70.6 32.8  FDEILEASDGIMVAR 
        75.4 32.8  FGVEQDVDMVFASFIR 
        96.3 32.8  ASSQSTDPLEAMAMGSVEASYK 
 Protein DJ-1 Rat O88767 19961 6.32 6 3 57.8 32.5 26% GLIAAICAGPTALLAHEVGFGCK 
        102.9 32.6  GPGTSFEFALAIVEALSGK 










channel protein 1 Rat Q9Z2L0 30737 8.62 18 11 70.6 32.9 58% LTLSALLDGK 
        61.2 32.4  LTLSALLDGKNVNAGGHK 
        76.8 32.6  VTQSNFAVGYK 
        69.7 32.8  KLETAVNLAWTAGNSNTR 
        53.3 32.0  GYGFGLIKLDLK 
        59.0 32.7  YQVDPDACFSAK 
        84.5 32.7  LTFDSSFSPNTGKK 
        61.8 32.7  SENGLEFTSSGSANTETTK 
        113.2 32.2  VNNSSLIGLGYTQTLKPGIK 
        122.1 32.8  WNTDNTLGTEITVEDQLAR 




channel protein 2 Rat P81155 31726 7.44 14 10 37.0 32.1 48% SNFAVGYR 





        62.3 32.6  LTFDTTFSPNTGK 
        67.2 32.7  YQLDPTASISAK 
        59.7 32.7  LTFDTTFSPNTGKK 
        59.1 32.5  DIFNKGFGFGLVK 
        33.4 32.8  AECCVPVCQRPICIPPPYADLGK 
        106.8 32.6  SCSGVEFSTSGSSNTDTGK 
        69.1 32.4  VNNSSLIGVGYTQTLRPGVK 




dehydrogenase Rat P04797 35805 8.14 7 4 70.1 32.7 29% VVDLMAYMASKE 
        83.5 32.1  VIHDNFGIVEGLMTTVHAITATQK 
        121.0 32.6  WGDAGAEYVVESTGVFTTMEK 





ATPase subunit E 1 Rat Q6PCU2 26112 8.44 3 3 89.2 32.6 21% ARDDLITDLLNEAK 
        106.7 32.0  YQVLLDGLVLQGLYQLLEPR 




mitochondrial Rat P15999 59717 9.22 58 32 38.0 33.5 62% STVAQLVK 
        42.4 31.3  RVGLKAPGIIPR 
        39.2 32.6  LTDADAMK 
        60.3 33.1  QMSLLLR 
        37.5 32.9  LELAQYR 
        41.6 32.8  VLSIGDGIAR 
        32.7 32.9  RSTVAQLVK 
        48.1 32.8  RLTDADAMK 
        48.5 32.0  AVDSLVPIGR 
        43.9 32.5  QVAGTMKLELAQYR 
        56.1 31.9  VGLKAPGIIPR 
        56.9 32.6  VVDALGNAIDGKGPVGSK 





        71.0 32.7  VVDALGNAIDGK 
        91.3 32.3  FESAFLSHVVSQHQSLLGNIR 
        53.3 32.8  ELIIGDRQTGK 
        69.2 32.7  HALIIYDDLSK 
        83.7 32.8  TSIAIDTIINQK 
        77.4 31.6  ITKFESAFLSHVVSQHQSLLGNIR 
        81.1 32.5  TGTAEMSSILEER 
        80.9 31.8  GIRPAINVGLSVSR 
        80.3 32.6  ILGADTSVDLEETGR 
        54.8 32.4  LKEIVTNFLAGFEP 
        92.2 32.6  TGAIVDVPVGDELLGR 
        96.0 32.9  GMSLNLEPDNVGVVVFGNDK 
        43.7 31.9  ILGADTSVDLEETGRVLSIGDGIAR 
        61.6 32.1  GMSLNLEPDNVGVVVFGNDKLIK 
        35.9 31.3  
TGAIVDVPVGDELLGRVVDALGN
AIDGKGPVGSK 
        138.1 32.6  QGQYSPMAIEEQVAVIYAGVR 
        130.4 32.7  EVAAFAQFGSDLDAATQQLLSR 
        38.3 32.0  ISEQSDAKLKEIVTNFLAGFEP 





Rat P09606 42240 6.64 28 6 44.5 32.9 24% ATSASSHLNK 
        37.2 32.8  CIEEAIDKLSKR 
        75.9 32.3  RLTGFHETSNINDFSAGVANR 
        47.2 32.9  TCLLNETGDEPFQYK 
        38.5 32.3  IQLMYIWVDGTGEGLR 
        48.4 32.2  LTGFHETSNINDFSAGVANR 
 Phosphoglycerate 
kinase 1 
Rat P16617 44510 8.02 22 4 61.0 32.6 18% LGDVYVNDAFGTAHR 
        54.6 32.8  GCITIIGGGDTATCCAK 
        61.9 32.7  DCVGSEVENACANPAAGTVILLEN
LR 








alpha, somatic form, 
mitochondrial 
Rat P26284 43227 8.49 4 2 34.0 33.3 5% AAASTDYYK 
        43.6 32.9  VDGMDILCVR 
 Creatine kinase U-
type, mitochondrial 




Rat P04797 35805 8.14 29 5 51.0 32.9 23% VVDLMAYMASKE 
        56.4 32.5  VPTPNVSVVDLTCR 
        34.4 32.9  LISWYDNEYGYSNR 
        51.6 32.7  WGDAGAEYVVESTGVFTTMEK 




Rat P04636 35661 8.93 6 2 30.9 32.8 8% VNVPVIGGHAGK 




Rat Q5RJQ4 39294 6.67 3 2 40.3 32.6 10% CYTQNIDTLER 




Rat P09117 39259 6.67 41 10 40.5 31.5 36% PHSYPALSAEQKK 
        33.7 33.0  ALQASALSAWR 
        32.0 32.9  IVAPGKGILAADESVGSMAK 
        49.6 32.7  GILAADESVGSMAK 
        31.6 32.0  YEGSGDGGAAAQSLYVANHAY 
        46.9 31.9  ISDRTPSALAILENANVLAR 
        36.3 32.7  DNAGAATEEFIKR 





        45.1 31.2  TVPPAVPGVTFLSGGQSEEEASLN
LNAINR 





Rat P04797 35805 8.14 33 7 46.3 32.7 33% VVDLMAYMASKE 
        42.2 32.8  LEKPAKYDDIKK 
        51.4 32.7  VPTPNVSVVDLTCR 
        28.3 31.5  VIPELNGK 
        32.3 32.9  IVSNASCTTNCLAPLAK 
        62.8 32.7  WGDAGAEYVVESTGVFTTMEK 




Rat Q5RJQ4 39294 6.67 7 5 44.0 32.5 17% SPSTGLYANLEK 
        52.4 32.9  LLDELTLEGVTR 
        36.7 32.5  CYTQNIDTLER 
        64.0 31.7  REHANIDAQSGSQASNPSATVSP
R 




Rat Q00981 24822 5.14 39 8 23.0 32.8 55% MQLKPMEINPEMLNK 
        31.9 32.6  EFTEREQGEVR 
        39.0 32.4  QIEELKGQEVSPK 
        73.1 31.9  KQIEELKGQEVSPK 
        33.7 32.2  QFLSETEKLSPEDR 
        34.1 32.5  CFEKNEAIQAAHDSVAQEGQCR 
        58.3 32.7  NEAIQAAHDSVAQEGQCR 
















Rat P19234 27361 6.23 3 2 46.4 32.8 10% DSDSILETLQR 
        39.8 32.7  AAAVLPVLDLAQR 
1214 Glutathione S-
transferase P 
Rat P04906 23424 6.89 15 5 35.4 49.4 30% PPYTIVYFPVR 
        41.0 49.7  DQKEAALVDMVNDGVEDLR 
        34.5 49.6  YGTLIYTNYENGKDDYVK 
        60.4 49.6  EAALVDMVNDGVEDLR 
        33.5 49.7  FEDGDLTLYQSNAILR 
642 V-type proton 
ATPase subunit B, 
brain isoform 
Rat P62815 56515 5.57 61 11 46.4 32.9 34% RGFPGYMYTDLATIYER 
        49.8 32.7  AVVQVFEGTSGIDAK 
        48.0 31.6  QIYPPINVLPSLSR 
        40.5 32.2  IYPEEMIQTGISAIDGMNSIAR 
        32.5 32.3  TVYETLDIGWQLLR 
        46.8 32.2  YAEIVHLTLPDGTKR 
        40.8 32.1  DHADVSNQLYACYAIGKDVQAM
K 
        44.6 32.9  GFPGYMYTDLATIYER 
        38.2 31.9  GIVNGAAPELPVPTGGPMAGAR 
        50.0 31.9  IPIFSAAGLPHNEIAAQICR 
        29.7 32.9  SGQVLEVSGSK 
 Tubulin beta-2C 
chain 
Rat Q6P9T8 49769 4.79 19 2 32.0 32.7 7% EIVHLQAGQCGNQIGAK 
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60 Hemoglobin subunit beta (Hemoglobin beta chain) (Beta-globin) Human P68871 15988 6.75 1 6% LLVVYPWTQR 
 Peroxiredoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) Human Q06830 22096 8.27 1 5% QITVNDLPVGR 
61 Complement factor I precursor (EC 3.4.21.45) (C3B/C4B 
inactivator) 
Human P05156 65677 7.72 2 3% VFSLQWGEVK 
       AQLGDLPWQVAIK 
 Clusterin precursor (Complement-associated protein SP-40,40) Human P10909 52461 5.89 1 3% LFDSDPITVTVPVEVSR 
64 No Identification Assigned        
67 Protein S100-A8 (S100 calcium-binding protein A8) (Calgranulin-A) Human P05109 10828 6.51 1 11% LLETECPQYIR 
72 
Serum albumin precursor 
 
Human P02768 69321 5.92 26 42% AEFAEVSK 
 
Gelsolin precursor (Actin-depolymerizing factor) (ADF) (Brevin) 
(AGEL) 
Human P06396 85644 5.9 2 5% EVQGFESATFLGYFK 
QTQVSVLPEGGETPLFK 
92 Ig kappa chain C region Human P01834 11602 5.58 5 67% DSTYSLSSTLTLSK 
        SGTASVVCLLNNFYPR 
        VYACEVTHQGLSSPVTK 
        TVAAPSVFIFPPSDEQLK 
        VDNALQSGNSQESVTEQDSK 
 Ig kappa chain V-II region TEW Human P01617 12308 5.69 3 38% FSGSGSGTDFTLK 
        ASGVPDRFSGSGSGTDFTLK 
        DIVMTQSPLSLPVTPGEPASISCR 
94 Ig kappa chain C region Human P01834 11602 5.58 2 32% SGTASVVCLLNNFYPR 
        TVAAPSVFIFPPSDEQLK 
 Ig lambda chain C regions Human P01842 11230 6.92 2 37% AAPSVTLFPPSSEELQANK 
        ATLVCLISDFYPGAVTVAWK 
1286 Afamin precursor (Alpha-albumin) (Alpha-Alb) Human P43652 69024 5.64 8 15% FTFEYSR 
        AIPVTQYLK 
        FTDSENVCQER 
        AESPEVCFNEESPK 
        IAPQLSTEELVSLGEK 
        SDVGFLPPFPTLDPEEK 
        AESPEVCFNEESPKIGN 
        SCCEEQNKVNCLQTR 
1847 Complement C1r subcomponent precursor (EC 3.4.21.41) Human P00736 80122 5.89 17 32% GYGFYTK 
 Complement C4-A precursor (Acidic complement C4) Human P0C0L4 192650 6.65 10 9% QGSFQGGFR 
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